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The tick Ixodes ricinus is involved in the transmission of a large variety of pathogens 
of medical and veterinary importance in Norway. The most prevalent human tick-
borne disease in the country is Lyme borreliosis, caused by the bacterium Borrelia 
burgdorferi sensu lato (s.l.). Granulocytic anaplasmosis, caused by the bacterium 
Anaplasma phagocytophilum, is prevalent in livestock, but only a few human cases 
have been published. The viral infection tick-borne encephalitis (TBE), caused by the 
TBE-virus (TBEV), is endemic in the southernmost parts of the country. 
Aims: 
The aims of the present thesis were to assess the frequency and risk factors of tick 
bites, and the seroprevalence of antibodies to B. burgdorferi s.l., A. phagocytophilum 
and TBEV in Sogn og Fjordane county on the western coast of Norway. In addition, 
we wanted to assess any association between tick bites or seropositivity for B. 
burgdorferi s.l. and common subjective health complaints. Finally, we wanted to 
compare different laboratory methods for detection of antibodies to B. burgdorferi s.l. 
Methods: 
During the first half of 2010, serum samples and questionnaires were collected from 
1,213 blood donors at the four blood banks in the county.  
The questionnaire included questions about demographics, various life style factors, 
data on tick bites, and a set of questions designed to measure common and prevalent 
health complaints in the general population. 
Antibodies to B. burgdorferi s.l. were tested in Enzygnost Lyme link VlsE/IgG, 
Enzygnost Borreliosis IgM and Immunetics C6 Lyme ELISA kit. Sera showing 
positive or grey-zone reactivities in any of these tests were further tested in 
Euroimmun Borrelia-EUROLine-RN-AT IgG and Borrelia-EUROLine-RN-AT IgM. 
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A random subgroup of 301 sera was examined for IgG-antibodies to A. phagocyto-
philum by an indirect immunofluorescence assay (IFA). 
All 1,213 sera were analysed for IgG-antibodies to TBEV in Serion ELISA classic 
TBE IgG. 
Results: 
Among the participants, 65.7% had experienced tick bites during their lifetime, and 
30% had experienced tick bites during the last 12 months. Donors from the eastern-
most blood bank in Lærdal reported the lowest occurrence of ticks in their living area 
as well as the lowest number of tick bites. In the younger age-groups, males reported 
more bites than females. This was reversed in subjects older than 50 years of age, 
with females reporting more tick bites than males. Tick bites were more common 
among participants with the highest educational level, increased outdoor activity and 
among hunters and owners of domestic animals. 
Using the laboratory’s routine tests for detecting antibodies to B. burgdorferi s.l., 
Enzygnost IgG and IgM, 9.6% were positive for IgG and 8.2% for IgM. There was a 
positive association of IgG-seropositivity with age, and more males than females were 
positive for IgG (13.0% and 5.5%, respectively). IgG prevalence was higher in 
persons spending more time outdoors. There was a delayed age-related rise in 
seroprevalence in women compared to men. Subjects from the blood bank in Lærdal 
had the lowest prevalence of IgG.  
We found a substantial agreement between Enzygnost IgG and Immunetics C6 
ELISA, most discrepancies were found in weakly reactive sera. IgM only was seen in 
55 subjects (4.5%), of which more than half had a positive immunoblot for IgM. This 
pattern was seen more often in women and younger age-groups. 
Among the 301 blood donors tested for IgG-antibodies to A. phagocytophilum, 49 
(16.2%) were positive with a titer ≥80 (range 80-1280). 
 8 
Among the 1,213 sera tested, six (0.5%) gave positive or grey-zone results in the 
ELISA test for TBEV IgG. Five of these were from persons having received vaccines 
that might give positive reactions in the TBE ELISA, and the last was further 
examined by neutralising antibodies to TBEV, with negative result. 
We found no association between the number of tick bites or antibodies to B. 
burgdorferi s.l. and subjective health complaints, reduced general function or reduced 
physical fitness. The number of tick bites was positively associated with good 
physical fitness. 
Conclusions: 
The results provide insight into the epidemiology of tick bites and tick-borne diseases 
in western Norway, and confirm the endemicity of Lyme borreliosis in the region. 
There were no indications that TBE is established as a human disease in the area, but 
there were serological indications that human granulocytic anaplasmosis should be 
considered in patients with compatible symptoms after a tick bite. The results also 
give insight into strengths and weaknesses of serological methods in diagnosing Lyme 
borreliosis, and may help to establish prudent test algorithms for this disease. There 
were no indications of adverse chronic health effects of tick bites or B. burgdorferi s.l. 
infection in this overall healthy population.  
 
 9 
List of publications 
This thesis is based on the following papers, referred to in the text by their roman 
numerals: 
I Hjetland, R., Eliassen, K.E., Lindbaek, M., Nilsen, R.M., Grude, N., Ulvestad, 
E., 2013. Tick bites in healthy adults from western Norway: Occurrence, risk 
factors, and outcomes. Ticks Tick Borne Dis 4, 304-310. 
II Hjetland, R., Nilsen, R.M., Grude, N., Ulvestad, E., 2014. Seroprevalence of 
antibodies to Borrelia burgdorferi sensu lato in healthy adults from western 
Norway: risk factors and methodological aspects. APMIS 122, 1114-1124. 
III Hjetland, R., Henningsson, A.J., Vainio, K., Dudman, S.G., Grude, N., 
Ulvestad, E., 2015a. Seroprevalence of antibodies to tick-borne encephalitis 
virus and Anaplasma phagocytophilum in healthy adults from western Norway. 
Infect Dis (Lond) 47, 52-56. 
IV Hjetland, R., Reiso, H., Ihlebaek, C., Nilsen, R.M., Grude, N., Ulvestad, E., 
2015b. Subjective health complaints are not associated with tick bites or 
antibodies to Borrelia burgdorferi sensu lato in blood donors in western 









The published papers are reprinted with permission from Elsevier (paper I), John Wiley and 
Sons (paper II), and Taylor & Francis (paper III). All rights reserved. Paper IV is an Open 




SCIENTIFIC ENVIRONMENT 3 
ACKNOWLEDGEMENTS 4 
ABSTRACT 6 
LIST OF PUBLICATIONS 9 
CONTENTS 10 
ABBREVIATIONS 13 
1 INTRODUCTION 14 
1.1 Ticks 15 
1.1.1 Tick species globally and in Norway 15 
1.1.2 Life cycle 16 
1.1.3 Distribution of the Ixodes ricinus species complex globally 18 
1.1.4 Distribution of Ixodes ricinus in Norway 18 
1.1.5 Factors affecting the distribution of I. ricinus 21 
1.2 Tick bites 22 
1.3 Borrelia burgdorferi 24 
1.3.1 Borrelia species 24 
1.3.2 Borrelia burgdorferi sensu lato 25 
1.3.2.1 History 25 
1.3.2.2 Structure 27 
1.3.2.3 Genome 27 
1.3.2.4 Immune evasion by Borrelia burgdorferi s.l. 29 
1.3.2.5 Epidemiology and transmission of Borrelia burgdorferi s.l. 30 
1.3.3 Lyme borreliosis 34 
1.3.3.1 Epidemiology 34 
1.3.3.2 Pathogenesis 40 
1.3.3.3 Clinical disease 41 
1.3.3.4 Questionable  symptoms attributed to Lyme borreliosis 43 
 11 
1.3.3.5 Diagnostic testing 44 
1.3.3.6 Treatment 51 
1.3.3.7 Prevention of LB 51 
1.4 Anaplasma phagocytophilum 53 
1.5 Tick-borne encephalitis virus 55 
1.6 Other tick-borne infections 58 
1.6.1 Borrelia miyamotoi 58 
1.6.2 Rickettsia helvetica 58 
1.6.3 Candidatus Neoehrlichia mikurensis 59 
1.6.4 Francisella tularensis 59 
1.6.5 Babesia spp. 60 
2 AIMS OF THE STUDY 62 
3 MATERIALS AND METHODS 63 
3.1 Study area 63 
3.2 Study population 64 
3.3 Questionnaire 66 
3.4 Laboratory methods 67 
3.4.1 Borrelia burgdorferi s.l. 67 
3.4.2 Anaplasma phagocytophilum 68 
3.4.3 Tick-borne encephalitis virus 68 
3.5 Statistical methods 68 
3.6 Ethical issues 69 
4 SUMMARY OF RESULTS 70 
4.1 Paper I 70 
4.2 Paper II 71 
4.3 Paper III 72 
4.3.1 Anaplasma phagocytophilum 72 
 12 
4.3.2 TBEV 73 
4.4 Paper IV 73 
5 GENERAL DISCUSSION 75 
5.1 Methodological considerations 75 
5.1.1 Blood donors as representatives of the general population 75 
5.1.2 The county of Sogn og Fjordane as representative of the country of Norway 75 
5.1.3 Questionnaire 76 
5.1.4 Statistics 77 
5.1.5 Laboratory methods 78 
5.1.5.1 Borrelia antibodies (paper II and IV) 78 
5.1.5.2 Antibodies to Anaplasma phagocytophilum (paper III) 85 
5.1.5.3 Antibodies to TBEV (paper III) 86 
5.2 Epidemiological results– tick bites and Borrelia antibodies (paper I and II) 86 
5.2.1 The relationship between tick bites and seropositivity for Borrelia burgdorferi 86 
5.2.2 Geography (paper I and II) 86 
5.2.2.1 Europe and USA 86 
5.2.2.2 Norway and Sogn og Fjordane county 87 
5.2.3 Age and gender (paper I and II) 88 
5.2.4 Lifestyle factors (paper I and II) 91 
5.2.5 Disease (paper I, II and III) 92 
5.3 Anaplasma phagocytophilum (paper III) 93 
5.4 Tick-borne encephalitis (paper III) 94 
5.5 Subjective health complaints in relation to tick bites and Borrelia antibodies (paper IV) 95 
6 CONCLUSIONS 97 
7 FUTURE PERSPECTIVES 98 
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The many different microorganisms that cause tick-borne diseases in humans are 
transferred from animal to animal by tick vectors. Such serial transfers are illustrated 
in Figure 1 for the bacterium Borrelia burgdorferi sensu lato and the tick Ixodes 
ricinus. As indicated, humans are outside the enzootic cycle and are thus not able to 




In the following introduction, the different aspects of this cycle are reviewed; the ticks, 
the animal hosts, the microorganisms, and the diseases in humans, including clinical 
presentation and diagnosis. Special emphasis is given to the bacterium Borrelia 
burgdorferi sensu lato (s.l.) and its associated human disease, Lyme borreliosis. 
Figure 1. The enzootic cycle of Borrelia burgdorferi  (Radolf et al., 2012). 




1.1.1 Tick species globally and in Norway 
About 900 tick species exist in the world. These are broadly divided into two families; 
the hard ticks (Ixodidae), and the soft ticks (Argasidae) (Table 1). The hard ticks – 
some of which are relevant in this thesis – comprise members of five subfamilies and 
six genera. The most important of these are various Ixodes, Dermacentor, 
Amblyomma, Haemaphysalis, Hyalomma, and Rhipicephalus species (Dennis and 
Piesman, 2005). The hard ticks are so called because of the presence of a hard plate 
(scutum), covering the dorsal body surface (dorsum). The soft ticks lack a scutum, and 







Ixodidae Ixodinae Ixodes 
 Amblyomminae Amblyomma 
 Haemaphysalinae Haemaphysalis 
 Hyalomminae Hyalomma 
 Rhipicephalinae Dermacentor, Rhipicephalus 
Argasidae Argasinae Ornithodoros 
 
Of these 900 tick species, only 26 are found in north-west Europe, and barely 10 in 
Norway (Table 2). 
 
  
Table 1. Grouping of principal tick vectors of disease to humans 
Modified from (Dennis and Piesman, 2005).  ©2005 American Society for Microbiology. Used with 
permission. No further reproduction or distribution is permitted without the prior written permission 




In male ixodid ticks, the scutum covers most of the dorsum, whereas in the females, it 
is usually restricted to the anterior third to half of the dorsum. Several characteristics 
are utilized for classification of ixodid ticks to the genus level, including the length of 
the mouthparts, presence or absence of eyes, presence or absence of festoons, colour or 
markings on the scutum, and shape and orientation of the anal groove (Mathison and 
Pritt, 2014) (Figure 2). The mouthparts of the tick includes two chelicerae (cutting 
tools), two palps (limbs with sensory organs), and one hypostome, a barbed tube that 
anchors the tick to the host, and through which blood is drawn up into the tick gut. 
1.1.2 Life cycle 
The life cycle of ticks includes the four stages of egg, larva, nymph, and adult. Ixodid 
ticks have only one nymphal stage, whereas argasids have two or more. All ticks feed 
Species Norwegian name English name Common host animals 
 
Common Norwegian species 
Ixodes ricinus Skogflått Sheep tick Many mammals and birds 
Ixodes uriae Fuglefjellflått Seabird tick Birds (seabirds in colonies) 
Ixodes frontalis  Passerine tick Birds 
Ixodes lividus Sandsvaleflått Sand martin tick Birds (sand martins) 
Ixodes hexagonus Piggsvinflått Hedgehog tick Hedgehogs 
Ixodes trianguliceps Museflått Vole tick, shrew tick Bank vole, mouse, rat 
Ixodes caledonicus  Northern bird tick Birds (normally found in 
nests on cliffs or buildings) 
Ixodes arboricola  Tree-hole tick Birds 
Argas vespertilionis Flaggermusflått Bat tick Bats 
 
Sporadically found tick species 
Rhipicephalus 
sanguinea 
Husflått Brown dog tick Dogs 
Hyalomma spp.   Migratory birds 
Dermacentor spp.   Migratory birds 
Table 2. Ticks found in Norway  
Modified from (Mehl, 1983; Kjelland et al., 2014), with permission 
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on blood during some or all stages of the life cycle. The larvae have six feet, while the 






Ixodes ricinus, the major vector for enzootic transmission of disease-inducing 
microbes in Norway, has a three-host cycle, i.e., feeding occurs in each of the three 
parasitic stages, and on three different host animals (Figure 3). Larvae seek hosts, 
attach, feed, detach, and develop in sheltered microenvironments where they molt to 
nymphs. Following the same pattern, nymphs molt to adults. The adults again seek 
hosts, feed and mate. Mating in I. ricinus can occur on or off the host. After having 
completed her feeding, the mated female drops off and after varying time deposits her 
thousands of eggs (oviposition), whereupon the female dies. The development of I. 
Figure 2. Anatomy of a female hard tick (Ixodidae) 
 (Mathison and Pritt, 2014) ©2014 American Society for Microbiology. Used with permission. 
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ricinus typically spans over a period of 2-3 years. During winter in arctic or temperate 




1.1.3 Distribution of the Ixodes ricinus species complex globally 
The primary tick vectors for B. burgdorferi s.l. are members of the I. ricinus complex, 
a group of closely related hard ticks (Xu et al., 2003). I. ricinus is the main vector in 
Europe, while I. persulcatus is most important in Asia. I. scapularis is the main vector 
in north-eastern and upper mid-western USA, as is I. pacificus in western USA, see 
Figure 4 (Stanek et al., 2012). 
1.1.4 Distribution of Ixodes ricinus in Norway 
I. ricinus is the predominating tick species in Norway, and three estimates of the 
distribution of ticks in Norway have been published (Tambs-Lyche, 1943; Mehl, 1983; 
Jore et al., 2011).  
In 1943, the veterinarian Hans Tambs-Lyche published a distribution of I. ricinus 
based on collected ticks as well as information of bovine babesiosis from veterinarians 
Figure 3. Life stages of Ixodes ricinus  
Modified from Norwegian Institute of Public Health (2016), with permission 
 19 
around the country (Tambs-Lyche, 1943). According to his findings, I. ricinus was 
found at altitudes lower than 150-160 meters above sea level in the south-eastern part 
of Norway, below 350-500 meters in the south-western part, and below 100-150 







A new estimate of the distribution of different tick species was published in 1983 by 
Reidar Mehl on the basis of extensive field surveys (Mehl, 1983). His findings on I. 
ricinus corresponded to those of Tambs-Lyche (Figure 6). 
A third publication on the distribution of I. ricinus was published in 2011 by Solveig 
Jore and co-workers (Jore et al., 2011) (Figure 7). The study was based on five inputs; 
the incidence data for Lyme borreliosis reported to the National surveillance system 
for infectious diseases (MSIS) 1991-2008, the incidence of bovine babesiosis reported 
to Norwegian School of Veterinary Science 1996-2008, cervid hunters’ webpage 
Figure 4. Global distribution of the Ixodes ricinus species complex  
(Stanek et al., 2012)  Reprinted from The Lancet, 379, Stanek, G., Wormser, G.P., Gray, J., Strle, F. 
Lyme borreliosis, 461-73, Copyright 2012, with permission from Elsevier. 
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registration in 2007 on http://www.flattogflue.no of tick infestation on roe deer, red 
deer and moose, a newspaper webpage registration of tick observations in 2009, and a 
web-based questionnaire to Norwegian veterinarians in 2009. The authors concluded 
that I. ricinus at the time was found further north (to approximately 69 oN) and at 
higher altitudes (up to 583 meters above sea level) than previously reported. Recently, 
Hvidsten and co-workers studied the distribution of ticks near the northern distribution 
limit in Norway, and found that tick occurrence is high in the Brønnøy district (65°28′ 




Figure 6. The 
distribution of Ixodes 
ricinus in Norway 





Solid circles = localities 
where ticks have been 
collected and identified. 
Open circles = localities 
where hosts for the individual 
tick species were examined 
without finding ticks. 
Triangles = observations 
which originate from 
localities outside of the 
species “normal” range. Such 
observations are ascribed to 
transportation with birds or 
domestic animals.  
 
Figure 5. The distribution of 
Ixodes ricinus in Norway 
according to Tambs-Lyche (1943)  
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In Sogn og Fjordane county, the distribution maps (Figures 5-7) clearly demonstrate 
that the density of ticks is lower in the eastern, more inland-like parts of the county, 
compared to the western regions nearer to the coast.  
1.1.5 Factors affecting the 
distribution of I. ricinus 
I. ricinus requires a humidity of the 
microenvironment of at least 80%, as 
uptake of water occurs by direct sorption 
from the atmosphere (Sonenshine, 2005; 
Stanek et al., 2012).  
The temperature is also critical for 
maintaining the life cycle of ticks. 
Tambs-Lyche stated in 1943 that the 
year isotherm of 5 oC was the best 
predictor of I. ricinus occurrence in 
Norway. In addition, he stated that the 
tick needed an oceanic climate (Tambs-
Lyche, 1943). Later, Ottesen (2010) 
argued that the occurrence in Norway is 
better correlated to the vegetation 
period, i.e., the mean number of days 
with a mean temperature of at least  
5 oC, exceeding 170-180 days. A similar conclusion has also been reached in Swedish 
studies (Jaenson et al., 2009). 
The effects of climate on the occurrence of ticks as well as the epidemiology of 
different tick-borne diseases have been discussed in several publications (Lindgren and 
Jaenson, 2006; Gray et al., 2009; Randolph, 2010; Mannelli et al., 2012). Table 3 
summarises thresholds for temperature and humidity for I. ricinus. 
Figure 7. The distribution of Ixodes 
ricinus in Norway according to Jore et 
al. (2011) 
The present distribution of Ixodes ricinus in 
Norway depicted by the weighted mean obtained 
by the first principal component (PC1) of a 
PCA-analysis of four different sources, see 




The availability of host animals for I. ricinus is also of major importance for the 
occurrence and density of the tick, as the feeding of blood from vertebrates is 
necessary for survival. 
More than 300 species of vertebrates have been recorded as hosts for I. ricinus. While 
larvae and nymphs can feed on almost any vertebrate, including birds, small mammals, 
and larger mammals like dogs, sheep, and humans, adult ticks restrict their host range 
to medium-sized or larger mammals, especially deer or other ungulates  (e.g., sheep, 
cattle, goats and pigs) (Sonenshine, 2005). In Norway, the most important small 
mammal hosts are the common shrew (Sorex araneus), the wood mouse (Apodemus 
sylvaticus) and the bank vole (Myodes glareolus), while the most important medium-
sized animal hosts are red fox (Vulpes vulpes), marten (Martes martes), mountain hare 
(Lepus timidus) and also domestic cats (Felis catus). Birds may be important hosts for 
Ixodes species, and are probably important for spreading ticks and associated 
microorganisms over greater distances (Hasle, 2010). Among large animals in Norway 
are moose (Alces alces), roe deer (Capreolus capreolus) and red deer (Cervus elaphus) 
the most important tick vectors (Mysterud et al., 2015). 
1.2 Tick bites 
During questing for vertebrates to find a blood meal, I. ricinus ticks exhibit a 
stationary and mostly passive “ambush” strategy. They climb onto grasses, bushes, or 
Table 3. Climate factors linked to tick vector survival and activity 
(Lindgren and Jaenson, 2006)  Reprinted with permission from WHO Regional Office for 
Europe 
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other leafy vegetation to wait for passing host animals. Adult ticks usually climb 
higher on such vegetation than larvae and nymphs. They can remain there for hours, 
until they have to descend to regain their water balance. As a host animal brushes by, 
they extend their forelegs and cling to the hair or clothing of the animal. This 
behaviour is excited by different stimuli including odorants and physical factors. 
The tick then seeks a protected area of the skin, e.g. under the hair coat or between 
adjoining body parts, such as the groin or axillae in humans. 
The “tick bite” starts by the tick’s cutting through the skin into the dermis by using a 
pair of appendices on its head, the chelicerae. Thereafter the tick starts to secrete a 
cement substance, which anchors the tick to the wound site. After completion of this 
process, which can last for 1 to 2 days, the tick starts sucking blood. The tissue 
damage attracts the host’s leukocytes, thereby enlarging the feeding pool. Periods of 
blood sucking alternate with salivation. The saliva which is excreted into the wound, 
contains a variety of pharmacologically active substances including anticoagulants, 
antihistamine, apyrase (catalysing ATP hydrolysis), and other enzymes that facilitate 
successful bloodsucking activity. Excess water and salt from the blood meal is also 
excreted in the saliva. The blood meal allows the weight of an adult female ixodid tick 
to increase 100-120 fold, while larvae and nymphs increase their weight 10 to 20 fold. 
The increase in size following the blood meal necessitates growth of a new cuticle. 
The cycle from attachment to completed feeding lasts from 2-3 days for larvae, and as 
much as 13 days for adult females (Sonenshine, 2005; Richter et al., 2013). 
The risk of humans being bitten by ticks depends on the density of questing ticks in the 
local area and the degree to which humans expose themselves to the tick-infested 
areas. Exposure depends on whether people live in urban or rural settings, on the 
amount of time spent outdoors in tick infested areas during the tick season, and on 
whether they protect themselves by clothing, use of repellants, awareness of ticks, etc. 
The literature on occurrence and risk factors for tick bites in the general population is 
scant. Two Dutch and one Belgian investigation demonstrated local geographical 
differences within these small countries (de Mik et al., 1997; den Boon et al., 2004; 
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Vanthomme et al., 2012). In Sweden, Stjernberg and Berglund (2002) found a 4% risk 
of being bitten by ticks after 10 hours spent outdoors, and another Swedish study 
found an increased risk of contracting tick bites for women more than 40 years of age 
(Bennet et al., 2007). In a study from the island of Åland in Finland, 85% of the 
general population older than 8 years of age reported having been bitten by ticks 
(Wahlberg, 1990). In Connecticut and Wisconsin, 4.1% of blood donors reported 
having been bitten by ticks during a 6 month period (Leiby et al., 2002). In a recent 
study of blood donors, 10.8% of donors in the three northernmost counties of Norway 
had been bitten by ticks at least once during their lifetime, as opposed to 70.6% in the 
county of Vestfold in the south-eastern part of the country (Dag Hvidsten, personal 
communication 2016). 
1.3 Borrelia burgdorferi 
1.3.1 Borrelia species 
Bacteria in the genus Borrelia belong to the order Spirochaetales, family 
Spirochaetaceae, of which two genera, Borrelia and Treponema, cause human disease. 
Among the Treponema spp., T. pallidum is the cause of syphilis. Based on genetic 
relatedness, the genus Borrelia is divided into the relapsing fever (RF) and Lyme 
borreliosis groups. The latter is called B. burgdorferi sensu lato (hereafter abbreviated 
Bbsl, sensu lato meaning “in a broad sense”). All these have blood-feeding arthropods 
as vectors, and most cause zoonotic infections, with humans being rare and dead-end 
hosts (Schriefer, 2015).  
RF Borrelia species are transmitted by lice or ticks. Louse-borne RF Borrelia is 
endemic only in east Africa (Schriefer, 2015), but imported cases have recently been 
seen in refugees in Europe (Hoch et al., 2015). Tick-borne RF is caused by a variety of 
Borrelia spp., and occurs in focal areas throughout the world. Most tick-borne RF 
species have soft ticks of the genus Ornithodoros as vectors (Schriefer, 2015). 
However, a newly discovered species of Borrelia belonging to this group, B. 
miyamotoi, has hard ticks as vector (Platonov et al., 2011). In Norway, tick-borne RF 
is occasionally seen as imported cases (Norwegian Institute of Public Health, 2015b).  
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1.3.2 Borrelia burgdorferi sensu lato 
1.3.2.1 History 
The cause of Lyme borreliosis, Borrelia burgdorferi, was first described by Wilhelm 
Burgdorfer and co-workers in the early 1980s (Burgdorfer et al., 1982). This occurred 
after several years of search for the etiology behind an outbreak of what was initially 
thought to be juvenile rheumatoid arthritis in the Old Lyme district in Connecticut, 
USA (Steere et al., 1977). Clinical disease compatible with what we now recognise as 
manifestations of Lyme borreliosis was, however, described in Europe and 
Scandinavia at a much earlier time. The Swedish dermatologist Arvid Afzelius 
described the common skin manifestation seen in Lyme disease, erythema migrans  in 
1910 and 1921 (he named it erythema chronicum migrans), and connected this to the 
bite of an Ixodes tick (Afzelius, 1910, 1921). Radiating pain compatible with what we 
today would call neuroborreliosis was described by Bannwarth in Germany in 1941 
(Bannwarth, 1941). In the early 1960s, Brennaas and Ræder (1962) described a disease 
corresponding to Lyme neuroborreliosis on the island of Stord in western Norway.  
Bbsl has been divided into different genospecies. The term genospecies denotes a 
taxonomic category subordinate to a genus (or subgenus) and superior to the 
subspecies or variety. It is thus at the same taxonomic ranking as the species. The 
difference between the two terms relates to their characteristics of inclusion; a species 
is composed of individuals similar in certain morphologic and physiologic 
characteristics, while a genospecies can be identified only by its genotype, not by its 
phenotype (http://medical-dictionary.thefreedictionary.com/, accessed 02.11.2016). 
Significant differences between strains may also exist within the genospecies, e.g. as 
demonstrated by Cerar et al. regarding B. burgdorferi sensu stricto (s.s.) in USA and 
Europe (Cerar et al., 2016). In the literature on B. burgdorferi, the words species and 
genospecies are used interchangeably.  
Studies published since 1992 have divided Bbsl into three prevalent, human-
pathogenic genospecies - B. burgdorferi sensu stricto (hereafter abbreviated Bbss), B. 
afzelii, and B. garinii – and 12 other genospecies, some of which have been linked to 
human disease (Table 4).  With few exceptions, Bbss is the only well-documented  
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human-pathogenic Lyme borreliosis genospecies found in North America; in contrast, 
all three genospecies have been isolated from humans in Europe. From central to 
eastern Asia, B. garinii and B. afzelii are the agents causing almost all human cases of 











Ixodes scapularis Rodents Eastern and north-
central United States 
Lyme borreliosis 
 Ixodes pacificus Rodents Western United States Lyme borreliosis 
 Ixodes ricinus Rodents Europe Lyme borreliosis 
B. garinii Ixodes ricinus, 
Ixodes persulcatus 
Birds Europe, Asia Lyme borreliosis 
 Ixodes uriae Birds Europe, Asia ? 
B. afzelii Ixodes ricinus, 
Ixodes persulcatus 
Rodents Europe, Asia Lyme borreliosis 
B. bavariensis Ixodes ricinus, 
Ixodes persulcatus 
Rodents Europe, Asia Lyme borreliosis 
B. spielmanii Ixodes ricinus Rodents Europe Lyme borreliosis 
(few cases) 
B. japonica Ixodes ovatus Rodents Japan ? 
B. andersonii Ixodes dentatus Rabbits United States ? 
B. bissettii Ixodes scapularis, 
Ixodes pacificus 
Rodents United States Lyme borreliosis 
(few cases) 
B. tanukii Ixodes tanukii, 
Ixodes ovatus 
Rodents Japan ? 
B. turdi Ixodes turdus ? Japan ? 
B. sinica Ixodes ovatus  China ? 
B. valaisiana Ixodes ricinus Birds Europe, Asia Lyme borreliosis 
(one case) 
B. lusitaniae Ixodes ricinus Reptiles 
(birds?) 
Europe, North Africa Lyme borreliosis 
(few cases) 
B. californiensis ? Rodents Western United States ? 
B. carolinensis Ixodes minor Rodents Southeastern United 
States 
? 
Table 4. Species belonging to Borrelia burdgdorferi sensu lato   
Modified from (Schriefer, 2015). ©2015 American Society for Microbiology. Used with permission. 
No further reproduction or distribution is permitted without the prior written permission of American 
Society for Microbiology. 
 27 
A further division of Borrelia occurred in 2009 when Margos and co-workers 
suggested that OspA serotype 4 of B. garinii (rodent-associated) was sufficiently 
distinct from bird-associated B. garinii strains to deserve species status as B. 
baviariensis (Margos et al., 2009). A few studies have reported the detection of this 
and other Borrelia species (B. valaisiana, B. spielmanii, B. bissettii, and B. lusitaniae) 
in patient samples in Europe (Stanek et al., 2012). 
1.3.2.2 Structure 
Borrelia spp. are similar in length (8 to 30 μm) but wider (0.2 to 0.5 μm) than the two 
other human pathogenic spirochetes, Treponema and Leptospira spp. The cell wall of 
Borrelia consists of an outer membrane, flagellar filaments, peptidoglycan and an 
inner membrane (Figures 8 and 9). The outer membrane contains outer-surface 
lipoproteins (Osps) in high density and β-barrel outer-membrane-spanning proteins in 
lower density. The inner membrane is rich in integral membrane proteins, many of 
which are transporters (Schriefer, 2015). 
Borrelia spp. are highly motile, with a corkscrew and oscillating motility that enables 
movement through highly viscous mediums. The flagella of spirochetes are 
endoflagella, in contrast to the exoflagella of most other bacteria. The endoflagella (7 
to 20 per terminus) are localised beneath the outer membrane and insert subterminally 
at one end of the protoplasmic cylinder (Schriefer, 2015).  
Cystic variants of Bbsl have been described (Mursic et al., 1996; Brorson and Brorson, 
1997).  
1.3.2.3 Genome 
Borrelia spp., unlike most bacteria, have a small linear chromosome of approximately 
1,000 kb and both linear and circular plasmids. Also unlike most other bacteria, 
Borrelia spp. have a low G+C content (approximately 30 mol%). The complete 
nucleotide sequences of the chromosome and the 21 plasmids (9 circular and 12 linear) 
have been published for the type strain Bbss B31 (originally recovered from an I. 
scapularus tick). The large linear plasmid lp54 encodes two major outer surface 
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proteins, OspA and OspB. Another major outer surface protein, OspC, is encoded on a 
circular plasmid (cp26). 
Many genes in Bbss B31, of which several are plasmid borne, are differentially 
expressed at 23 oC and 35 oC. This demonstrates the potential importance of plasmid-
borne genes in the adaptation of Bbsl to mammalian hosts and tick vectors (Schriefer, 
2015). 
There are no recognisable genes for toxins or other virulence factors in the Bbsl 
genome (Steere et al., 2005). 
 
 
 Figure 8. Structure and morphology of Borrelia burgdorferi 








1.3.2.4 Immune evasion by Borrelia burgdorferi s.l. 
Bbsl has evolved several mechanisms for avoiding destruction by the host’s immune 
system. 
One important mechanism involves the inactivation of host complement attack through 
acquisition of human complement regulatory molecules, including factor H (CFH), 
factor H-like protein 1 (FHL1), factor H-related protein 1 (CFHR1), CFHR2, and/or 
CFHR5. Binding of these host proteins to the bacterium is primarily mediated by 
bacterial surface-exposed proteins that have been collectively referred to as 
complement regulator-acquiring surface proteins, or CRASPs (Kraiczy and Stevenson, 
2013). 
Figure 9. The cell envelope of Borrelia spp.  
(Radolf et al., 2012) Reprinted by permission from Macmillan Publishers Ltd: Nat 
Rev Microbiol 
This drawing of the borrelial cell envelope shows the outer membrane, flagellar filaments, 
peptidoglycan and inner membrane. The outer membrane contains outer-surface lipoproteins 
(Osps) in high density and β-barrel outer-membrane-spanning proteins such as BamA in low 
density. The inner membrane is rich in integral membrane proteins, many of which are 
transporters. BbCRASP, complement regulator-acquiring surface protein; OppA1, 
oligopeptide permease A1; PTS, phosphotransferase system 
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The bacterium also evades the immune system by antigenic variation of distinct 
surface antigens, thus making antibodies induced against one form of the antigen 
unable to recognise subsequent variants. In RF Borrelia, a Variable Major Protein 
(VMP) system was described in the 1980s (Barbour et al., 1982). In 1997, a similar 
antigenic variation system was identified in Bbss B31. Because of sequence similarity 
between this system and the VMP system, its genetic locus was referred to as vls 
(VMP-like sequence).  Its expression site, called “vls Expressed” (vlsE), has several 
neighbouring vls silent cassettes (Figure 10). The vlsE locus undergoes remarkable 
sequence variation involving segmental gene conversion events from these silent 
cassettes. vls sequences have been identified in every Bbsl organism for which a 
genomic sequence is available, and the antigenic variation system is thus ubiquitous 
among all Lyme disease Borrelia spp.  (Norris, 2014). Molecules encoded from the 
vlsE are strong inducers of antibody responses, predominantly directed against the 
conserved, non-variable regions of vlsE. The immune responses are particularly strong 
against the invariable region 6 (IR6, also called C6) within the vls cassette, but 
serologic reactivity has also been demonstrated against other regions outside this area. 
Either full-length VlsE protein or the C6 peptide have been incorporated into many 
serological diagnostic tests for Lyme borreliosis in humans (Norris, 2014).  
1.3.2.5 Epidemiology and transmission of Borrelia burgdorferi s.l. 
The prevalence of vector-competent ticks and their infection-permissive vertebrate 
hosts largely defines human risk and case number.  
Tick-host-pathogen interactions 
The bacterium is maintained in nature in an enzootic cycle that involves transmission 
from a tick vector to a vertebrate host and subsequent acquisition from a vertebrate 
host to a new tick vector, see Figure 1. There are several  spirochetal factors that 
promote persistence, maintenance and dissemination of B. burgdorferi in the tick, 
some of which were recently reviewed (Caimano et al., 2016).   
Bbsl has its natural habitat in the midgut of unfed ticks. The major lipoprotein OspA is 




downregulates expression of OspA and instead upregulates OspC. OspA probably 
mediates Bbsl adherence to gut epithelial cells, while OspC is involved with 
dissemination of the bacterium to the salivary glands. Osp C expression also correlates 
with acquisition of the bacterium by the mammalian host. Migration of spirochetes 
from the midgut of the feeding I. ricinus tick, via its salivary glands, to the skin of the 
animal host takes >17 hours (Munderloh et al., 2005; Schriefer, 2015). Inside the 
mammalian host, OspC is again downregulated, while vlsE expression is increased 
(Liang et al., 2004). 
Figure 10. Characteristics of the vls locus of B. burgdorferi B31  
(Norris, 2014) ©2014 American Society for Microbiology. Used with permission. No further 
reproduction or distribution is permitted without the prior written permission of American 
Society for Microbiology. 
A. Arrangement of the vlsE expression site and the 15 silent cassettes near the telomere of 
the linear plasmid lp28-1. The promoter for vlsE is indicated by the short arrow and the 
orientation of the silent cassettes is shown by the large arrow. B. The cassette regions 
contain six variable regions (VR1 through VR6) separated by relatively invariant regions 
(IRs). The graph indicates the number of different amino acids encoded by the silent 
cassettes at each codon in the aligned sequences. C. Unidirectional, random, segmental 
recombination occurs sequentially during mammalian infection, as indicated by this 
hypothetical example of sequential recombination between vlsE and silent cassettes 9, 7 and 
10. 
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Reservoir hosts for Bbsl 
A reservoir host is a vertebrate animal species that participates significantly in the 
circulation of the spirochete in nature. The spirochetes multiply and disseminate in the 
host and also persist for a considerable time, and ticks feeding on such an animal 
become infected (Gern et al., 1998). Ticks may also be infected by short term 
amplifying hosts, i.e., animals where the bacterium is present only for a shorter time, 
and by co-feeding transmission. This last mechanism of transmission from infected to 
uninfected ticks will be dealt with later (page 55-56). An overview of European 
reservoir hosts for Bbsl was given by Gern et al. (1998) and can also be found at 
www.eucalb.com. 
Many mammalian species serve as reservoirs for Borrelia. The majority of these are 
rodents, the most important probably being mice (Apodemus spp.), voles (Myodes 
(formerly Clethrionymus) spp.) and squirrels (Sciurus). B. afzelii appears to be 
especially associated with these species, though B. bavariensis has also been found in 
Apodemus spp. Several insectivores are also involved including shrews (Sorex, 
Neomys) and hedgehogs (Erinaceus). Amongst the lagomorphs, hares (Lepus) have 
been shown to be reservoirs, but rabbits (Oryctolagus cuniculi) appear to have low 
reservoir capacity.  
The role of carnivorous species is also probably limited. Both foxes (Vulpes vulpes) 
and dogs (Canis familaris) probably have small significance as reservoir hosts.  The 
role of feral cats (Felis catus), which may be numerous in some areas, is uncertain.  
Ungulates are hosts for a great number of ticks. However, most evidence suggest that 
ungulates do not transmit Borrelia to a high proportion of the ticks that feed on them, 
though they are very important in the epidemiology of borreliosis as maintenance hosts 
for the ticks (www.eucalb.com). They may in fact help “dilute” the occurrence of 
Borrelia in ticks and thus reduce the prevalence of Borrelia in ticks in the area 
(Mysterud et al., 2013). 
Birds are often infested with ticks, and B. valaisiana seems to be transmitted 
exclusively from birds, especially members of the thrush family. Most strains of B. 
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garinii are also transmitted from birds, especially pheasants (Phasianus clochicus) and 
blackbirds (Turdus merula). Certain seabirds can transmit strains of B. garinii to 
Ixodes urea, but whether these Borrelia strains are transmitted to other hosts is 
uncertain.  The role of birds as hosts for Borrelia and other pathogens in Norway has 
recently been studied by Gunnar Hasle. He found that of almost 10,000 passerine birds 
examined in southern Norway, 713 carried a total of 517 larvae and 1,440 nymphs. 
The highest prevalence of tick infestation was observed in the Turdus species and 
other ground-feeding birds. The predominant tick species was Ixodes ricinus. The 
prevalence of tick infestation and the number of ticks per bird varied with location, 
year and month. Borrelia spp. were found in 70/513 nymphs (19 B. afzelii, 38 B. 
garinii, 2 B. turdi and 11 B. valaisiana) and in 14/172 larvae (10 B. garinii, 1 B. turdi 
and 3 B. valaisiana) (Hasle et al., 2009; Hasle et al., 2011a; Hasle et al., 2011b; Hasle, 
2013). 
The association of different B. burgdorferi genospecies to specific reservoir hosts is 
likely due to different capacities of the bacteria to  inactivate complement-mediated 
destruction through CRASPs (Kraiczy and Stevenson, 2013).  
Humans are unable to transmit Bbsl back to bloodsucking ticks, and are thus dead ends 
for Borrelia propagation. This means that the bacterium will be unable to adapt to 
humans during a co-evolutionary cyclic race, and consequently that there should be 
little evolution of virulence characteristics in the Borrelia. In addition – since Bbsl is 
nontransmissible when locked within humans – antibiotic treatment will not select for 
increasing resistance patterns in the enzootic B. burgdorferi population. Long term 
treatment of the bacterium with antibiotics may nevertheless have an impact on the 
evolution of antibiotic resistance in other bacteria. 
The prevalence of Bbsl in ticks 
The prevalence of Bbsl in Ixodes ricinus in Norway has been examined in a number of 
studies (Jenkins et al., 2001; Rosef et al., 2009a; Kjelland et al., 2010b, a; Kjelland et 
al., 2011; Jenkins et al., 2012; Mysterud et al., 2013; Soleng and Kjelland, 2013; 
Tveten, 2013; Hvidsten et al., 2014). Generally, a prevalence of 5%-30% is found. The 
highest prevalence is found in adult female ticks, less in nymphs. The bacterium has 
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also been found in larvae. There seems to be a south-north gradient, with a lower 
prevalence in the north, although a high prevalence has been demonstrated in 
Brønnøysund. A distinct south-north gradient was also found in Sweden (Gustafson et 
al., 1995). 
The bacterium was detected in host-seeking I. ricinus ticks in 22.1% – 31.3% of 
nymphs and adults in the southernmost part of Norway (Kjelland et al., 2010b). In 
Sogn og Fjordane county, the prevalence was 12% and 3.5% in ticks at two different 
locations (Rosef et al., 2009a), while a recent study from the county found a 
prevalence of 21.6% in adult female ticks, 11.5% in adult male ticks and 10.9%  in 
nymphs (Mysterud et al., 2013). 
Of interest is the low prevalence found in ticks from roe deer and moose in the 
southernmost counties of Norway, contrasted to the findings in questing ticks in that 
region (Kjelland et al., 2011).  
1.3.3 Lyme borreliosis 
1.3.3.1 Epidemiology 
Notification of clinical disease 
Countries around the world have different methods for surveillance of infectious 
diseases. A common method of surveillance is making selected important diseases 
notifiable to the health authorities. The actual diseases included, the case definitions, 
and the adherence to the notification system will vary. Of 30 countries in the 
EU/EFTA region, 17 have comprehensive surveillance systems for Lyme borreliosis. 
Twenty-one countries have surveillance systems which operate at a national level, 
others at a sub-national or regional level. Mandatory reporting operates in 16 countries 
and voluntary reporting in five. Heterogeneity of applied case definition and absence 
of a centralised reporting and surveillance system at an EU level make data acquisition 
and comparison challenging. Also, laboratory diagnosis in the EU is not standardised, 
leading to both under and over-reporting (European Centre for Disease Prevention and 
Control, 2011).  
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Seroprevalence 
Seroprevalence studies are widely used to assess the occurrence of infectious diseases 
in a population. The prevalence of especially IgG antibodies to a pathogen reflects to a 
certain degree the extent to which a population has been exposed to the pathogen. It 
does not, however, reflect actual prevalence of clinical disease. IgG antibodies can be 
lost in some persons despite earlier exposition and infection, especially if the antigenic 
stimulus ceases. An additional level of uncertainty is added by the fact that different 
laboratory methods used for demonstration of the antibodies may give differing 
results. 
Blood donors are often used for seroprevalence studies because of the ease with which 
sampling can be performed. Due to differences in laboratory methods, comparisons 
between populations in different regions should, however, be made cautiously. The 
direct comparison between prevalence numbers of 1.1% using Immunetics C6 ELISA 
in the USA (Wormser et al., 2013), and 30% in Dar es Salaam, Tanzania, using the 
DAKO flagellar ELISA (Mhalu and Matre, 1996), is – for example – not advisable. In 
Europe, prevalence numbers between 4% and 20% for IgG in different ELISAs have 
been published, as summarised by Tjernberg et al. (2007). Quite analogously, a report 
by Dessau et al. (2011) showed that seropositivity rates for blood donors in some 
Scandinavian laboratories  were markedly different depending on the ELISA method 
used. For example, one Swedish laboratory using Immunetics C6 ELISA reported a 
positivity rate of 16.0%, whereas three laboratories using the IDEIA flagellar ELISA 
found 1.1% -3.0%. Two Swedish laboratories using Liaison assays had IgG rates of 
7.0% and 8.0%, and IgM of 3.0% and 0%, respectively.  
Epidemiology of LB in Norway 
In the Norwegian Surveillance System for Communicable Diseases (MSIS), only cases 
of systemic disease and chronic manifestations of Lyme borreliosis are notifiable, 
while the most prevalent manifestation, erythema migrans, is not 
(http://www.msis.no/). The notification system for LB has recently been evaluated, 
and a case is made for revising the criteria (MacDonald et al., 2016). In the period 
2005-2014, the mean reported annual incidence in Sogn og Fjordane was 17.3 cases 
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per 100,000 inhabitants, compared to 24.5 in the southernmost county of Vest-Agder, 
and 6.2 nation-wide, see Table 5 (http://www.msis.no/).  
The actual practice for notifying MSIS may vary from county to county, i.e., from 
laboratory to laboratory, as well as over the years. There is therefore some uncertainty 
in comparing the numbers both geographically as well as over time. In addition, 
different laboratories use different serological methods. Still, during the last 10 years 
these numbers should be comparable on a longitudinal basis within each county, as 
few major methodological changes have been introduced, and since the notification 
criteria have not changed. 
As notified LB cases in Norway only represent a minor fraction of all LB cases, an 
estimate of this fraction would be of interest. As will be seen from section 1.3.3.3 on 
clinical disease, the number of notified cases should probably be multiplied with a 
number between 3 and 20. One recent survey found that almost 96% of cases of LB in 
Norwegian general practice were erythema migrans, and the authors estimated a 
national incidence of 148 EM/100,000 inhabitants/year (Eliassen et al., 2017).  Using 
this result for the proportion of EM cases in relation to notified cases, the mean 
incidence of EM in Sogn og Fjordane county should be close to 400 EM/100,000 
inhabitants/year. 
In Norway, an IgG seropositivity rate of 18% was found in 247 blood donors from the 
county of Vest-Agder, using the Enzygnost ELISA (Mygland et al., 2006). This is the 
county with the highest incidence of notified Lyme borreliosis cases in Norway, see 
Table 5. Using the same method, Hvidsten and co-workers in a recent study of blood 
donors found a seroprevalence of 0.45% in the three northernmost counties (n=1048), 




Table 5. Annual incidence of Lyme borreliosis notified to MSIS 2005-2014, cases 


































Østfold 5.0 6.9 5.3 4.9 5.6 6.3 6.9 3.2 2.8 4.6 5.2 
Akershus 1.6 2.6 2.2 5.0 3.0 1.3 2.6 3.2 3.2 2.6 2.7 
Oslo 1.5 2.0 1.3 8.0 5.9 3.2 1.8 0.8 1.6 3.2 2.9 
Hedmark 1.6 0.5 1.1 1.1 0.5 0.5 0.0 0.0 0.5 1.0 0.7 
Oppland 2.2 0.0 1.6 1.6 1.6 1.6 0.0 0.5 2.1 1.6 1.3 
Buskerud 3.3 2.4 4.4 2.4 2.7 1.6 1.5 4.1 4.1 1.8 2.8 
Vestfold 10.9 6.3 8.5 4.4 13.1 10.8 9.4 5.5 8.0 11.6 8.8 
Telemark 19.2 42.1 16.9 18.0 12.5 14.9 9.5 10.6 14.0 14.6 17.2 
Aust-Agder 26.1 16.3 30.5 25.4 14.0 11.1 10.9 22.4 18.6 18.5 19.4 
Vest-Agder 37.8 29.0 37.9 35.6 14.3 14.7 12.8 18.4 29.5 15.1 24.5 
Rogaland 7.4 9.8 10.9 6.1 5.7 9.3 7.6 6.5 8.4 10.0 8.2 
Hordaland 5.1 4.6 2.4 3.0 5.1 7.8 6.6 8.2 10.8 13.5 6.7 
Sogn og Fjordane 14.0 23.4 26.4 17.9 22.5 13.1 12.1 10.2 15.6 17.4 17.3 
Møre og Romsdal 6.1 8.6 14.7 17.0 10.5 18.7 10.6 10.1 11.2 8.0 11.6 
Sør-Trøndelag 1.5 2.5 3.2 4.2 2.4 1.7 6.1 4.4 1.3 1.0 2.8 
Nord-Trøndelag 2.3 2.3 3.9 3.1 0.0 3.0 1.5 2.2 3.0 3.7 2.5 
Nordland 1.3 0.4 1.7 3.0 0.8 1.3 0.8 0.4 0.4 0.4 1.1 
Troms 0.0 0.7 1.3 0.6 0.0 0.0 0.6 0.6 0.0 0.0 0.4 
Finnmark 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 
Total 6.1 6.8 7.0 7.3 5.7 5.9 5.0 5.1 6.2 6.3 6.2 
 
There are also wide variations between regions within a county, as visualised for Sogn 
og Fjordane county, see Figure 11. 
 
 
Fig 11. Cases of Lyme 
borreliosis notified to MSIS 
in Sogn og Fjordane 2005-
2014 by municipality. Mean 
yearly incidence per 
100,000 inhabitants 
(www.msis.no). Map source: 
Norwegian Map Authority 
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Age and gender 
Most studies find that seroprevalence of Borrelia antibodies increases with age. Thus, 
a recent Norwegian study by Vestrheim and co-workers (2016) found that the 
seroprevalence among children 2-4 years old was about 1.8%  using the Enzygnost 
Lyme link VlsE for Borrelia IgG antibodies, as opposed to 6.3% in persons 50 years 
or older. Children constitute a substantial part of notified cases of borreliosis in 
Norway, see Table 6. In Sweden, using the Dako ELISA test, Skogman and co-
workers found a Borrelia IgG antibody seroprevalence of 3.2% in young Swedish 
children.  
In the USA, prevalence of IgG 
antibodies towards Bbsl in males 
slightly outnumbered the same 
prevalence in females during the 
period 1992-1998, especially among 
children and adolescents aged 5-19 
years, but also in adults aged ≥ 60 
years. In most European countries, 
e.g. Austria, Czech Republic, 
Germany, Slovakia, Slovenia, and 
Switzerland, there is a slight female 
preponderance (usual range of 54-60% females among recorded LB patients) 
(Hubalek, 2009). Similar numbers were found in south-eastern Sweden; among 3,442 
EM cases reported in 1997-2003, 54.5% were females, and the predominance of 
females was especially marked in the age-group 50-74 years (60.1%) (Bennet et al., 
2007). Reinfection with Borrelia was reported 6 times more frequently for females 
than for males in southern Sweden and nearly all reinfected women were older than 40 
years and postmenopausal (Jarefors et al., 2006). Tick bites vary in their localization 
on the human body between genders; the predilection sites for ticks are the lower 
limbs and breast region in females, and the lower limbs and genital region in males 
(Berglund et al., 1995). In Slovenia, Strle and co-workers found a marked gender 
disparity in different clinical manifestations of LB, in that more women than men were 
Age-group 
(years) Females Males Total 
0 - 9 356 377 733 
10 - 19 94 171 265 
20 - 29 31 68 99 
30 - 39 67 140 207 
40 - 49 120 209 329 
50 - 59 203 287 490 
60 - 69 217 259 476 
70 - 79 165 121 286 
80+ 36 50 86 
Total 1289 1682 2971 
Table 6. Cases of Lyme borreliosis notified 
to MSIS 2005-2014, according to age and 
gender (www.msis.no). 
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diagnosed with skin manifestations such as EM (59.3%) and ACA (68.6%), while men 
outnumbered women in Lyme neuroborreliosis (LNB) (39.2% females) and Lyme 
arthritis (25% females) (Strle et al., 2013).   In Norwegian general practice, Eliassen 
and co-workers found a male dominance of EM-patients in the <40-year-old age-
groups of 54.1%, in contrast to a female dominance in the >40-year-old age-groups of 
55.6%. The difference could not be explained by the age and gender distribution in the 
population (Eliassen et al., 2017). Among notified cases of LB in Norway 2005-2014 
males constitute 1,682 out of 2,971 cases, i.e., 56.6%, see Table 5. Pertaining to 
severity and complications of disease, Weitzner and co-workers (2016) found that 
males and females with culture-confirmed early Lyme disease had similar clinical 
features, rates of seropositivity, and long-term outcomes. Females were, however, 
significantly more likely than males to return for follow-up visits. 
 
Geography 
The global distribution of LB correlates closely with the range of ticks of the I. ricinus 
complex, see Figure 4. It thus occurs between 30 oN and 55 oN in North America, most 
of Europe, parts of North Africa, and northern Asia. In Europe in general, LB occurs 
between approximately 35 oN and 60 oN, although further north along the Norwegian 
coast line. Also the LB occurrence according to altitude corresponds to the occurrence 
of the vector tick, i.e., there are fewer cases at higher altitudes (Hubalek, 2009). 
LB reveals a distinctly focal pattern of distribution, even within small countries and 
regions. This is mainly owing to the heterogeneous spatial distribution of the vector 
ticks.  
Time span 
Although some countries have reported no marked trends in the incidence of LB over 
time, many countries have reported a growing incidence of this disease during the last 
decades, among them Norway. Some of these increasing trends might be biased and 
owing to improved notification systems, greater awareness/vigilance, and better 
diagnostics for LB (Hubalek, 2009).  
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Seasonality 
To a great extent, the annual distribution pattern of LB reflects the seasonal pattern of 
host-seeking (questing) tick activity, although delayed by the incubation period of the 
different manifestations of LB. Also, human behaviour and outdoor activity, i.e., the 
coincidence of maximum tick activity with summer-related leisure behaviour of 
people, enhances the risk of infection. For instance, vacation times overlapping with 
enhanced exposure to ticks during hiking and berry/mushroom picking in forests are 
usually June, July, and August in Europe. Therefore, LB incidence is low in winter and 
early spring and high during summer and autumn (Hubalek, 2009). 
Occupation 
Examples of population groups at risk are forestry workers, military field personnel, 
farmers, deer handlers, gamekeepers, hunters, rangers, and outdoor workers in general. 
For instance, seropositivity to Bbsl is high among forestry workers in most countries 
tested; France 22% (while only 4% in the general population), Austria 14-18%, 
Bulgaria 18% and Italy up to 27%. Farmers also often have a higher seropositivity 
rate, e.g. 15% in Bulgaria (Hubalek, 2009). 
In most European countries, occupational exposure generally constitutes only 2% of 
LB cases (Gray, 1999); it is typically a recreation time disease, contracted during 
holidays and leisure time exposure, including sport in forested areas. In Switzerland, 
8.1% of 558 orienteers seroconverted during one season, but only 0.8% of them 
revealed clinical symptoms of LB – the ratio of apparent to inapparent infection was 
therefore 1:9 (Fahrer et al., 1991). 
 
1.3.3.2 Pathogenesis 
Following subcutaeneous injection of Bbsl, the bacterium multiplies locally in the 
dermis, where it may reach a concentration of 105 bacteria per gram tissue. Thereafter, 
the bacterium remains localised at the site of the bite for several days before it 
disseminates further, probably reflecting a process of adaptation to the new host. The 
organism then disseminates from the inoculation site by both a direct and an indirect 
haematogenic route. The spirochete adheres to host molecules, especially prominent in 
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connective tissue, by means of many different adhesins, and may migrate across the 
vascular epithelium by utilizing the endoflagellae. Unlike many other bacteria, Bbsl 
does not produce toxins or proteases that directly cause tissue damage. Debilitation of 
the host is rather caused by the multiple molecules that activate host responses and 
thus lead to localised and generalised inflammatory pathogenic responses (Moriarty et 
al., 2008; Samuels and Radolf, 2010; Weis, 2011).  
1.3.3.3 Clinical disease 
The spectrum of clinical disease in Lyme borreliosis may be divided into skin 
manifestations, nervous system manifestations, musculoskeletal manifestations, 
cardiac manifestations and ocular manifestations (Stanek et al., 2011). Division of the 
disease into stages I-III analogous to syphilis is often used, but is not always in 
agreement with clinical findings (Stanek et al., 2012). Interesting differences exist in 
clinical manifestations of the different genospecies of Bbsl. B. afzelii and B. garinii 
infections account for most Lyme borreliosis cases in Europe. B. afzelii is mostly 
associated with skin manifestations, B. garinii seems to be the most neurotropic, while 
Bbss seems to be the most arthritogenic (Stanek et al., 2012). 
Infections are also divided into localised versus disseminated. Localised infection is 
typically manifested by an erythema migrans skin lesion. Early disseminated disease is 
usually characterised by two or more erythema migrans skin lesions or as Lyme 
neuroborreliosis or Lyme carditis. Late Lyme borreliosis usually manifests as arthritis 
or acrodermatitis chronica atrophicans, but can also include specific rare neurological 
manifestations (Stanek et al., 2012). 
Erythema migrans (EM) usually occurs 2-30 days after a tick bite. The lesion starts 
from a macule or papule and expands over a period of days to weeks to form a red or 
bluish-red patch, with or without central clearing. The EM may be accompanied by 
fatigue, fever, headache, mild stiff neck, arthralgia and myalgia, but such symptoms 
are not indicative of LB if they occur in the absence of EM (Stanek et al., 2011).  
Acrodermatitis chronica atrophicans (ACA) is almost exclusively seen in adults, 
predominantly women, though ACA-like lesions in children have been reported 
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occasionally. It is a long-lasting, usually progressive manifestation of LB, 
characterised by red or bluish-red lesions, usually on the extensor surfaces of the 
extremities. Initially there is a bluish-red discolouration, often with doughy swelling. 
Later on skin atrophy becomes more and more prominent (Stanek et al., 2011).  
Borrelia lymphocytoma is a bluish-red nodule usually localised to an ear lobe, scrotum 
or nipple. The disease is seen more often in children than in adults (Stanek et al., 
2011). 
Lyme neuroborreliosis (LNB) is most often an acute disease that develops within a 
few weeks of infection. In adults, the disease typically presents as painful 
meningoradiculoneuritis (Garin-Bujadoux-Bannwarth syndrome) and unilateral or 
bilateral affection of the seventh cranial nerve, n. facialis (facial palsy). Less frequent 
manifestations include other cranial neuropathies involving the sixth cranial nerve (n. 
abducens), less frequently the fourth (n. trochlearis) or third (n. oculomotorius) and 
occasionally others. Isolated meningitis, myelitis, encephalitis and cerebral vasculitis 
presenting as stroke are other rare manifestations in adults. The most frequent 
symptoms and signs in children are headache due to meningitis, and facial palsy. 
Borrelia infection of the central nervous system lasting for at least six months (chronic 
borreliosis), including manifestations such as chronic meningitis, encephalomyelitis, 
and radiculomyelitis, are very rare (Øymar and Tveitnes, 2009; Stanek et al., 2011; 
Ljøstad and Mygland, 2012, 2013). 
Lyme arthritis manifests as recurrent attacks or long-lasting objective joint swelling 
(synovitis), usually in one or a few large joints, most commonly the knee (Stanek et 
al., 2011; Haugeberg et al., 2014).  
Cardiac manifestations in LB appear to be rare. They are most frequently observed 
during or shortly after an EM, but may also occur in association with neurological 
symptoms or arthritis. Varying degrees of atrioventricular conduction defects are 
typical manifestations. Other rhythm disturbances, endomyocarditis and pericarditis 
have also been reported (Stanek et al., 2011). A case of late Lyme carditis presumably 
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manifesting 17-18 years after the primary infection was published from Førde General 
Hospital in 1993 (Vegsundvåg et al., 1993). 
Ophtalmic changes may present as conjunctivitis in the course of an early 
manifestation of LB. Uveitis (anterior, intermedia, posterior and panuveitis), papillitis, 
keratitis, and episcleritis may occur occasionally (Stanek et al., 2011). However, a 
recent Dutch study found that uveitis due to Borrelia is so seldom that there was no 
value for routine serologic screening for Bbsl in patients with uveitis in the 
Netherlands (Kazi et al., 2016). 
Of the various objective clinical presentations of Lyme borreliosis in Europe, erythema 
migrans is the most common. In one case series of patients with Lyme borreliosis, 
89% had erythema migrans only, 5% had arthritis, 3% had early neurological 
manifestations, 2% had borrelial lymphocytoma, 1% had acrodermatitis chronica 
atrophicans, and less than 1% had cardiac manifestations. None of the patients had late 
neurological Lyme borreliosis (Huppertz et al., 1999). Only 11% of these would have 
been notifiable in the Norwegian system (MSIS). A survey from southern Sweden 
found that the most frequent clinical manifestation was erythema migrans (seen in 
77% of all cases), followed by neuroborreliosis (16%) and arthritis (7%). Carditis was 
rare (Berglund et al., 1995). In this series, 29% of the cases would have been notifiable 
in Norway.  
1.3.3.4  Questionable  symptoms attributed to Lyme borreliosis 
There has been much controversy about the clinical manifestations of Lyme 
borreliosis, especially regarding chronic health consequences of treated and untreated 
disease (Cameron et al., 2004; Cairns and Godwin, 2005; Shapiro et al., 2005; Feder et 
al., 2007). Symptoms from many organ systems have been ascribed to “chronic Lyme 
borreliosis”, including fatigue, stiff neck, migrating arthralgias, myalgia, chest pain, 
palpitations, abdominal pain, nausea, back pain, headaches, etc. (Cameron et al., 
2004). In addition, other agents transmitted by ticks, e.g. Rickettsia spp., are 
increasingly claimed to cause health problems (Berghoff, 2012). 
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In follow-up studies of patients with neuroborreliosis, several symptoms have been 
found to persist in some of the patients compared to controls, including malaise, 
fatigue, memory problems, concentration difficulties and paresthesias (Henningsson et 
al., 2010; Eikeland et al., 2011; Eikeland et al., 2012).  
However, population based follow-up studies of patients treated for Lyme borreliosis 
in general have given discrepant results regarding long-term consequences. Some early 
American studies reported that Lyme borreliosis patients experience long-lasting 
symptoms (Shadick et al., 1994; Shadick et al., 1999), while more recent 
investigations found that symptoms at follow-up did not exceed that of a control 
population (Seltzer et al., 2000; Wormser et al., 2014; Wormser et al., 2015; Wills et 
al., 2016). Likewise, European studies have found that patients having suffered from 
early Lyme borreliosis do not have late manifestations that exceed the corresponding 
symptoms in matched controls (Cerar et al., 2010; Stupica et al., 2012).  
In a recent Swedish study, patients bitten by Borrelia-infected ticks were compared to 
patients bitten by non-infected ticks (Fryland et al., 2011).  The frequency of subjects 
reporting symptoms was higher in the group bitten by Borrelia-infected ticks 
compared to subjects bitten by uninfected ticks. There were, however, no differences 
between subjects bitten by a Borrelia-positive tick and subjects bitten by a Borrelia-
negative tick when comparing the frequency of reported single symptoms, such as 
fatigue, myalgia/arthralgia, headache, and neck pain.  
It thus seems that long-lasting symptoms after Lyme neuroborreliosis are frequent in 
adults; however, in properly controlled studies, lasting symptoms are rarely seen after 
early disease manifestations such as erythema migrans or after bites with Borrelia-
infected ticks. 
1.3.3.5  Diagnostic testing 
In most patients with erythema migrans, clinical observation suffices to ascertain 
whether or not a patient is infected by Bbsl . All other cases are in need of verification 
by laboratory tests. A variety of different methods have been used, of which some are 
well established, some have failed, some are controversial, and some recently launched 
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tests remain to demonstrate how well they perform in real patient populations. 
Borrelia testing is sometimes fraught with interpretational difficulties.  
Direct detection methods 
Microscopy 
Direct visualisation of Borrelia spp. in clinical samples is applicable only to cases of 
relapsing fever (Schriefer, 2015). During acute phases, spirochetaemia often reaches 
106 -108 organisms/ml, and motile spirochetes can be visualised by darkfield 
microscopy of wet preparations made from a drop of blood. 
It is generally believed that there are too few organisms present in the blood to be seen 
by microscopy in Bbsl infections. A methodological paper, claiming to demonstrate 
Borrelia in blood samples, stirred some hope that microscopy would suffice (Mysterud 
and Laane, 2013). However, the investigation did not include alternative tests to verify 
whether the structures seen in the microscope were Borrelia or artefacts, and not 
unexpectedly the method was later refuted in a double blinded study (Aase et al., 2016; 
Dessau, 2016). 
Antigen detection 
Enzyme-linked immunosorbent assay (ELISA) and immunoblotting have been used 
for the detection of Bbsl antigens in body fluids, including CSF and urine. However, a 
commercial assay for antigen-detection in urine was shown to lack reproducibility, and 
its use is not recommended (Schriefer, 2015). 
Recently, a test based on “nanotrap” technology was published, demonstrating OspA 
lipoprotein in urine specimens (Magni et al., 2015). Although the published results 
seem promising for identifying patients with current LB, further validation of the 
method in clinical settings will be necessary before its role can be consolidated. 
Likewise, a technique for demonstrating OspA in serum after high-speed 
centrifugation followed by targeted protein quantification by multiple reaction 
monitoring mass spectrometry (Cheung et al., 2015), also needs validation in clinical 
settings. 
 46 
Nucleic acid detection techniques 
The polymerase chain reaction (PCR) is widely used for detection of nucleic acids 
from Bbsl in clinical specimens. Tests for both chromosomal and plasmid targets have 
been developed, and an analytical sensitivity of 10-20 bacteria per test sample has 
been demonstrated. However, in a clinical setting, the sensitivity of the PCR has been 
disappointing for many specimen types. The best results have been achieved for 
synovial fluid and synovial biopsies in Lyme arthritis, with a sensitivity approaching 
80%. PCR from skin biopsies in EM or ACA is moderately sensitive (25%-70%). 
Disappointing results have been found for spinal fluid, serum and urine, with 
sensitivities lower than 20%. False positive PCR results have also been reported  
(Aguero-Rosenfeld et al., 2005). 
Isolation procedures 
Bbsl may be cultured in artificial media. The method is time-consuming and has a low 
sensitivity, making it unpractical in clinical practice. Variants of liquid Barbour-
Stoenner-Kelly medium (BSK-medium) are usually used. The culture is incubated at 
temperatures between 30 oC and 34 oC under microaerophilic conditions. Due to the 
slow generation time of 7-20 hours or longer, samples of Bbsl need to be incubated for 
6-12 weeks. Detection of growth is accomplished by periodic examination of culture 
supernatant for the presence of spirochetes by dark-field or fluorescence microscopy. 
Identification of cultured Borrelia may be performed by molecular or serological 
techniques (Aguero-Rosenfeld et al., 2005). 
The sensitivity of culturing is best for skin biopsies from EM and ACA lesions (40-
88% and 22-60%, respectively), but only 10-17% for spinal fluid, and very low for 
blood (1.2-9% in European studies) (Aguero-Rosenfeld et al., 2005) 
Serological tests 
Borrelia antigens and the human humoral immune response 
Bbsl possesses many antigens that elicit an immune response in humans. The various 
outer surface proteins (Osp A to OspF), tissue binding proteins, and parts of the 
flagellar apparatus are all strong inducers of immune responses. The antigens may 
differ from genospecies to genospecies as well as between strains. In addition, the 
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expression of antigens varies according to the bacterium’s environment, whether it is 
inside the tick’s midgut, in culture, or in the skin of a human patient. Some important 
antigens that are poorly expressed in culture, such as OspC and vlsE, are highly 
expressed during human infection. 
The immune response of humans infected with Bbsl usually starts with an IgM 
response that subsequently develops into an IgG response.  
The IgM response is often directed against OspC, the flagellar antigens p41 (FlaB) and 
p37 (FlaA), and p35 (BBK32, fibronectin binding protein), and is typically detectable 
within the first few weeks. Unlike the response towards many other microbes, the IgM 
response may by detectable for many months or years after the infection (Schriefer, 
2015). 
The early IgG response is typically against OspC, p35 (BBK32), p37 (FlaA), vlsE and 
p41 (FlaB). IgG-levels then increase and reactivity broadens during early-
dissemination of the disease, and reactivity against Osp17 (DbpA (decorin binding 
protein A)), p39 (BmpA) and p58 often appears. The late-stage immune response is 
characterised by IgG antibodies to a wide variety of antigens (Aguero-Rosenfeld et al., 
2005; Schriefer, 2015).  
Laboratory methods for detecting antibodies to Bbsl 
The most important method for detecting antibodies to Bbsl are the enzyme 
immunoassay (EIA), also called enzyme-linked immunosorbent assay (ELISA), and 
the immunoblot. Other methods, such as indirect immunofluorescence assay (indirect 
IFA) and indirect haemagglutination assay (IHA) are no longer used in diagnostic 
contexts in Europe. 
ELISA 
In the ELISA reaction, solubilized Borrelia antigens are first coupled to a solid phase. 
After incubation with patient serum, specific antibodies are bound to the 
corresponding antigens, and irrelevant antibodies are removed in a washing step. The 
nature of the bound antibodies are then ascertained by adding an enzyme-labelled 
antibody (called a conjugate) towards human IgG or IgM, which in turn will catalyse 
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the colour change in a chromogenic substrate, making detection possible (Figure 12). 
Depending on how the antigens are produced, ELISAs for Bbsl have been divided into 
first generation, using crude culture extracts as antigen, second generation, where the 
antigen preparation has been improved to limit cross-reactivity with other bacteria, and 
third generation, using synthetic peptides. Strains used as antigen source should 
express OspC, the immunodominant antigen of the IgM response, and DbpA, an 
immunodominant antigen for the IgG response. Recently, specific recombinant 
antigens (i.e., vlsE) or synthetic peptides (i.e., the C6 peptide derived from vlsE) have 
been introduced (Wilske et al., 2007).  A review of the diagnostic accuracy of 
serological tests for Lyme borreliosis in Europe was recently presented by Leeflang 





Western blot and immunoblot 
Antigen preparations for Western immunoblotting include whole-cell lysates or 
recombinant protein antigen mixtures that are resolved by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to blot 
Figure 12. Diagram of an EIA   
(Theel et al., 2015) ©2015 American Society for Microbiology. Used with permission. No 
further reproduction or distribution is permitted without the prior written permission of 
American Society for Microbiology. 
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membranes (Figure 13). An alternative test format is the line immunoblot, in which 
purified recombinant or native Borrelia antigens are applied directly onto membranes 
(Schriefer, 2015). The membranes are cut into strips. In practice most laboratories 
purchase ready-made commercially available strips. The serum is incubated together 
with the strip, specific antibodies are bound to the antigens, and thereafter visualised 
by using a conjugate coupled to an enzyme causing a colour change of the strip where 







Figure 13. Diagram of the Western blot procedure 
 (Theel et al., 2015) ©2015 American Society for Microbiology. Used with 
permission. No further reproduction or distribution is permitted without the 
prior written permission of American Society for Microbiology. 
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Testing algorithms in serology 
In the USA and central Europe, screening with an EIA test is recommended to be 
complemented with an immunoblot for confirmation of positve EIA results, known as 
two-tiered testing (Centers for Disease Control and Prevention, 1995; Brouqui et al., 
2004). There are several different EIAs and immunoblot assays on the market, with 
varying antigenic compositions and performance characteristics.  As a consequence, 
the laboratory’s choice of EIA and immunoblot manufacturer influences the 
conclusions of the diagnostic procedure (Ang et al., 2011).  
In Scandinavia, the two-tier principle has never been systematically adopted, as it is 
thought to reduce sensitivity and only gives a marginal add to specificity (Dessau et 
al., 2006). Thus, most laboratories either perform only EIA-testing, or perform 
additional testing in certain circumstances (Dessau et al., 2011). In Norway, optimal 
testing strategies are currently being discussed (Harbo, 2009; Grude et al., 2011). 
Different alternatives to or variants of the two-tier testing are currently discussed 
world-wide, e.g.  using C6 ELISA as the only test (Tjernberg et al., 2007; Steere et al., 
2008; Wormser et al., 2013), or using an ELISA different from the one used for 
screening for second-tier testing  (Branda et al., 2011; Theel, 2016).  
Tests demonstrating cellular immune response to Borrelia burgdorferi s.l. 
In parallel with the humoral immune response, the patient also mounts a specific T-
helper (CD4) and T-cytotoxic (CD8) cellular immune response towards antigens in the 
Borrelia bacterium. Assays designed to detect these reactions have not yet shown 
satisfactory sensitivity or specificity to be useful in the diagnosis of Lyme borreliosis 
(Dessau et al., 2014; Tveten et al., 2014).  
Also, a low count of CD57 positive lymphocytes (a subset of natural killer cells (NK 
cells)) has been associated with chronic Bbsl infection. The scientific basis for this 
assumption has been questioned (Tveten et al., 2014).  
Owing to their capability to detect an alternative immunologic response towards Bbsl, 
properly adjusted cellular tests have potentiality to become helpful tools in Borrelia-
testing. But so far the assays have delivered meagre results.  
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Other test principles 
Recently, a technique assessing small molecule metabolites in serum by liquid 
chromatography - mass spectrometry (LC-MS), has been reported to achieve 
significantly greater diagnostic sensitivity than current two-tier serology, while 
retaining high specificity (Molins et al., 2015). The usefulness and applicability of this 
principle has to be validated further. 
Conclusions on diagnostic methods 
Although serology is fraught with problems, it is still the most practical approach to 
laboratory testing of Lyme disease. In the case of arthritis, it may be supplemented 
with PCR of biopsies or joint fluid. Owing to the several shortcomings of 
contemporary Borrelia testing, new methods with better sensitivity and specificity for 
actual infection are needed.  
1.3.3.6 Treatment 
Bbsl is susceptible to tetracyclines, most penicillins, many second- and third-
generation cephalosporins, and macrolides in-vitro (Schriefer, 2015). The bacteria are 
resistant to fluoroquinolones, rifampicin, and first-generation cephalosporins. 
Treatment is recommended in all cases of LB, usually for 2 to 4 weeks. Recommended 
treatment regimens in Norway include penicillin, amoxicillin, doxycycline, ceftriaxone 
or cefotaxime, depending on the actual manifestation of LB (Norwegian Directorate of 
Health, 2016; Norwegian Directorate of Health and Antibiotic Centre for Primary 
Care, 2016). 
1.3.3.7 Prevention of LB 
General precautions against tick bites 
Reducing tick exposure 
Avoiding tick infested areas, which of course is a straight-forward approach, has the 
considerable drawback that it limits man’s freedom to engage with nature. 
As an alternative, wearing clothes covering naked skin and ideally using bright colours 
for easier detection of ticks has been advocated. The use of tick repellents on skin and 
clothing has some effect (Pages et al., 2014).  
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Reducing the number of questing ticks in human living areas may be achieved by the 
removal of leaf litter, by applying wood chips where lawns are adjacent to forests, by 
application of acaricides, and using fences to keep out deer.  
Removing attached ticks 
Having a shower or bath within 2 hours of tick exposure is shown to decrease the risk 
of LB.  
Inspection of entire skin after exposure, especially hairy areas, may help removing 
ticks in a timely fashion, as the risk of infection with Bbsl increases with time of 
attachment. 
Attached ticks should be removed as soon as possible by using forceps or tweezers and 
gently pulling it out (Stanek et al., 2012). 
Specific precautions against Bbsl 
Antibiotic prophylaxis 
Chemoprophylaxis with the antibiotic doxycycline is shown to reduce the chance of 
developing LB after removal of I. scapularis or I. persulcatus ticks. In the USA, such 
prophylaxis with one dose of 200 mg doxycycline should be considered for individuals 
in highly endemic areas who are known to have been bitten by a nymphal or adult I. 
scapularis tick that has been attached for at least an estimated 36 hours. In Europe, 
only observation is recommended for I. ricinus tick bites, because the infection rate of 
ticks is lower than in the USA, and studies have not been done on the efficacy of 
antibiotic prophylaxis (Stanek et al., 2012). 
Vaccine 
In the USA, a vaccine against Bbsl was developed and licenced in 1998. The 
mechanism of action involved vaccinating humans against OspA with the subsequent 
development of circulating bactericidal antibodies that would be ingested by the tick 
during a blood meal. In turn, these antibodies were sufficient to bind and neutralise 
viable Borrelia spirochetes present in the tick gut, effectively preventing infection. 
The vaccine was withdrawn in 2002, on the background of low public demand as well 
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as safety issues of uncertain significance (Poland, 2011). There are currently no 
licenced Bbsl vaccines for human use on the market. 
1.4 Anaplasma phagocytophilum 
Ehrlichia and Anaplasma spp. are related Gram-negative obligate intracellular bacteria 
that reside and propagate within membrane-lined vacuoles found in the cytoplasm of 
bone marrow-derived cells, such as granulocytes, monocytes, erythrocytes, and 
platelets (Reller and Dumler, 2015). The taxonomy of these bacteria has changed 
several times since their discovery, and Anaplasma phagocytophilum was earlier 
classified as Ehrlichia phagocytophila (Dumler et al., 2001). They form 
intracytoplasmic clusters of bacteria as small dense core forms (0.2 to 0.4 μm) and 
larger forms (0.8 to 1.5 μm) (Reller and Dumler, 2015). This clustered inclusion-like 
appearance of a microcolony in the host cell vacuole is called a morula, from the Latin 
word for mulberry (Dumler and Walker, 2015).  
The major animal reservoirs for A. phagocytophilum are incompletely documented. 
Viable A. phagocytophilum organisms have been isolated from several hosts, such as 
cattle, sheep, goat, dog, horse, human, red deer, roe deer and white-tailed deer (Stuen 
et al., 2013).  Another group of animals in which A. phagocytophilum is found in 
endemic countries is in small mammals such as rodents and insectivores. These 
animals also are major feeding hosts for ticks, especially for the developmental stages 
(Stuen et al., 2013).  Tick bite is the most frequent route of transmission; however, 
there are others, including perinatal transmission, accidental inoculation of infected 
blood, and blood transfusion (Dumler and Walker, 2015). 
Many strains of A. phagocytophilum have a restricted host range, and some strains 
appear to be apathogenic (Dumler and Walker, 2015). 
Ixodes ticks are the primary vectors for A. phagocytophilum. In ticks, the bacterium is 
transmitted transstadially but not transovarially. Thus, nymphs and adults ticks may 
infect humans, but not larvae (Stuen et al., 2013). The organism was detected in 8.8% 
of I. ricinus in Sogn og Fjordane in a survey performed in 2011 (Mysterud et al., 
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2013), while an earlier study performed in 2006-7 found a lower prevalence (1.4% and 
0.0% in two different locations, respectively) (Rosef et al., 2009b).  
Granulocytic anaplasmosis, caused by the bacterium A. phagocytophilum,  is prevalent 
in livestock in Norway (Stuen and Bergström, 2008), and probably as much as 
300, 000 lambs are infected yearly. The infection in domestic ruminants in Europe is 
called “tick-borne fever” (TBF). The Norwegian synonym of TBF is “sjodogg”, and 
this name was used as early as year 1780 to describe a devastating illness in ruminants 
(Stuen et al., 2013).  
After the verification of human infections in the United States in 1994 (Bakken, 1998), 
and from 1997 onwards also in Europe (Strle, 2004), two cases from 1998 were 
reported from southern Norway (Kristiansen et al., 2001). Serological evidence for 
human infection in the country has also been demonstrated (Bakken et al., 1996).  In a 
recent Swedish study, seroconversion following bites by Anaplasma-infected ticks was 
estimated to be very low. After being bitten, none of 30 patients developed serological 
evidence of anaplasmosis, whereas one patient out of 60 bitten by ticks negative for 
Anaplasma seroconverted, probably due to another, unrecognised bite. The 
seroprevalence in this study population (90 patients) was 17% (Henningsson et al., 
2015). 
Human granulocytic anaplasmosis (HGA) has a median incubation period of 5 to 11 
days after the bite of an infected tick. Patients most often present with high fever 
(93%), myalgias (68%), headache (62%), and malaise (93%). Gastrointestinal, 
respiratory, musculoskeletal, and central nervous system involvement occurs in fewer 
than half of the patients. Leukopenia with lymphopenia, thrombocytopenia, and 
increased serum aspartate transaminase activity is common early in the disease. The 
clinical course is worse for patients with cancer, diabetes, immunosuppression related 
to treatment, and functional or anatomic asplenia (Reller and Dumler, 2015).  
Treatment of choice for HGA is doxycykline or tetracycline (Dumler and Walker, 
2015). Vaccines against A. phagocytophilum are not yet available (Stuen et al., 2013).  
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The diagnosis of anaplasmosis is based on one or more of the following; microscopy 
of peripheral blood or buffy coat, antigen detection by immunohistology, analysis of 
blood specimens by nucleic acid detection techniques, cultivation in cell lines, or 
serologic tests. Among the serological methods, IFA with A. phagocytophilum 
propagated in cell lines is the preferred method. The typical serological response 
during acute infection is a rapid rise (within two weeks of onset) in antibody levels, 
reaching high titers (≥640) within the first month. In treated patients, antibody titers 
decline gradually over several months. About half of the patients have antibodies 
detectable by IFA one year after infection. False positive reactions may be observed in 
patients infected with Rickettsia spp., the Q fever agent Coxiella burnetii, and Epstein-
Barr virus. Autoantibodies to platelets and other leukocyte components may also lead 
to a false-positive IFA test (Dumler and Walker, 2015).  
1.5 Tick-borne encephalitis virus 
Tick-borne encephalitis virus (TBEV) belongs to the genus Flavivirus within the 
family Flaviviridae. These are about 50 nm in diameter, icosahedral, and have a lipid 
envelope covered with surface projections consisting of M (membrane) and E 
(envelope) glycoproteins (Mansfield et al., 2009; Thomas et al., 2015). Included 
among the Flaviviruses are other arthropod-borne viruses such as Japanese 
encephalitis virus (JEV), dengue virus (DENV), yellow fever virus, (YFV) and West 
Nile virus (WNV). Three closely related subtypes of TBEV exist, whose names reflect 
the geographic areas that they principally affect; European, Siberian, and Far Eastern. 
The enzootic cycle of TBEV involves ixodid ticks and wild mammalian hosts, 
particularly rodents. In the tick, the virus passes transovarially and transstadially, from 
egg to larva, nymph, and adult, so all stages of the tick and both male and female ticks 
transmit infections to animals and humans (Thomas et al., 2015). Rodents probably 
maintain a persistent infection with TBEV throughout the year. Larger animals are not 
thought to have an important role in virus transmission. The infected tick can transmit 
the virus to a vertebrate host during feeding and is also able to pass on the virus to a 
non-infected tick during so-called co-feeding at the same site on the host (Mansfield et 
al., 2009). This concept of transmission by co-feeding states that natural hosts having 
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neutralising antibodies to TBE virus (and no detectable viremia) still may support 
virus transmission between infected and uninfected ticks feeding closely together on 
the same animal. This is thought to occur via cellular infiltration of tick feeding sites 
and the migration of cells from these sites (Labuda et al., 1997). Evidence of co-
feeding of nymphs and larvae was recently demonstrated in ticks in Sogn og Fjordane 
(Mysterud et al., 2015). 
Infection by the virus leads to symptoms of TBE in as high as one in three persons. 
The time from tick bite to symptoms is 4-28 days (median 8 days). A small number of 
infections occur through consuming infected unpasteurised milk. The illness usually 
begins with nonspecific symptoms of fever, malaise, headache, nausea, vomiting, and 
myalgias. Within one week, these symptoms resolve spontaneously, and many patients 
do not experience further symptoms (“febrile form”). However, in some patients, after 
an asymptomatic period lasting 2–10 days, the disease then progresses to neurological 
involvement, when high fever, headache and vomiting resume. This second phase may 
be limited to a “meningeal form” with aseptic meningitis (common in children), or it 
may manifest as a “meningoencephalitis form”, or a “poliomyelitic form” with a 
Guillain-Barré-like paralysis. Neurologic infections are usually benign in children, 
whereas severe disease occurs more often in elderly persons. Sequelae are reported in 
up to 40% to 60% of patients, most frequently consisting of psychological 
disturbances such as asthenia, headache, memory loss, etc. (Mansfield et al., 2009; 
Thomas et al., 2015). 
Historically, the disease has been given a range of different names, including Central 
European encephalitis (CEE), Russian spring-summer encephalitis (RSSE), Far 
Eastern encephalitis, and biphasic milk fever. Descriptions of a disease compatible 
with TBE appeared in Austria and in the far eastern part of Russia in the early 1930s. 
In 1937 the virus was isolated from the blood of patients and from Ixodes spp. tick 
vectors (Thomas et al., 2015). 
While TBE has been recognised throughout Europe, endemic transmission is most 
intense in Austria, areas of Sweden, Switzerland, Slovenia, Czech Republic, the Baltic 
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countries, and Russia. In these countries, yearly incidence rates in unvaccinated 
populations have approached 20 in 100,000 persons, but the risk is highly focal. In 
Austria, national vaccination programs have reduced the yearly incidence of disease to 
fewer than 1 in 1 million (Thomas et al., 2015). 
In Norway, human cases of TBE acquired along the southern coastline have been 
diagnosed from 1998 onwards (Skarpaas et al., 2004; Blystad et al., 2009), and tick-
borne encephalitis virus (TBEV) has been detected in ticks in this area (Andreassen et 
al., 2012). According to the Norwegian Surveillance System for Communicable 
Diseases (MSIS), 87 TBE cases were reported in Norway in the period 1994 to 2014. 
TBE cases have been reported from coastal areas in the counties of Vest-Agder, Aust-
Agder, Telemark, and Vestfold (Norwegian Institute of Public Health, 2015a). In the 
county of Østfold, where no human cases of TBE have been notified so far, TBEV was 
recently detected in I. ricinus nymphs, and TBE IgG antibodies were detected in blood 
donors (Larsen et al., 2014). 
So far, no human cases acquired in western Norway have been described. However, a 
case of TBEV-seropositivity in a red dear in the county of Møre og Romsdal, just 
north of Sogn og Fjordane, was recently reported (Ytrehus et al., 2013), and the virus 
has been demonstrated in ticks in Møre og Romsdal and Sør-Trøndelag (Paulsen et al., 
2015). As far as we know, no recent survey of TBEV in ticks has been performed in 
Sogn og Fjordane county. 
The laboratory diagnosis of TBE infection may be accomplished by several methods. 
In early disease, i.e., in the first viraemic phase, demonstration of TBEV nucleic acid 
in serum or spinal fluid may be successful. Later, the demonstration of specific IgM 
and IgG antibodies is the preferred method, for which an ELISA method is usually 
performed (Holzmann, 2003). Because of serological cross reactions to other 
flaviviruses, positive serology may have to be confirmed by other methods, e.g. a 
neutralisation assay (Hunsperger, 2015). 
No specific antivirals are available for the treatment of TBE (Thomas et al., 2015). A 
vaccine against TBE is available, and this vaccine is currently recommended to 
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persons exposed to ticks in TBE-endemic areas in Norway, and to travellers at risk 
(www.fhi.no).  
1.6 Other tick-borne infections 
There are many tick-borne diseases other than those discussed above (Diaz, 2015). 
Such diseases are caused by bacteria, viruses, and protozoa. A number of these do not 
exist endemically in Norway, some have only recently been acknowledged, and some 
are of uncertain significance for human health. Many are transmitted by tick species 
not present in Norway or only in limited numbers. 
Those that are established or probably established in Norway will be shortly 
mentioned in the following. 
1.6.1 Borrelia miyamotoi 
The bacterium does not belong to the Bbsl complex, but is more related to the RF 
Borrelia spp. It was first demonstrated in Japan in 1995 in I. persulcatus, and 
thereafter in ixodid ticks including I. ricinus in parts of USA, in Russia and in Europe. 
Mean occurrence in ticks has been 1.9% (0-10.5%), i.e., about one third as prevalent as 
Bbsl. The bacterium has been found in I. ricinus in southern Norway (Kjelland et al., 
2015; Quarsten et al., 2015). It is transmitted transovarially and transstadially. It has 
not yet been cultured on artificial media, and the mode of demonstration is by PCR. A 
series of 46 Russian cases were published in 2011 (Platonov et al., 2011), and 51 
patients from USA in 2015 (Molloy et al., 2015). The symptoms include high fever, 
chills, marked headache, and myalgia or arthralgia (Platonov et al., 2011; Molloy et 
al., 2015). Human cases have so far not been demonstrated in Norway. 
1.6.2 Rickettsia helvetica 
Rickettsia spp. is a large group of intracellular bacteria, whereof the tick-borne 
Rickettsia spp. give rise to spotted fevers, i.e., Rocky Mountain spotted fever, African 
tick bite fever, and boutounneuse fever. R. helvetica is the only Rickettsia 
demonstrated in ticks in Sweden, and has been found in I. ricinus in Norway (Quarsten 
et al., 2015; Toledo et al., 2015). A seroepidemiological study in Sweden found a 
seroprevalence of 2.6%; 4.4% in patients positive for Borrelia antibodies, 3.0% of 
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tick-bitten Borrelia serology negative patients, and 0.6% in healthy blood donors 
(Elfving et al., 2008). Bacteriaemia with this organism has been demonstrated in birds, 
which may represent an important reservoir (Hornok et al., 2014). The bacterium has 
been linked to human cases of neurologic disease including meningitis (Nilsson, 2009; 
Nilsson et al., 2010). 
1.6.3 Candidatus Neoehrlichia mikurensis 
This Ehrlichia-like intracellular bacterium was first demonstrated in Japan in 2004, 
and has later been found in ixodid ticks in several European countries. In Sweden, it 
was found in 6% of ticks, and in Norway in 6-7% and 5.5% of ticks in two different 
studies (Jenkins and Kristiansen, 2013; Toledo et al., 2015). The reservoir is probably 
wild rodents (Andersson and Raberg, 2011). Since 2007, fourteen European human 
cases have been published, of these six in Sweden. Most patients have been 
immunocompromised, and the symptoms have been fever, cough, headache and 
arthralgia. The major complications have been aneurisms, thromboembolic events and 
bleeding (von Loewenich et al., 2010; Welinder-Olsson et al., 2010; Grankvist et al., 
2015; Labbé Sandelin et al., 2015). However, asymptomatic infection in 
immunocompetent forestry workers in Poland has been described (Welc-Faleciak et 
al., 2014). Recently, one patient was diagnosed in Norway (Hanne Quarsten, personal 
communication 2016). 
1.6.4 Francisella tularensis 
The bacterium Francisella tularensis is the cause of the zoonotic infection tularemia. 
The bacterium has two important subspecies; F. tularensis subsp. tularensis (type A), 
that gives serious human infections and occurs primarily in North America, and F. 
tularensis subsp. holarctica (type B), which occurs in Europe, Asia and North 
America and gives a milder disease. The bacterium occurs primarily in wild animals, 
especially hares and rodents, which themselves fall ill of this bacterium. Human cases 
occur after direct contact with, or bite from, ill or infectious animals, contaminated 
drinking water, by bites from mosquitos or ticks, or inhalation of contaminated dust. 
The  clinical pictures are to a certain degree dependent  upon the bacterium’s site of 
entry into the body (Penn, 2015). In Norway, there are occasional regional outbreaks 
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of the disease (Norwegian Institute of Public Health, 2016b) . The most common 
clinical presentations are the oropharyngeal form after drinking contaminated water, 
and the ulceroglandular form after contact with animals or insect- or tick bites 
(Norwegian Institute of Public Health, 2016b). Some cases that are probably tick-
borne have been published in Norway (Brantsæter et al., 1998). 
1.6.5 Babesia spp. 
Babesia spp. are intraerythrocytic protozoa. More than 100 Babesia species infect a 
wide array of wild and domestic animals, but only a few have been documented to 
infect humans. Babesiosis in cattle is prevalent in tick-endemic areas in Norway, and 
is called “blodpiss” due to the accompanying haematuria. 
In USA, the majority of human cases are caused by B. microti. In Europe, most 
reported human cases have been attributed to B. divergens (Vannier and Krause, 
2012). Moderate, mild, or asymptomatic infections generally occur in people who are 
immunocompetent. In contrast, severe B. microti is more common among patients who 
have undergone splenectomy and those with cancer, human immunodeficiency virus 
infection or other underlying diseases. In USA, more than 150 transfusion-related 
cases have been identified (Vannier and Krause, 2012). The clinical manifestations of 
babesiosis range from subclinical infection to fulminating disease resulting in death. 
There is one case report of babesiosis caused by B. divergens in Norway, in a 
splenectomised veterinarian (Mørch et al., 2015).  
Different Babesia species have been demonstrated in ticks in Norway, whereof B. 
venatorum is the most prevalent (Øines et al., 2012). The clinical picture in humans 
infected with this species has been dominated by fever, fatigue, and headache (Jiang et 
al., 2015). Whether clinical cases of infection with B. venatorum exist in Norway is 
not known. 
Of note is that a in a recent study of ticks recovered from domestic dogs in Denmark 
Babesia spp. was found in 8% of samples, of which B. microti constituted 82% 
(Stensvold et al., 2015). Likewise, in the Swedish STING study, B. microti constituted 
half of the findings of Babesia spp. in ticks that had bitten humans (Per-Eric Lindgren, 
 61 
personal communication, 2017). In the Norwegian study by Øines et al. (2012), the 
authors state that the PCR was not optimised for detection of B. microti. It is thus 
possible that B. microti so far has been underestimated in Scandinavia. 
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2 Aims of the study 
The general aim of this thesis was to increase the knowledge of tick-borne infections 
in Sogn og Fjordane county in a healthy adult population, including distribution, 
diagnosis and impact on health.  
The specific aims for each paper were: 
I. To assess the frequency of tick bites in a healthy adult population (blood 
donors) from Sogn og Fjordane county, western Norway, with regard to 
demographics and other risk factors. We also wanted to assess the frequency of 
symptoms following tick bites, visits to a medical doctor and antibiotic 
treatment, as well as to estimate whether tick occurrence leads to avoidance of 
outdoor activities in certain areas. 
 
II. To describe the seroprevalence of antibodies to B. burgdorferi s.l. in these 
blood donors. In addition, we wanted to relate seropositivity to tick bites, 
demographics and other risk factors. By using two different ELISAs as well as 
immunoblot, we also wanted to compare different test strategies. 
 
III. To estimate the prevalence of antibodies to A. phagocytophilum and TBEV in 
blood donors, to obtain an indication of whether diseases caused by these 
agents currently should be considered in the evaluation of patients after tick 
bites in this region. 
 
IV. To assess the association, if any, of general function, physical fitness and 
subjective health complaints with reported tick bites and antibodies to B. 
burgdorferi s.l. in this group of healthy adults. 
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3 Materials and methods 
3.1 Study area 
Located on the western coast of Norway at 61-62 oN and 5-7 oE, the county of Sogn og 
Fjordane encompasses coastal, fjord and mountainous areas. The fjords penetrate 100-
200 km inland from the coast (Figure 14). In the coastal and middle areas, the climate 
is temperate, with a high yearly rainfall of 1,500 to 3,000 mm, with mean winter 
temperatures in the coldest month, February, of 1-2 oC, while in summer, mean 
temperature in the warmest month (August) is 14 oC. The eastern part has a more 
inland-like climate, with a yearly rainfall of less than 500 mm, and mean winter 
temperatures (January) of -3 to -6  oC, and summer temperatures (July) of 15-17 oC 
(Dannevig, 2009). The North Atlantic Drift of the Gulf Stream makes the temperature 
higher than the latitude would indicate.  
The topography is rugged with summits reaching 1,000–1,500 m above sea level, just 
a few kilometers from the sea. The vegetation is within the so called boreonemoral 
vegetation zone. Forests are dominated by Scots pine (Pinus sylvestris) on marginal 
soils, with alder (Alnus incana) dominating in richer soils, and birch (Betula spp.) 
dominating at higher elevations. There are scattered stands of Norway spruce (Picea 
abies) planted by forestry mainly on better soils at low elevation (Mysterud et al., 
2013). 
The county spans an area of 18,623 km2. As of January 1, 2010, the county had 
107,080 inhabitants, i.e., 5.75 individuals per km2.  The society is predominantly rural, 
the two biggest towns had each about 10,000 inhabitants. The area is mostly 
agricultural, although there are some small industrial towns. 
There are dense populations of red deer in the county. The number has been steadily 
increasing during the last two decades, and the number of harvested red deer in 2010 
was 10,532, as opposed to 303 in 1993 (Hjorteviltregisteret, 2015). The red deer 
populations are partially migratory. There are few roe deer and moose. There are 
livestock in several areas, mainly free-ranging sheep (Ovis aries) during summer. 
Other available large hosts (>1 kg) are red fox, marten, mountain hare, and domestic 
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cats. Densities of these are not known, but the impression is that there are low 
densities of hare and marten, while red fox is more common (Mysterud et al., 2013). 
Information regarding densities of smaller hosts such as voles, mice and birds are 
unavailable. 
3.2 Study population 
The Helse Førde Hospital Trust serves the county of Sogn og Fjordane, and has four 
blood banks in the county (Figure 14). One is situated at the western coast (Florø), two 
by fjords somewhat further east (Førde and Nordfjordeid), and one is located in the 
easternmost part of the county (Lærdal), about 150 km from the coast. During the 
period January 13th to June 15th 2010, blood donors at the four blood banks were 
asked to participate in the Tick-borne Infection Study in Sogn og Fjordane. A total of 
1,213 blood donors participated, a response rate of 76%. Characteristics of these are 
shown in Table 7. Owing to practical circumstances at the blood bank in Lærdal, with 




Figure 14. The localisation of the four participating blood banks (red circles) 
Map source: Norwegian Map Authority. 
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Characteristic No. of subjects1 Percentage 
Blood bank   
    Førde 614 50.6 
    Florø 355 29.3 
    Lærdal 73 6.0 
    Eid 171 14.1 
   
Gender   
    Female 544 44.8 
    Male 669 55.2 
   
Age   
    19-29 80 6.8 
    30-39 235 19.9 
    40-49 414 35.0 
    50-59 344 29.1 
    60-69 110 9.3 
   
Marital status   
    Single 189 15.7 
    Married or cohabitants 1,014 84.3 
   
Education    
    Primary school 9 years or less 87 7.2 
    Secondary school 598 49.8 
    University/college 1-4 years 342 28.5 
    University/college >4 years 175 14.6 
     
Household yearly gross income (EUR)     
    <50,000 156 13.2 
    50-99,000 647 54.7 
    100-150,000 355 30.0 
    >150,000 25 2.1 
     
Daily smoking   
    No 935 81.9 
    Yes 207 18.1 
 
1Because of missing data, not all numbers total the number of participants (n = 1,213). 
 
  
Table 7. Characteristics of the 1,213 participants  
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3.3 Questionnaire 
The questionnaire included questions about demographics such as gender, age, marital 
status, education, household income and occupation. Questions on pet animals, farm 
animals, hours spent outdoors during summertime, amount of ticks in their living area, 
hunting, orienteering, smoking, and symptoms and treatment after tick bites were also 
included. This part of the questionnaire was made specifically for this study.  
The questionnaire included two questions on tick bites; tick bites ever experienced, 
and tick bites experienced during the last 12 months. The responses for both questions 
were given in the categories “none”, “one”, “2-5”, “6-20” and “more than 20”.  
Another section of the questionnaire was constituted by the Subjective Health 
Complaints (SHC) Inventory, a set of questions designed to measure common and 
prevalent health complaints in the general population (Eriksen et al., 1999; Ihlebaek et 
al., 2002). The respondents were asked to report to what extent they had been affected 
by 29 different health disturbances during the last month. The response options were 
“Not at all” (score 0), “A little” (score 1), “Some” (score 2), and “Serious” (score 3). 
The question related to general function was “How do you assess your ability to 
perform ordinary activity, your general function, is today?” The response options were 
“Good, as it usually is” (score 0), “Hardly reduced at all” (score 1), “Not much 
reduced” (score 2), “Moderately reduced” (score 3) and “Much reduced” (score 4), 
adapted from (Reiso et al., 2000). 
Physical fitness was assessed by the question “«During the past 2 weeks: What was the 
hardest physical activity you could do for at least 2 minutes?», with the response 
alternatives «Very heavy (ex. run, at fast pace)» (score 0), « Heavy (ex. jog, at slow 
pace)»  (score 1), « Moderate (ex. walk, at a fast pace)» (score 2), «Light (ex. walk, at 
a medium pace)» (score 3), and «Very light (ex. walk, at a slow pace or not able to 
walk)» (score 4). This question was taken from the COOP/WONCA charts (Weel et 
al., 1995). 
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The questionnaires were answered anonymously, and most were completed during the 
time spent at the blood bank for routine donation. 
3.4 Laboratory methods 
Blood samples were collected in serum separator tubes with gel, and after 
centrifugation, sera were frozen in aliquots at -70oC until testing. 
Testing for antibodies to Bbsl was performed at the Department of Microbiology, 
Helse Førde. The tests for anti-TBEV were performed at the Department of Virology, 
National Institute of Public Health, Oslo, while the testing for antibodies to Anaplasma 
phagocytophilum was performed at Department of Clinical Microbiology, Ryhov 
County Hospital, Jönköping, Sweden. 
3.4.1 Borrelia burgdorferi s.l. 
Antibodies to Bbsl were tested in Enzygnost Lyme link vlsE/IgG, Enzygnost 
Borreliosis IgM (DADE Behring, Marburg, Germany) and Immunetics C6 Lyme 
ELISA kit (Immunetics, Cambridge, MA, USA). Sera showing positive or grey-zone 
reactivities in any of these tests were further tested in Borrelia-EUROLine-RN-AT 
IgG and Borrelia-EUROLine-RN-AT IgM (Euroimmun AG, Lübeck, Germany). 
The Enzygnost Lyme link vlsE/IgG is based on a mixture of native Borrelia antigens 
from B. afzelii strain PKo and recombinant VlsE from the three genospecies Bbss, B. 
garinii and B. afzelii. Enzygnost Borreliosis IgM assay is based on a detergent extract 
from B. afzelii strain PKo. For both assays, sera were absorbed with antigens from 
Treponema phagedenis, and for the IgM assay they were treated with anti-IgG for 
removal of rheumatoid factor. The Enzygnost assays were processed by automated 
instrumentation (Behring BEP 2000 Advance), and the results were interpreted 
following the manufacturer’s instructions, including retesting of grey-zone results. 
The Immunetics C6 Lyme ELISA kit uses the conserved synthetic peptide (C6 
peptide) derived from the vlsE protein as antigen, and both IgG and IgM antibodies are 
detected simultaneously. The analyses were performed semi-manually, using an 
automatic washer and spectrophotometer. Grey-zone results were repeated according 
to the manufacturer’s instructions. 
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The EUROLINE-RN-AT IgG and IgM test kits are qualitative assays for antibodies of 
the IgG and IgM class against Borrelia antigens. The IgG and IgM assays differ in 
antigen composition. The assay is a combination of the classical Western blot and a 
line blot, in that some of the antigens are applied directly in lines to membranes, while 
some are derived from a classical Western blot. Recombinantly produced and purified 
vlsE antigen from the three dominating Bbsl  genospecies are included in the IgG 
assay, and OspC from the three species in the IgM assay.  The resulting blots were 
scanned using the EuroBlot Scanner, and interpreted according to the manufacturer’s 
instructions using the EuroLineScan software (Euroimmun AG, Lübeck, Germany). 
3.4.2 Anaplasma phagocytophilum 
A random subgroup of 301 sera (every fourth serum) was examined for IgG to A. 
phagocytophilum by an indirect immunofluorescence assay (IFA) (Anaplasma 
phagocytophilum IFA IgG Kit, Focus Diagnostics, CA, USA). A screening analysis 
was performed at a serum dilution of 1:80, and sera with a positive reaction in this 
dilution were further examined in two-fold titrations. 
3.4.3 Tick-borne encephalitis virus 
All 1,213 sera were analysed for IgG-antibodies to TBEV in Serion ELISA classic 
TBE IgG (Institute Virion\Serion GmbH, Würzburg, Germany) according to the 
manufacturer’s instructions. Grey-zone results were repeated. One serum positive in 
this test was further tested for neutralising antibodies to TBEV at the Swedish Institute 
for Communicable Disease Control (Vene et al., 1998).  
3.5 Statistical methods 
Data were analysed using the latest version of the SPSS statistical package (SPSS Inc., 
Chicago, IL, USA) (version 18 in paper I, version 20 in paper II and III, and version 
21 in paper IV). In addition, Stata/SE version 13.1 for Windows (StataCorp LP, 
College Station, TX, USA) was used (paper IV). 
All data were categorical and described as frequencies and percentages. Age was with 
few exceptions categorised into age-groups. 
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Chi-squared test and Fisher’s exact test were used when comparing ratios (paper I and 
III), and Student’s t-test was used for comparing age distributions (paper II).  
Binary logistic regression was used for dichotomised outcomes, allowing for 
adjustment for gender, age-group and location of blood bank, when appropriate (paper 
II and IV). 
Proportional odds models, i.e., logistic regression models with more than two ordinal 
categorical outcomes, were used when assessing the association of demographics and 
various life style factors with number of tick-bites (paper I), and when assessing the 
association between number of tick bites and general function and physical fitness 
(paper IV) (Armstrong and Sloan, 1989; Scott et al., 1997). 
The kappa statistic was used to compare the different ELISA methods, to determine 
“consistency among raters” where kappa values < 0 were interpreted as poor, 0.0 – 
0.20 as slight, 0.21 – 0.40 as fair, 0.41 – 0.60 as moderate, 0.61 – 0.80 as substantial, 
and 0.81 – 1.00 as almost perfect agreement (Landis and Koch, 1977) (paper II). 
A linear regression model with robust variance estimation was used to estimate 
differences in the total number of subjective health complaints (SHC) and the total 
SHC score between groups with and without the risk factors (paper IV). 
All p-values were two-sided and values below 0.1 (paper I) and 0.5 (paper II-IV) were 
considered statistically significant. 
3.6 Ethical issues 
Informed consent was obtained from each participant before the study, and the study 
was approved by the Regional Committee for Medical Research Ethics (2009/950). In 
order to keep the blood specimens frozen for a long time for the possibility of follow-
up projects, an approval of «general biobank» was granted (2009/2248). 
Participants wanting information on their laboratory results, 834 in all, were informed 
by letter in 2014, together with a short explanation of the results. 
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4 Summary of results 
4.1 Paper I 
Among the 1,213 participants, 65.7% had experienced tick bites during their life time, 
and 30% had experienced tick bites during the last 12 months. 
Donors from the blood bank in Lærdal reported the lowest occurrence of ticks in their 
living area as well as the lowest number of tick bites, both total and recent. The 
estimated mean total number of tick bites of 1.5 from this area contrasts with 5.6 – 7.2 
from the other locations.  
The number of tick bites increased with age, but there was no gender difference in 
overall analyses. In the younger age-groups, males reported more bites than females. 
In subjects older than 50 years old, this was reversed, with females reporting more 
tick bites than males.  
Adjusted analyses further showed that both recent and total tick bites were more 
common among participants with the highest educational level, increased outdoor 
activity and among hunters and owners of domestic animals.  Daily smokers reported 
fewer total tick bites. 
Among simple medical outcomes of tick bites, the most common occurrence was a 
rash around the bite, reported by 22.7% of the bitten respondents. Joint pain or 
swollen joints was reported by 2.0%, followed by headache (1.0%), fever (0.5%) and 
palsy in the face or elsewhere (0.5%). A total of 12.7% of the bitten persons reported 
to have seen a doctor because of tick bite or consequence thereof, and 7.7% had 
received antibiotics. As most responders reported many bites, these percentages refer 
to the life-time risk of ever having experienced the symptoms after a tick bite, and do 
not reflect the risk after each single bite. 
Avoidance of certain areas because of concern for tick bites was reported by 15.7% of 
1,194 respondents in this study, 22.2% of women and 10.3% of men, respectively 
(p<0.001). There was no significant age difference. 
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4.2 Paper II 
Using the laboratory’s routine method, Enzygnost IgG and IgM, 117 (9.6%) of the 
1,213 sera were positive for IgG and 99 (8.2%) for IgM, totalling 172 subjects 
(14.2%), of which 78 (45.3%) were positive in the IgG blot, and 66 (38.4%) in IgM 
blot. In the C6 assay, 102 sera (8.4%) were positive, of which 70 (68.6%) were 
positive in IgG blot, and 28 (27.5%) in IgM blot. The further data refer to the results 
obtained by the Enzygnost ELISA. 
The relationship between tick bites and seropositivity to Bbsl showed a close 
correlation both for IgG and IgM.  Among the 409 subjects reporting not to have 
experienced any tick bite, 20 (4.9%) were positive for IgG and 22 (5.4%) were 
positive for IgM. There was a close relation between the number of tick bites and 
seropositivity in men. This relationship was less obvious in women. 
Amongst the blood banks, there were fewer IgG positives in Lærdal (p = 0.021), and 
there were more C6 positives in Førde (p = 0.004). 
There was a positive association of IgG-seropositivity with age, and more males than 
females were positive for IgG (13.0% and 5.5%, respectively). There was a delayed 
age-related rise in seroprevalence in women compared to men. 
Cat or dog owners had a significantly lower seropositivity rate for IgG. There were no 
statistical differences regarding educational level, household yearly gross income, 
daily smoking, outdoor hours per week during summertime, hunting during the 
preceding 12 months, orienteering, or ownership of domestic animals.  
Comparing the qualitative results (positive or negative), the two EIA-methods 
showing the highest agreement was Enzygnost IgG and C6, with a kappa value of 
0.654 (CI 0.578 – 0.730), indicating a substantial agreement between these two 
assays. Comparing the combined seropositivity in Enzygnost ELISA (IgG and/or 
IgM) with C6, the kappa value was 0.502 (CI 0.428 – 0.576), indicating moderate 
agreement. There was poor agreement between C6 and isolated IgM, with a kappa 
value of -0.049 (CI -0.077 –  -0.021). 
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Comparing the quantitative results (% of cut-off value), the concordance of positivity 
for IgG and C6 was good at strong reactions in both assays, but there were more 
discrepancies between the two tests in the lower ranges of reactivity. Thus, all IgG 
results stronger than 260% of the cut-off value, corresponding to 36 Units/ml as 
categorised by the manufacturer, were also positive in C6, and conversely, all C6 
results stronger than 465% of the cut-off were positive for IgG. Similarly, we found 
that IgG reactions stronger than 252% of the cut-off (34 U/ml) were positive in IgG 
blot, and for C6 EIA, the corresponding limit was 504%.  
Among the 60 sera with a positive IgG weaker than 260% of the cut-off, 18 (30.0%) 
were positive also in C6. Of these, 11 (61.1%) were positive in IgG blot, while among 
the 42 C6 negatives, only 6 (14.3%) were positive. 
Vice versa, among the 60 sera with a positive C6 weaker than 465% of the cut-off, 33 
(55.0%) were positive also in IgG. Of these, 26 (78.8%) were positive in IgG blot, 
while among the 27 C6 negatives, only 2 (7.4%) were positive. 
IgM only was seen in 55 subjects (4.5%), whereas IgM concomitant with IgG was 
seen in 44 subjects (3.6%). Of these, immunoblot for IgM was positive for 31 (56.4%) 
and 28 (63.6%), respectively. The IgM alone compared to IgM accompanying IgG 
had some distinctions: More women than men had IgM alone (81.4% vs 35.7%, p < 
0.001, Fisher’s exact test), the mean age of the subjects with IgM alone was lower 
(44.5 vs 53.4 years, p < 0.001, Student’s t-test), and IgM alone had no statistically 
significant correlation with the number of tick bites, contrary to IgM accompanying 
IgG (binary logistic regression). 
4.3 Paper III 
4.3.1 Anaplasma phagocytophilum 
A random selection of 301 blood donors were analysed for antibodies to A. 
phagocytophilum. Of these, 49 (16.2%) were positive with titer ≥80 (range 80-1280). 
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We found no association between seropositivity and gender, age, geography (location 
of blood bank), self-reported number of tick bites or presence of antibodies to Bbsl. In 
this subgroup, 192 (63.8%) reported to ever having been bitten by a tick.  Among 
these, 23 (12.0%) had IgG antibodies to Bbsl, 32 (16.7%) to A. phagocytophilum, and 
6 (3.1%) to both agents. The latter group was overrepresented among the 23 persons 
reporting to ever having consulted a doctor after a tick bite (p=0.024), and among the 
12 persons having received antibiotic treatment after a tick bite (p=0.047, Fisher’s 
exact test).  
4.3.2 TBEV 
Among the 1,213 sera tested, five (0.4%) gave positive and one (0.1%) gave grey-
zone results in the ELISA. Among these six subjects, five reported having received 
vaccines that might give positive reactions in the TBE ELISA; two had received 
vaccines against yellow fever, one against Japanese encephalitis (in addition to yellow 
fever), and three against TBE. A positive serum from one subject denying having 
received any of these vaccines, and also denying symptoms of TBE, was further 
examined by neutralising antibodies to TBEV, with negative result. 
4.4 Paper IV 
In this study, there were three variables designated as risk factors; tick bites ever 
experienced, Borrelia IgG and Borrelia IgM, and three outcomes; general function, 
physical fitness and 29 different subjective health complaints.  
The proportion reporting reduced general function did not differ significantly between 
subjects with and without the risk factors. The number of tick bites was positively 
associated with good physical fitness (adjusted p for trend < 0.001). 
For the SHC-questions, we calculated the total number of complaints reported by each 
participant. In addition, a total SHC score was computed as the sum of the severity 
scores of all 29 items in the questionnaire. The proportion of subjects reporting any 
complaint within five subscales are reported as well; these included “musculoskeletal” 
complaints (headache, neck pain, shoulder pain, pain in arms, pain in upper back, low 
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back pain, leg pain, and pain in the feet during exercise), “pseudoneurological” 
complaints (extra heartbeats, heat flushes, sleep problems, tiredness, dizziness, anxiety 
and sadness/depression), “gastrointestinal” complaints (heartburn, stomach discomfort, 
ulcer/non-ulcer dyspepsia, stomach pain, bloating, diarrhoea and constipation), 
“allergic” complaints (asthma, breathing difficulties, eczema, allergies and chest pain) 
and “flu” (cold/flu and cough). 
There were no significant associations between the sum score of “musculoskeletal” 
complaints or the individual related complaints with any of the risk factors. 
For the sum score of “pseudoneurological” complaints, there were fewer complaints in 
the subjects with Borrelia IgG than in those without these antibodies (adjusted p = 
0.010). None of the individual complaints in this group of questions were significantly 
associated with any of the risk factors; still, for all questions there were fewer in the 
group with IgG that reported symptoms than among the IgG negatives. 
In the group “gastrointestinal” complaints, some more subjects with more than one 
tick bite reported ulcer- and non-ulcer dyspepsia , and there was a trend towards more 
IgM positives reporting constipation, but these did not reach statistical significance 
(adjusted p = 0.079 and 0.081, respectively). 
There were no significant associations between the sum score of “allergy” or the 
individual related complaints with any of the risk factors. 
The “flu”-related questions all showed a higher percentage of IgM positives reporting 
symptoms. These associations were weakened when adjusted for gender, age-group 
and blood bank location. 
We found no significant associations between the total number of subjective health 
complaints or the total SHC score and any of the risk factors. There was a negative 
association between positive IgG and number of complaints (p = 0.031), that no longer 
was significant when tested separately for men (p = 0.575) and women (p = 0.140), as 
women as a group had more complaints, whereas more men had positive IgG. 
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5 General discussion 
The topic of this thesis is tick-borne infections in the county of Sogn og Fjordane as 
manifested in a group of healthy adults, represented by blood donors. Methods 
employed included a questionnaire, different laboratory methods to detect antibodies 
to Bbsl, A. phagocytophilum and TBEV, and statistical tools. The results included 
data on tick bites, on laboratory results, and subjective health complaints. 
5.1 Methodological considerations 
5.1.1 Blood donors as representatives of the general population 
Blood donors are not completely representative of the general population. They are 
healthy, and children and persons over 70 years are not represented. As seen in Table 
7, there was a fair distribution regarding gender and age-groups amongst the blood 
donors. The area surrounding the innermost part of the Sognefjord was somewhat 
underrepresented, as were some municipalities distant from the blood banks. 
According to Norwegian blood bank regulations, persons that have been bitten by 
ticks should not donate blood within four weeks of the bite, and persons with 
suspected or verified Lyme borreliosis should not donate until six months after 
adequate treatment has been given. Donors with recent tick bites and/or Lyme 
borreliosis may therefore be underrepresented. Nevertheless, blood donors are widely 
used in medical literature because of the practicalities of obtaining blood specimens, 
informed consent, etc. Furthermore, scientific readers are aware of the shortcomings 
of blood donors as representatives of the general population. 
5.1.2 The county of Sogn og Fjordane as representative of the 
country of Norway 
Both the densitiy of the tick I. ricinus (Tambs-Lyche, 1943; Mehl, 1983; Jore et al., 
2011), the number of borreliosis cases notified to MSIS (Table 6) as well as 
seroprevalence in blood donors in Norway – with 9.6% seropositivity for Borrelia IgG 
in the present study, as opposed to 18 % in the Agder counties (Mygland et al., 2006), 
9.3% in Vestfold, and 0.5% in the three northern counties (Dag Hvidsten, personal 
communication 2016) – indicate that Sogn og Fjordane is representative of coastal 
 76 
areas in southern Norway when it comes to ticks and borreliosis, with a prevalence 
between the southernmost counties and those further north. Also, the data are 
comparable to those from many areas in Sweden (Tjernberg et al., 2007; Dessau et al., 
2011). 
Anaplasma phagocytophilum is probably present wherever I. ricinus is endemic. 
There is reason to believe that the situation in Sogn og Fjordane is equivalent to other 
tick-endemic areas in Norway and Europe (Stuen and Bergström, 2008; Rosef et al., 
2009a). 
The epidemiology of TBE is, however, different from that of borreliosis, and our 
findings, together with data from MSIS, suggest that human TBE is not endemic in 
our county. 
5.1.3 Questionnaire 
The usefulness of questionnaires depends on their reliability and validity. Reliability 
(or consistency) refers to the stability of a measurement scale, i.e. to what extent it 
will give the same results on separate occasions, whereas validity is the degree to 
which a scale measures what it is intended to measure (Bannigan and Watson, 2009).  
The first part of the questionnaire used in the present investigations, i.e. on 
demographics, should be without risk of major systematic errors. The questions on 
number of tick bites ever experienced and experienced during the latest 12 months is, 
however, subject to different sources of error. Firstly, whether or not everybody has 
the same notion of a tick bite is not self-evident.  We cannot exclude the possibility 
that participants report ticks on the body that in fact did not bite, nor can we exclude 
the possibility that some individuals fail to recognise a tick. Adult ticks are large 
enough to be noticed, but they may have bitten in areas of the body not readily 
available for inspection, e.g. in hairy areas, or on the back, etc. The nymphs are very 
small, and may easily be overlooked. Thus, in several reports on clinically verified 
tick-borne infections, only a portion of the patients were able to recall a recent tick 
bite (Berglund et al., 1995; Strle et al., 1999) Thirdly, recollection error must be 
supposed to be present when asking an adult person on the number of tick bites ever 
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experienced. If we compare the number of tick bites reported during the last year and 
the number of tick bites ever experienced by the same person, we see that these 
number do not correspond (paper II). In our adult population, the estimated mean 
number of 1.2 tick bites the latest 12 months does not correspond to the mean 
estimated number of tick bites ever experienced, which was 5.7. 
Also, the awareness of tick bites may vary between persons. Especially, our results 
may indicate that men fail to recognise and/or remember tick bites to a greater extent 
than women, as will be discussed later.  
The questions on physical fitness and reduced general function are taken from other, 
validated questionnaires (Weel et al., 1995; Reiso et al., 2000).  
The questions on the 29 different subjective health complaints, the SHC inventory, 
have shown good validity and reliability in other studies (Eriksen et al., 1999; 
Ihlebaek et al., 2002; Filipkowski et al., 2010). 
Nevertheless, responses to several of the questions are based on the respondents' 
subjective estimations, and the reliability of data must therefore be interpreted with 
caution.   
5.1.4 Statistics 
Most of the data in this thesis are either categorical or ordinal. To make the most of 
the ordinal results, statistical methods for ordinal data were used wherever possible 
(Paper I, II and IV). Proportional odds models are logistic regression models with 
more than two ordinal categorical outcomes (Armstrong et al., 1989; Scott et al., 
1997). By using this method in paper I we avoided dichotomising the outcome 
variable, number of tick bites, which possibly would have led to loss of information 
and decreased statistical power. The method, however, assumes that the odds ratio for 
a risk factor is homogenous for all possible cut-off points of the outcome variable (i.e. 
the proportional odds property). Given the correctness of this homogeneity 
presupposition, the odds ratio can be viewed as a constant and interpreted as the odds 
of being higher or lower on the outcome variable across the entire range of the 
variable. For some data sets with very few participants scoring in some categories, 
 78 
this premise could not be substantiated, and the outcome data had to be dichotomised, 
e.g. for the SHC parameters in paper IV. 
5.1.5 Laboratory methods 
5.1.5.1 Borrelia antibodies (paper II and IV) 
General remarks 
Although serological testing is the primary tool for diagnosing Lyme borreliosis, 
several issues regarding sensitivity, specificity and predictive values are challenging. 
A recent meta-analysis of the diagnostic accuracy of serological tests for Lyme 
borreliosis in Europe by Leeflang and co-workers found that sensitivity was highly 
heterogeneous and varying with the clinical condition. Specificity was around 95 % in 
studies with healthy controls, but around 80 % in cross-sectional studies (Leeflang et 
al., 2016). This may be owing to the fact that different commercial EIA assays show 
differences in results for the detection of IgG and IgM-antibodies to Bbsl (Ang et al., 
2015).  
Sensitivity 
Sensitivity is the proportion of patients with a defined disease that are positive in a 
test for that disease. The sensitivity of antibody testing for Lyme borreliosis is rather 
low in early disease, and increases in later phases. Not all cases of erythema migrans 
give rise to a measurable serologic response, and the development of antibodies may 
also be halted by early antibiotic treatment. On the other hand, almost all cases of 
longstanding infection, e.g. arhtritis and acrodermatititis chronica atrophicans (ACA) 
have positive IgG (Schriefer, 2015). 
Though IgG antibodies may be present for many years after an infection, many 
patients will lose their IgG antibodies to Bbsl after some time. A seroprevalence study 
in healthy people may therefore underestimate the number of persons that have 
endured an infection. 
Traditionally, for most agents, IgM antibodies are indicative of actual infection, and 
this is partly true also for Bbsl.  Measuring IgM antibodies to Bbsl may be helpful in 
early stages of infection, especially in children, and combining IgG and IgM analysis 
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is therefore widely used to increase the sensitivity in early Lyme borreliosis, but is of 
little relevance in a seroprevalence study. 
Specificity 
Specificity in general 
Specificity is defined as the proportion of individuals without a disease that are 
negative in a test for that disease. Thus, false positive reactions in a test lower the 
specificity. Since all donors in the present investigations were healthy, all positive 
tests should be regarded as false positives. There are a number of reasons for false 
positive test results.  
Some of the antigenic properties of molecules in B. burgdorferi are quite similar to 
antigenic structures in other spirochetes, and this may give rise to false positive 
diagnostic tests for Borrelia owing to crossreacting antibodies, e.g. towards the 
syphilis spirochete Treponema pallidum and to apathogenic spirochetes that are part of 
the normal human microflora (Magnarelli et al., 1990). The first generation EIAs for 
Bbsl were prone to such cross reactions, but later test generations show higher 
specificities in this regard (Schriefer, 2015).  
A variety of infectious agents may also trigger polyclonal activation of B-cells into 
producing antibodies to a variety of microbes other than the stimulating agent. Known 
inducers of such polyclonal stimulation include Epstein-Barr virus, cytomegalovirus, 
parvovirus B19, and Mycoplasma pneumoniae (Montes et al., 2007; Landry, 2016). 
Some antibodies may also interact directly or indirectly with components in the test 
itself. One example is rheumatoid factor (RF), typically IgM antibodies directed 
against the Fc portion of IgG antibodies. RF binds to IgG that has bound its antigen or 
is present in immune complexes, but is not reactive with soluble IgG. If a serum that 
contains both RF and anti-Borrelia IgG is allowed to react with the solid phase of the 
EIA test, the Borrelia-specific IgG will bind to the antigens. Thereafter, the RF will 
bind to the IgG. If the test utilises an anti-IgM conjugate antibody to detect IgM, the 
conjugate will bind the RF and thus give a false positive signal. Therefore, in many 
EIA tests, steps are taken to avoid this interference. E.g. in the Enzygnost IgM assay 
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used in this study, the patient serum is pretreated with antibodies from sheep against 
human IgG to generate IgG-immune-complexes. This allows RF to bind to the 
complexes, and RF is thus neutralised and made non-reactive in the ELISA.  Also 
heterophilic antibodies in the patient’s serum – that is antibodies directed against 
immunoglobulins from other animal species – may interfere with the conjugate 
antibody of animal origin, see Figure 12.  
As both Borrelia IgG and IgM antibodies may be detected for a long time after 
infection with Bbsl (Stanek et al., 2012), these antibodies should also be regarded as a 
source of “false positive” reactions in specificity measures. 
Specificity problems in tests for Borrelia IgM 
A positive IgM to Bbsl may indicate an early phase of Lyme borreliosis. On the other 
hand, false positive IgM reactions without relation to Bbsl infection are well known. 
The clinical significance of IgM-antibodies detected in the absence of IgG-antibodies 
in patients suspected of Lyme borreliosis thus represents a continuous dilemma 
(Ulvestad et al., 2001; Panelius et al., 2002).  
In this study (Paper II), we chose to include measurement of IgM antibodies mostly to 
assess how common they are in healthy adults, not to use them as indicators of current 
or earlier infection.  
IgM only was seen in 4.5% of these healthy subjects, whereas IgM concomitant with 
IgG was seen in 3.6%. More than half of both categories were positive in immunoblot 
for IgM.  
As IgM alone, compared to IgM accompanying IgG, was seen more often in younger 
women, and was unrelated to geography and number of tick bites, we suspect that 
these IgM were false positives unrelated to actual or earlier Lyme borreliosis, and that 
they probably were due to cross-reacting antibodies or polyclonal IgM stimulation.  
The time of year for obtaining our specimens (January – June) also points to the same 
conclusion, as this is a period with a relatively low incidence of Lyme borreliosis, but 
with a high incidence of other infections. 
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Repeat specimens to look for the development of specific IgG is often suggested by 
the laboratory to resolve the dilemma of isolated Borrelia IgM. In the absence of 
development of specific IgG during e.g. 6 weeks, an IgM only is generally regarded 
as of little significance. American guidelines thus argue against using IgM blot in the 
second-tier testing when disease duration is longer than one month (Centers for 
Disease Control and Prevention, 1995). Our findings support this view.  
Increasing specificity 
Specificity may be increased by selecting a test giving fewer false positive results, or 
by adding a second test in cases of positivity in the first, the so-called two-tiered test 
algorithm. Western blot and immunoblot are traditionally recommended as this second 
test, but using another EIA than the one used for screening may be an alternative.  
In paper II, we presented both the ELISA result as well as immunoblot results of the 
ELISA positive specimens. We did this to facilitate comparison with other 
Scandinavian laboratories, where immunoblot is seldom used, as well as for 
comparisons with studies presenting results after two-tier testing. In paper IV, we 
used the immunoblot verified results as the risk factors for subjective health 
complaints, in order to avoid the use of unspecific results. 
The C6 ELISA has been reported to be more specific than EIAs with other antigens. 
Wormser et al. (2013) reported a specificity of 99.2% for C6 ELISA in blood donors 
from non-endemic and 98.6% in blood donors from endemic areas for Lyme 
borreliosis in USA, contrasted to 95.9% and 96.5% for a whole cell sonicate ELISA 
for IgG/IgM, respectively.  In endemic areas in Europe, the reported specificities for 
the C6 assay are not as high. Thus, in Italy, the specificity of this assay was 97.6% in 
210 blood donors from a non-endemic area, and 87.5%  in 24 donors from an endemic 
area (Marangoni et al., 2005). High seropositivity rates in blood donors for C6 
antibodies are also found in some Scandinavian laboratories, where 16% and 8% have 
been reported (Tjernberg et al., 2007; Dessau et al., 2011). In this study, we found a 
seroprevalence of 8.4% in the C6 assay, thus giving a specificity of 91.6%, not very 
different from that of Enzygnost IgG (90.4%). The proportions of IgG immunoblot 
positives were comparable between the two assays, 63.2% and 68.6%, respectively. 
 82 
The main difference seems to be that the C6 ELISA did not detect the isolated IgM’s 
found in the Enzygnost assay, even though the C6 assay detects IgM as well as IgG 
antibodies.  
It has been suggested that C6 antibodies tend to normalise after the clinical infection 
has resolved (Philipp et al., 2003; Philipp et al., 2005; Tjernberg et al., 2007), but 
others dispute this (Peltomaa et al., 2003; Fleming et al., 2004). Our findings of a 
relatively high prevalence of C6 antibodies in this healthy population support the 
latter view.  
Immunoblots increase the specificity, but lower the sensitivity somewhat in early 
phases of infection (Aguero-Rosenfeld and Wormser, 2015). It is recognised that also 
immunoblot for IgM is prone to false positive reactions (Goossens et al., 1999; 
Seriburi et al., 2012). E.g. antibodies not specific for Bbsl may bind to the OspC 
antigen in the strip (Probst et al., 2012). The company Euroimmun AG has recently 
released a new immunoblot test, the “EUROLINE-RN-AT-adv” which includes a new 
formulation of the OspC antigen, and this test has been claimed to be 30% more 
specific than the one used in this study, the “EUROLINE-RN-AT”.  
Comparing tests 
In 89 patients, among them 59 with suspected Lyme borreliosis, Ang et al. (Ang et al., 
2011) found a kappa value of 0.86 when comparing the Enzygnost IgG and/or IgM 
with C6 ELISA. This was a better agreement than the 0.502 found in our study. They 
also found a higher proportion of Enzygnost IgG and/or IgM and C6 positives being 
positive in blot (83%-100% and 77%-100%, respectively) than we did (60.6%, data 
not shown).  The reasons for these discrepancies are unknown, but may be related to 
differences in groups of individuals tested, as our study only included asymptomatic, 
healthy individuals. 
In clinical practice, the  magnitude of optical density values in ELISA tests are often 
used as a quantitative interpretation of results, in addition to the categorisations into 
positive versus negative. The rationale for this is partly that specificity is thought to 
be higher for strongly reactive specimens than for weakly reactive. In Figure 15, we 
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see that the concordance of positivity for Enzygnost IgG and C6 was good at strong 
reactions in both assays, and that there were more discrepancies between the two tests 
in the lower ranges of reactivity. These results indicate that strong IgG responses in 
Enzygnost do not have to be verified by C6 or blot, as one can presume that they are 
positive. Ang et al. (2011) similarly found a good correspondence between the 
strength of the reactions in C6 and blot in patients, in that almost all samples stronger 
than 400% of the cut-off in C6 also were positive in blots. However, this 
correspondence was not as good for another EIA (Vidas), indicating that this 
relationship should be investigated for each assay separately. 
Among sera with a positive Enzygnost IgG weaker than 300% of the cut-off, one third 
were positive also in C6. Most of these were positive in IgG blot, while among the C6 
negatives, only a few were positive. Using C6 as a second-tier test in weak positive 





Figure 15.  Relationship between quantitative results of Borrelia 
antibodies in Enzygnost IgG and C6 ELISA (n = 1,213)  
The X-axis represents Enzygnost IgG reactivity, while the Y-axis represents C6 
reactivity, both in percentage of cut-off. The vertical and horizontal lines mark the 
boundary between negative and grey-zone results for the two tests, at 64% and 90% of 
the cut-off value, respectively. Note the linear scale of both axes, in paper II the same 
figure is presented with logarithmic scales. 
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Positive and negative predictive values 
In endemic areas for Lyme borreliosis, the positive and negative predictive values of 
test results are important factors for the overall evaluation of patients suspected of 
suffering from an actual, symptomatic Lyme borreliosis.  
The positive predictive value (PPV) is defined as the probability that a positive test 
result reflects that a patient suffers from the disease in question. In addition to the test 
characteristics of sensitivity and specificity, the PPV also takes into consideration the 
prevalence of the disease in the patient group (Altman and Bland, 1994).  
 
Vice versa; the negative predictive value (NPV) is the probability that a negative test 
result reflects that the patient does not suffer from the disease. 
 
For a specific patient, the prevalence in these equations may be exchanged by the pre-
test probability, i.e. the chance that the history and clinical picture at hand is caused 
by the actual disease. This pre-test probability will be high when there is a typical 
history of preceding tick bite and typical LB clinical manifestations. On the other 
hand, if the history and clinical picture is less typical, the pre-test probability is lower. 
As depicted in Figure 17 (page 90), the seroprevalence was highest in the older age-
groups in this healthy population. The test for IgG thus has a lower specificity in these 
groups, reducing its positive predictive value for elderly patients in our geographical 
area. The evaluation of the pre-test probability is therefore of utmost importance when 
applying the test in a clinical situation. E.g., the clinical information “chronic fatigue” 
and “musculoskeletal symptoms”, relatively common conditions in elderly and 
comparatively seldom caused by Borrelia, are frequently stated reasons for testing in 
our laboratory. Combined with low specificity, the resulting predictive value of the 
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test is very low. Thus, Dessau et al. (2010) in Denmark found that among sera 
submitted from persons with suspected Lyme arthritis, a relatively rare disease in 
Scandinavia, the rate of seropositivity did not exceed the background prevalence for 
Danish blood donors.  
Consequences for diagnostic algorithms in the laboratory 
A test algorithm that reduces the positivity rate in normal individuals while still 
detecting a maximum of clinical cases would be preferable. As our data reflect normal 
individuals only, constructing an algorithm for clinical situations based on these data is 
not possible. Nevertheless, our data do suggest that a two-tiered test strategy using 
only Enzygnost IgG or C6 as screening could eliminate the problem of probably 
unspecific solitary IgM results.  A positive screening test should be followed by testing 
for IgM, and for weak positives also the other ELISA (C6 or IgG as appropriate). 
Including IgM ELISA in the second-tier test would give some information on whether 
the infection is recent. Immunoblot could be reserved for weak positive isolated C6 or 
IgG in clinically suspect cases. The algorithm would miss cases with isolated IgM as a 
single early finding. An option could be to include IgM in the screening for selected 
patients with a short clinical history. Follow-up test after some weeks in case of 
negative screening test would be sensible if clinical suspicion is still present. In 
children, a screening including IgM seems prudent. 
Conclusion – Borrelia antibodies 
Enzygnost IgG and C6 ELISA were comparable in this group of blood donors, and 
specimens strongly reactive in Enzygnost IgG and C6 were all positive in immunoblot 
for IgG.  False positive IgM results, including immunoblot positive, seem to be a 
challenge. The findings may help laboratories in developing prudent testing 
algorithms and in assessing predictive values of testing for these antibodies. 
5.1.5.2 Antibodies to Anaplasma phagocytophilum (paper III) 
For epidemiological purposes like in this study, a cut-off in the IFA test of 1:64 or 
1:80 is widely used. However, as discussed by several authors (Aguero-Rosenfeld et 
al., 2002; Walder et al., 2003), this may be set too low, as a significant proportion of 
adults and children without clinical evidence of human granulocytic anaplasmosis 
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(HGA) will test positive for A. phagocytophilum antibodies when these cut-offs are 
used. Thus, Walder and co-workers in Austria chose a cut-off of 1:128, the 98th 
percentile of a control population with low likelihood of having had HGA (Walder et 
al., 2003). In this study (paper III), we have therefore listed the titers of the positive 
reactions, in order to assess the seroprevalence critically. 
5.1.5.3 Antibodies to TBEV (paper III) 
For testing immunity after TBEV infection or after vaccination, most often the IgG 
ELISA is used. Due to the interference of flavivirus cross-reactive antibodies in 
ELISA (e.g. following vaccinations against yellow fever or Japanese encephalitis, or 
upon dengue virus infections), the performance of a neutralisation assay is necessary 
for assessing positive tests (Holzmann, 2003). Therefore, questions on vaccination 
data for TBE vaccine and other potentially cross-reacting vaccines were included in 
the questionnaire in this study, and this explained five of the six non-negative 
reactions in this cohort. The last specimen was negative in a neutralisation assay. 
5.2 Epidemiological results– tick bites and Borrelia 
antibodies (paper I and II) 
5.2.1 The relationship between tick bites and seropositivity for 
Borrelia burgdorferi 
As expected, we found a close correlation between the number of tick bites and the 
seropositivity rate for both IgG (Figure 18) and IgM. The seropositivity rate was lower 
in women, and the relationship to the self-reported number of tick bites was less 
obvious in women than in men. This discrepancy will be discussed further below. 
5.2.2 Geography (paper I and II) 
5.2.2.1 Europe and USA 
Comparing our results with studies from other countries, we found that a lower 
percentage of the population has experienced tick bites than in Åland (Wahlberg, 
1990), 66% as contrasted to 85% . On the other hand, a survey in Alsace, France, 
found that only 16.5% of the general population had experienced one or more tick 
bites during the last year (Mitschler et al., 2004), which is lower than reported in our 
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study (30%). Also Leiby and co-workers’ findings from Connecticut and Wisconsin 
indicated a lower frequency of tick bites in blood donors than we found (Leiby et al., 
2002). Explanations for these differences may include variations in tick abundance, 
general awareness of ticks, and outdoor and recreational habits in the respective 
populations. 
Studies from the Netherlands and Belgium showed an uneven geographical 
distribution of tick bites (de Mik et al., 1997; den Boon et al., 2004; Vanthomme et 
al., 2012). Difference in test populations (patients in general practice versus blood 
donors) precludes any direct comparison with our findings, other than stating that 
local geographical differences are important risk factors for tick bites.  
5.2.2.2 Norway and Sogn og Fjordane county 
A recent serological survey of Borrelia antibodies in 9 Norwegian counties found a 
seroprevalence of Borrelia IgG of 4.0% (95% CI: 2.4–6.6%) when using the 
Enzygnost Lyme link vlsE test on sera submitted for clinical chemistry (Vestrheim et 
al., 2016). The seroprevalence varied by geography and increased by age. For the 120 
sera from Sogn og Fjordane the same study found that 3 (2.5%) were positive, giving 
an estimated seroprevalence of 3.6% (CI 2.1-5.9). This prevalence is lower than the 
9.6% found in paper II, and Vestrheim et al. (2016) speculate that healthy blood 
donors might have a more active life-style with a higher risk of exposure to ticks and 
Borrelia than persons who have blood drawn for purposes of clinical chemistry 
analyses. 
In accordance with current estimates of tick distribution as well as the variation in 
notified cases of systemic borreliosis within the county, blood donors from the 
easternmost blood bank of Lærdal reported a significantly lower number of tick bites 
than those from the other blood banks. Although entirely based on their subjective 
estimate, the respondents from this blood bank also reported a correspondingly low 
occurrence of ticks in their living area. As expected, we also found the seroprevalence 
of IgG antibodies to Bbsl to be lower in these donors.  
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The difference in IgM was, however, not significant (p = 0.268) between the different 
locations, and for isolated IgM especially, there was no difference whatsoever (p = 
1.000). Why the donors from the blood bank in Førde had more positive reactions in 
C6 than the others is difficult to explain, as Nordfjordeid had the highest 
seropositivity rate for IgG.  
5.2.3 Age and gender (paper I and II) 
As expected, we found a significant age related trend in reported total tick bites ever 
experienced. The somewhat lower reported number in the oldest group from 60-69 
years may be related to sampling variation, a cohort effect in the oldest group 
reflecting a change in outdoor habits in the general population, or an increased density 
of ticks during the last decades. The same age trend was also present for recent tick 
bites (paper I). There was also a positive correlation between seroprevalence of IgG 
and age, see Figure 17 (Paper II). 
For IgG, we found a significant difference in gender; men had a higher seroprevalence 
than women. This is not fully in accordance with self-reported tick bites, where no 
statistically significant difference between the genders across all age-groups was 
found. This lack of consistency may be caused by differences in subjective awareness 
of tick bites between the genders, leading both to reporting less bites and not taking 
precautions in timely removal of ticks in men. The findings by Wilhelmsson and co-
workers (2013), that the size of removed ticks was bigger in men than women, 
indicating that the tick had been feeding for a longer time, may support this view. 
Male dominance regarding Borrelia IgG antibodies has also been reported by others 
(Dehnert et al., 2012), but not universally (Hubalek, 2009) (paper II).  
Looking at age and gender combined, we note that the seroprevalence in women rises 
at an older age than in men, see Figure 17 (Paper II).  This may be in accordance with 
the age distribution of reported tick bites, as young men reported more bites than 
young women, while this was reversed in subjects older than 50 years of age (paper 
I).  The steep rise in prevalence of IgM accompanying IgG in elderly women may also 
be in accordance with the self-reported increase in tick bites in this group. Also, 
women reported more tick bites before seroconversion, see Figure 18. 
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In accordance with our findings, a number of studies have shown that women past the 
age of 40-50 years display an idiosyncratic Borrelia epidemiology. Bennett and co-
workers (2007) found that women aged 40 years or older had a higher risk than men 
in the same age-group for contracting tick bites, and also higher than younger women. 
A similar tendency is also apparent in our study for women 50 years or older (Figure 
16). A plausible hypothesis for the increased risk in middle-aged women could be the 
traditional but now declining custom of picking wild berries (e. g. blueberries, 
cloudberries, lingonberries) for the household, that shows a similar distribution in age 
and gender (Vaage, 2004). Unfortunately, questions on berry picking were not 
included in the questionnaire. Other hypotheses could be related to other behavioural 
or biological aspects of postmenopausal women, as discussed by Bennett and co-
workers (2007).  
Several studies have found gender differences in clinical manifestations of Lyme 
borreliosis, and there is some evidence that immunologic differences between men 
and women may be relevant in this disease (Jarefors et al., 2006; Bennet et al., 2007; 
Strle et al., 2013). Also, our finding of more isolated, probably nonspecific, Borrelia 
IgM antibodies in younger women (paper II), indicates differences in immunological 
characteristics.  
 
 Figure 16. Estimated number tick bites the preceding 12 months 










Figure 17. Prevalence of Borrelia IgG (Enzygnost) according to gender and 
age group (n = 1,183) 
Figure 18. Occurrence of Borrelia IgG-antibodies in relation to  reported 
number of tick bites ever experienced (n = 1,171) 
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5.2.4 Lifestyle factors (paper I and II) 
We found that tick bites were more common among participants with the highest 
educational level (paper I). This is in accordance with observed life style differences 
in other studies (Vaage, 2004). We found no relation between risk of tick bites and 
household yearly gross income.  
After adjustment for gender, age and blood bank, daily smoking seemed to protect 
against tick bites (p = 0.007), but after statistical correction also for outdoor hours per 
week, this association was no longer significant (p = 0.017) (paper I) according to the 
significance level chosen in this study. 
As expected, the number of outdoor hours per week during summertime showed a 
significant relationship to the risk of tick bites. The estimated mean number of tick 
bites the preceding year increased from 0.5 in those spending less than 5 hours 
outdoors per week, to 1.7 in subjects spending more than 10 hours. This is in 
accordance with Stjernberg and Berglund’s findings of a 4% risk of being tick-bitten 
per 10 hours spent outdoors in an endemic area in Sweden (Stjernberg and Berglund, 
2002) (paper I).  
Outdoor activities are in general regarded as positive for public health and quality of 
life, and it would be a concern if the population chose to avoid certain recreational 
outdoor areas in fear of tick bites. In our study, 15.7% reported such avoidance. 
Whether this is a sensible approach is difficult to ascertain. The marked gender 
difference, with avoidance-behaviour being twice as common in women as compared 
to men, is not easy to explain. It may reflect a general gender difference in risk 
avoidance (paper I). 
The number of total and recent tick bites in this study population increased also with 
educational level, ownership of domestic animals, and hunting (paper I). Although we 
found an overall positive relationship of seropositivity of IgG to the number of tick 
bites, the other associations mentioned above were not reflected in IgG 
seroprevalence (paper II).  Interestingly, we found a lower seroprevalence in owners 
of pet animals (cats or dogs), although this group reported some more tick bites. This 
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is in contrast to the findings of Dehnert et al. (2012), who in Germany found a higher 
seroprevalence in children and adolescents from households with cats. 
Hunting, especially for deer, is a common leisure activity in Sogn og Fjordane, and 
19.7% of the respondents had been hunting during the preceding 12 months. We 
found an increased risk of tick bites in this group, even after adjustment for “hours 
spent outdoors per week in summertime”. This question does not discriminate 
between tick-infested and non-infested outdoor areas, and there is reason to believe 
that the increased risk in hunters reflects their activity in tick habitats. 
Among our respondents, 65 (5.5%) reported to have been active orienteers. A Swiss 
study published in 1991 found that 78% of 995 orienteers had experienced at least one 
tick bite (Fahrer et al., 1991). In our material, that was the case for 92.3%. A Swedish 
study found that 53% of Swedish orienteers were bitten by ticks in one year 
(Gustafson et al., 1993), and we found a similar rate of 53.8%. We found that 
orienteers reported more tick bites than non-orienteers, but this association was not 
statistically significant at the chosen significance level of 0.01, possibly due to small 
numbers. 
5.2.5 Disease (paper I, II and III) 
This study was on healthy blood donors, and little emphasis has been given to disease. 
Some simple questions on symptoms after tick bites were included in the 
questionnaire, and these scores have been correlated to data on tick bites and 
laboratory results. 
Several reports have investigated the risk for developing disease after a single tick 
bite, and most of them find the risk to be low (Shapiro et al., 1992; Maiwald et al., 
1998; Nadelman et al., 2001; Stjernberg and Berglund, 2002; Nahimana et al., 2004; 
Jacobs et al., 2008; Fryland et al., 2011). 
Wahlberg (Wahlberg, 1990) found that out of 441 bitten subjects, 14 reported ever 
having had erythema chronicum migrans and 73 had had other rashes around the tick 
bite, all together 19.7%.  In our material, we found a similar frequency of “rash” of 
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22.7%. We did not try to discern between erythema migrans and other rashes, as we 
believe that to be an error-prone task in a retrospective questionnaire survey.  
The overrepresentation of subjects with IgG antibodies both to A. phagocytophilum 
and Bbsl among those having seen a doctor after a tick bite and among those having 
received antibiotic treatment, is an interesting observation.  Because of low numbers, 
this result should be interpreted with caution. 
5.3 Anaplasma phagocytophilum (paper III) 
Uncertainty of the proper cut-off as well as the possibility of serological cross-
reactions may complicate the judgement of IFA results.  
Surveys of antibodies to A. phagocytophilum among blood donors using the IFA have 
found seroprevalences of 11.3% (18/159) among Borrelia blot negative donors in 
Westchester county, New York, using a cut-off of ≥80, 0.5% (5/992) in Wisconsin and 
3.5% (35/992) in Connecticut, USA (cut-off ≥64) (Leiby et al., 2002), and 9.0% 
(32/357) in Tyrol, Austria (cut-off ≥128) (Walder et al., 2003). In Denmark, 
Skarphedinsson and co-workers (2001) found that 2 out of 100 blood donors from 
Odense, Denmark and 5 out of 100 blood donors from Iceland were positive (cut-off 
≥64).  
In a survey of blood samples from patients with physician-diagnosed Lyme borreliosis 
in the county of Telemark in southern Norway, 10.2% (6/58) were positive in IFA 
(≥80, range 1:80 – 1:160) (Bakken et al., 1996). Dumler and co-workers (1997) found 
that 11.4% (21/185) of inhabitants at the island of Koster at the western coast of 
Sweden were positive (≥80), whereas Wittesjö and co-workers (2001) found a 
seroprevalence of up to 28% in inhabitants in Aspö island at the Baltic sea coast of 
Sweden. In Denmark, 21.0% (63/300) of sera from patients clinically suspected of 
having Lyme borreliosis were positive for antibodies to A. phagocytophilum 
(Skarphedinsson et al., 2001). 
Compared to these studies, the seroprevalence of 16.2 % in our material was relatively 
high. As discussed above, this may represent an over-estimate, but the selected cut-off 
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allows for the comparison. To my knowledge, no clinical cases of HGA have been 
diagnosed in Sogn og Fjordane. 
In conclusion, this study indicates that A. phagocytophilum is a potential pathogen for 
humans in Sogn og Fjordane, and should be taken into consideration when dealing 
with suspected tick-borne disease with compatible clinical picture. 
5.4 Tick-borne encephalitis (paper III) 
Traavik and co-workers found evidence of tick-borne encephalitis-like virus in the 
western counties of Sogn og Fjordane and Hordaland in studies of animals and humans 
in the 1970s (Traavik, 1973; Traavik et al., 1978; Traavik, 1979). However, there is 
evidence that these findings represented other flaviviruses (Gao et al., 1993; Haglund, 
2002). The serological methods used at the time, haemagglutination inhibition (HAI) 
and gel diffusion, were probably not specific for TBEV, and the positive results 
probably reflect infection with one or more related viruses. Traavik and co-workers 
reported a seropositivity rate for humans in HAI of 19.6%. In contrast, in the present 
study, we found no true positive non-TBE-vaccinated cases, as all but one could be 
explained by vaccines giving cross-reacting antibodies, the only exception being 
negative in neutralisation test. Thus, current ELISA tests seem to be more specific than 
former tests, and the study results give no evidence for the existence of TBE in 
humans in Sogn og Fjordane. 
Our negative findings are in accordance with the known current distribution of TBE 
in Norway (Blystad et al., 2009). In contrast, Skarpaas and co-workers found that 3 
out of 126 (2.4%) inhabitants of Tromøy in Aust-Agder county at the southernmost 
coastline of Norway were seropositive (Skarpaas et al., 2002).  A study from Sweden 
found a seropositivity rate of 4-22% in non-immunised participants, depending on the 
area investigated (Gustafson, 1994). The same study reported that in 362 orienteers 
from the county of Stockholm, 1% of the individuals were seropositive. Among the 
65 subjects reporting to ever having been orienteers in our material, none were 
positive. 
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5.5 Subjective health complaints in relation to tick bites and 
Borrelia antibodies (paper IV) 
The main findings in this study was the lack of association between the risk factors 
tick bites and Borrelia antibodies with the outcomes subjective health complaints, 
reduced general function and reduced physical fitness.  On the contrary, we found a 
positive association between tick bites and good physical fitness, and between 
presence of Borrelia IgG and low occurrence of “pseudoneurological” complaints. For 
most complaints, we found no association. 
The risk factor “number of tick bites” was included in this study to explore the 
possibility that seronegative LB or other tick-borne infectious agents not tested for, 
e.g. Rickettsia spp., etc., could give rise to chronic health problems of some 
magnitude.  
IgG and IgM antibodies to Bbsl verified by blot were chosen as risk factors in this 
study in order to minimise the risk of including false positive ELISA results.  
In several studies of symptoms after LB, the Medical Outcomes Study 36-Item Short-
Form Health Survey (SF-36) has been used (Shadick et al., 1994; Shadick et al., 1999; 
Seltzer et al., 2000; Eikeland et al., 2011). In addition, several questionnaires for 
assessing somatic symptoms in the general population exist (Zijlema et al., 2013). We 
are not aware of other studies using the SHC Inventory in blood donors in relation to 
LB. 
Compared to other surveys using the SHC Inventory in the general population, 
summarised by Eriksen et al. (1999), and for a working population more recently by 
Ihlebæk and co-workers (2007), the proportion of subjects with any complaint were 
lower in our material for most complaints, reflecting the overall healthy status of the 
blood donors. 
Comparing our results to those of other studies is not straight forward, for two main 
reasons. Firstly, the selection of study population differs between studies, e.g. blood 
donors, subjects having been bitten by ticks, patients having suffered from LB, 
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patients having suffered from LNB, etc. Secondly, the choice of questionnaire also 
varies.  
According to alternative views on LB, there are many undiagnosed patients with 
nonspecific chronic symptoms attributable to the disease (Cameron et al., 2004). 
Among the listed symptoms, some are included in the SHC inventory. The prevalence 
of these was not significantly higher for any of the risk factors tick bites, IgG or IgM 
in our study. A number of symptoms are not explicitly included in the SHC inventory.  
If these symptoms were of any significance in our study population, it should be 
reflected in the score on “reduced general function” in subjects with the risk factors. 
This was, however, not the case. 
The clear correlation between the number of tick bites and physical fitness is not 
surprising. Persons more exposed to ticks are presumably more involved in outdoors 
activities such as hiking and hunting, and are in a generally good physical condition. 
The negative association of “pseudoneurological” complaints and Bbsl IgG antibodies, 
but not number of tick bites or IgM, is difficult to explain. Also here, a spurious 
relationship connected to confounding lifestyle factors can be suspected. 
The strength of this study is the relatively large representation of healthy subjects from 
Sogn og Fjordane county, the good response rate, and the frequent occurrence of tick 
bites and seropositivity to Bbsl, as well as the scope of the questionnaire, covering a 
broad range of health complaints.  Thus, major chronic health effects of tick bites and 
seropositivity to Bbsl should have been detected. 
It is to be expected that persons with significant chronic health problems do not 
volunteer as blood donors, or will be excluded. Persons of this category are therefore 
likely underrepresented in this material. Still, given the commonness of these “soft” 
symptoms also in blood donors, one would expect that mild degrees of such 




A majority of blood donors in the western part of Norway had experienced tick bites. 
Age, gender, outdoor activities, animal contact and geography affected the risk. 
Symptoms of disease were seldom reported. 
We have shown that seropositivity to B. burgdorferi s.l. was common in healthy blood 
donors in western Norway.  The seroprevalence of IgG increased with age, male 
gender and number of tick bites. Owners of cats or dogs had a lower prevalence.  
Enzygnost IgG and C6 ELISA were comparable in this group of blood donors, and 
specimens strongly reactive in either of these tests were all positive in immunoblot for 
IgG.  False positive IgM results, including immunoblot positive, seem to be a 
challenge. The findings may help laboratories to develop prudent testing algorithms 
and in assessing predictive values of testing. 
We found no evidence of tick-borne encephalitis as an endemic disease in the county 
of Sogn og Fjordane. There was, however, serological evidence for the existence of 
human granulocytic anaplasmosis, indicating that clinicians should be aware of this 
condition in the diagnostic considerations after tick bites in this geographic area. 
There was no association between number of tick bites or seropositivity to B. 
burgdorferi s.l. and more subjective health complaints, reduced general function or 
reduced physical fitness.  
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7 Future perspectives 
Many unsolved questions remain in the field of tick-borne infections, both world-wide 
and locally in Norway and Sogn og Fjordane. 
In view of the findings in this thesis, a re-examination of the same blood donors for 
Borrelia antibodies after some years would be interesting, to elucidate the normal 
timely development of the antibody response, including probably false positive IgMs. 
Likewise, one would get an estimate of newly seroconverted persons. 
Also, it would be of interest to examine the specimens for tick-borne agents not 
performed in this thesis; e.g. Babesia spp., B. myiamotoi, N. mikurensis, and R. 
helvetica. 
Likewise, testing of selected samples for potentially cross-reacting antibodies, 
especially for Borrelia IgM positive samples, would be of interest, to learn more about 
this diagnostic caveat. This could be autoantibodies of different kinds, as well as 
antibodies to different microorganisms, e.g., Mycoplasma antibodies. 
Testing the blood donors for other possible immunological factors, e.g. blood group 
antigens or HLA types, could possibly help elucidate differences in immunological 
response to B. burgdorferi. 
As TBEV seems not yet to be established in Sogn og Fjordane county, our results may 
serve as a reference for later seroepidemiological studies some further years ahead, as 
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a  b s  t  r  a  c t
The frequency  of  tick bites, risk  factors,  as  well  as  simple  outcome  measures  after tick bites  in a healthy
adult population  (blood  donors)  from  Sogn and Fjordane  county  situated  at the western  coast  of Norway,
was assessed.  The study  was based on  cross-sectional  data  from  blood  donors  at 4 different blood  banks
in the  county  during  the  period January  to  June 2010. Data  on  tick  bites  and potential  risk  factors  were
collected from  1213 blood donors using  a  questionnaire.  Among participants,  65.7%  had experienced
tick bites  during  their  life time,  whereas  30%  reported  recent  tick  bites  (during the latest 12 months).
There were  fewer  tick bites  in the eastern,  inland  part  of the county,  where the tick  Ixodes  ricinus  is  less
prevalent compared  to  the western,  coastal regions.  The number  of total  and recent tick  bites  increased
with the respondent’s age,  hours spent  outdoors  during  summertime,  educational  level,  ownership  of
domestic animals,  and  hunting.  Women  older  than  50  years  reported more bites  than  similarly aged  men
and younger  females.
Among  bitten  subjects,  22.7%  reported  ever  having had a rash  around  a tick bite,  whereas  12.7%  had
seen a medical  doctor  and  7.7%  had received  antibiotics  owing  to  tick  bite. Avoiding  certain locations
owing to  a  fear of tick  bites  was reported by 15.7% of all  respondents,  more women  than  men.
In conclusion,  tick  bites  are common in the  western  part  of Norway. The risk  of being  bitten  varies  with
age and  outdoor  activities,  animal contact,  and geography.  The consequences  in terms  of disease  seem
modest.
© 2013 Elsevier GmbH. All rights reserved.
Introduction
Ixodes ricinus,  the predominating tick species in Norway, is
present in coastal areas with its highest abundance along the south-
ernmost coast. In earlier studies, its northern distribution limit
was estimated to approximately 66◦ N (Tambs-Lyche, 1943; Mehl,
1983). Recent data indicate that the latitudinal and altitudinal bor-
ders for I. ricinus in Norway are  expanding and that the tick now is
present as far north as 69◦ N (Jore et al., 2011).
Human tick-borne diseases in Norway are dominated by Lyme
borreliosis, with a distribution corresponding to that of I.  ricinus,
with the highest incidence along the southern coastline. Cases
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of  systemic disease and  chronic manifestations of Lyme borre-
liosis are notifiable to the Norwegian Surveillance System for
Communicable Diseases (MSIS), i.e., erythema migrans alone is
not reported. In  the period of 2001–2010, the mean reported
annual national incidence was  5.3  cases per 100,000 inhabi-
tants, with 14.1 in Sogn and Fjordane, compared to 26.1 in the
southernmost county of Vest-Agder (http://www.msis.no/). Bor-
relia burgdorferi sensu lato has been detected in host-seeking I.
ricinus ticks in 22.1–31.3% of  nymphs and adults in the south-
ernmost part of Norway (Kjelland et al., 2010). In  Sogn and
Fjordane county, B. burgdorferi s.l.  has been demonstrated in
12.0% and 3.5% of ticks at 2 different locations (Olav Rosef,
personal communication). Tick-borne encephalitis has recently
been detected along the southern coastline of Norway (Skarpaas
et al., 2004; Andreassen et al., 2012). The incidence of human
granulocytic anaplasmosis is not known, but 2 cases have been
described so far (Kristiansen et al., 2001),  and serological evi-
dence for human infection has been demonstrated (Bakken et al.,
1996).
1877-959X/$ – see front matter ©  2013 Elsevier GmbH. All rights reserved.
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Fig. 1. Norway with the county of  Sogn and Fjordane (shaded). The localization
of the 4 blood banks are indicated by  numbers. 1: Førde, 2:  Florø, 3: Lærdal, 4:
Nordfjordeid. Map  source: Norwegian Map Authority.
Sogn and Fjordane county, located at the western coast
of Norway, encompasses coastal, fjord, and mountainous areas
at 61–62◦ N and 5–8◦ E; it stretches from the coast nearly
200 km eastwards (Fig. 1). The climate is temperate, with a
high yearly rain fall in the western and middle areas, but
with a more inland-like climate in the eastern part, with
less precipitation and lower winter temperatures. Ticks  are
prevalent in the coastal areas and along the fjords and  neigh-
bouring valleys, up to about 400 m above sea level, but less
so in the eastern parts (Jore et al., 2011). This distribu-
tion is reflected in the skewed incidence within the county
of notified cases of disseminated Lyme borreliosis in humans
(http://www.msis.no/).
The literature on occurrence and risk factors for tick bites in the
general population is sparse. Two surveys from the Netherlands
demonstrated marked geographical differences in the occur-
rence of tick bites, and the incidence seemed to double from
1994 to 2001 (de Mik  et al., 1997; den Boon et al., 2004). A
recent Belgian investigation likewise demonstrated local geo-
graphical differences (Vanthomme et al., 2012). In a study from
the island of Åland in Finland, 85% of  the general population
more than 8 years old reported having been bitten by  ticks
(Wahlberg, 1990), and in Sweden, Stjernberg and Berglund (2002)
found a 4% risk of being tick-bitten per 10 h spent outdoors.
Another Swedish study found an increased risk of contracting tick
bites in women more than 40 years old (Bennet et al., 2007).
In Connecticut and Wisconsin, 4.1% of blood donors reported
having been bitten by  ticks during 6 months (Leiby et al.,
2002).
In the present study, we wanted to assess the frequency of tick
bites in a healthy adult population (blood donors) from Sogn and
Fjordane with regard to demographics and other risk factors. We
also wanted to assess the frequency of  symptoms following tick
bites, visits to a medical doctor and  antibiotic treatment, as  well as
to estimate whether tick occurrence leads to avoidance of  outdoor
activities in certain areas.
Materials and methods
The  Helse Førde Hospital Trust has 4 blood banks in Sogn and
Fjordane county (Fig.  1). One is situated at the western coast (Florø),
2 by fjords somewhat further east (Førde and Nordfjordeid), and
one is located in the easternmost part of the county (Lærdal). Dur-
ing the period January 13th to June 15th 2010, blood donors at the
4 blood banks were asked to participate in the Tick-borne Infection
Study in Sogn and Fjordane. A total of 1213 blood donors partic-
ipated, a response rate of 76%. Owing to practical circumstances
at the blood bank in Lærdal, with its several different small sites
for donation, the response rate at that blood bank was only 39%.
Informed consent was  obtained from each participant before the
study, and the study was  approved by the Regional Committee for
Medical Research Ethics. The study included a  questionnaire as  well
as serum samples for antibodies to Borrelia burgdorferi sensu lato,
tick-borne encephalitis virus, and Anaplasma phagocytophilum, the
results of which are to be published separately.
Questionnaire
The questionnaire included questions on demographics such
as gender, age, marital status, education, household income, and
occupation. Questions on pet animals, farm animals, hours spent
outdoors during summertime, hunting, orienteering, smoking, and
symptoms and treatment after tick bites were also included. A sec-
tion of the questionnaire related to subjective health complaints,
to be published separately.
The questionnaires were answered anonymously, and most
were completed during the time spent at the blood bank for rou-
tine donation. The characteristics of the participants are presented
in Table 1.
Table 1
Characteristics of the  1213 participants in  the Tick-borne Infection Study in  Sogn
and Fjordane, 2010.

















Married or cohabitants 1014 84.3
Education
Primary school 9  years or less 87 7.2
Secondary school 598 49.8
University/college 1–4 years. 342 28.5
University/college >4 years 175 14.6








a Because of  missing data, not all numbers total the number of  participants
(n =  1213).
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Outcome
The main outcomes of this study are the reported number of tick
bites ever experienced (referred to as “total”), and  tick bites expe-
rienced during the preceding 12 months (referred to as “recent”).
“Recent bites” are thus included in “total bites”, and  the responses
for both questions were given in the categories “none”, “one”, “2–5”,
“6–20”, and “more than 20”. The estimated mean numbers of tick
bites were calculated as the weighted averages of the midpoints of
these categories, weighted by their relative frequencies. The cat-
egory “more than 20” was  assigned a  value of 30.  The  resulting
numbers are presented for ease of perception only; the original
categorical data were used for statistical analyses.
Risk factors
Risk factors were reported as continuous (age) and categorical
(educational level, gross household income, hours spent outdoor
during summertime). Responses on questions on daily smoking,
hunting, orienteering, pet animals, domestic animals, doctor visits,
and avoidance of certain areas were given as yes or no.
Statistical analysis
We  used PASW Statistic for Windows version 18 (SPSS Inc.,
Chicago, Illinois) for statistical analyses. Because of multiple testing,
all p values were two-sided and values below 0.01  were considered
statistical significant. All  data were categorical and described as fre-
quencies and percentages. Age was categorized into age groups. To
examine the association of the number of  self-reported tick bites
with blood bank locations, we used the chi-square test. To  exam-
ine whether one blood bank deviated significantly from the others,
tick bite frequencies from each blood blank were compared with
the total frequencies of the others, using Fisher’s exact test.
The association between self-reported tick bites and various
risk factors was analyzed by using proportional odds models, i.e.,
logistic regression models with more than 2 ordinal categorical out-
comes (Armstrong and Sloan, 1989; Scott et al., 1997). By using this
method, we avoided dichotomising the tick bites  variable which
possibly would have led to a  loss of  information and decreased sta-
tistical power (Scott et al., 1997). The  method, however, assumes
that the odds ratio for a risk factor is homogenous for all possi-
ble cut-points of the tick bite variable (i.e., the proportional odds
property). Given this homogeneity, the odds ratio can be viewed
as a constant and interpreted as the odds of being higher or lower
on the tick bites variable across the entire range of the variable. In
PASW, the odds ratio was estimated by  using the “plum” command.
The proportional odds assumption was  tested using the “tparallel”
option.
The odds ratios for tick bites with 95% confidence intervals were
estimated with and without adjustment for the participants’ age,
gender, and blood bank localization, and  we used the method of list-
wise deletion to handle missing values. A significant deviation from
the proportional odds assumption was  only seen in the analyses
of tick bites in relation to outdoor hours per week during sum-
mertime, suggesting that the results from this variable should be
interpreted with some caution. p  value for trend was  obtained by
including the risk factor as a  linear term in the regression models.
Results
The self-reported numbers of total and recent tick bites are
presented in Table 2. The table also includes the respondents’ sub-
jective estimation of the occurrence of ticks in his/her living area.
Among participants, 65.7% had experienced tick bites during their
Fig. 2. Reported tick  bites during the past  12  months according to age  and gender in
1171 blood donors in  Sogn and  Fjordane, 2010. Number of tick bites was  estimated
by using midpoint averages as described in  the methods.
life time, whereas 30% had experienced tick bites during the latest
12 months.
Ticks and tick  bites in  relation to geography
Donors from the blood bank  in Lærdal reported the lowest
occurrence of ticks as  well as the lowest number of tick bites, both
total and recent. The estimated mean total number of tick bites of
1.5 from this area contrasts with 5.6–7.2 from the other locations.
Age and gender
The number of  tick bites increased with age, and  there was  no
gender difference in overall analyses (Table 3). In the younger age
groups, however, males reported more bites than females (Fig. 2).
In subjects older than 50 years old, this was  reversed, with females
reporting more tick bites then males. When testing for effect mod-
ification by gender on the relation between age group and  tick
bites, we  found a statistically significant interaction both  for total
(p =  0.008) and recent tick bites (p = 0.001).
Other risk factors
Adjusted analyses further showed that both recent and total
tick bites were more common among participants with the highest
educational level, increased outdoor activity, and among hunters
and owners of domestic animals (Table 3). Daily smokers reported
fewer total tick bites.
Consequences of tick  bites
Simple medical outcomes of  tick bites are listed in Table 4.  As
most responders reported many bites, these percentages refer to
the life-time risk of ever having experienced the symptoms and
do not reflect the risk after each single bite. The  most common
occurrence was  a rash around the bite, reported by 22.7% of the
bitten respondents. Joint pain or swollen joints was  reported by
2.0%, followed by  headache (1.0%), fever (0.5%), and palsy in the face
or elsewhere (0.5%). A total of  12.7% of the bitten persons reported
to have seen a doctor because of  tick bite  or a  consequence thereof,
while 7.7% had received antibiotics.
Avoidance of certain areas because of  concern for  tick bites
was reported by 15.7% of 1194 respondents in this study, 22.2% of
women and 10.3% of men, respectively (p  < 0.001, data not shown).
There was  no significant age difference.
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Table 2
Self-perceived occurrence of ticks and reported tick bites  among 1213 participants in  the Tick-borne Infection Study in Sogn and Fjordane, 2010, according to geographical
area (blood bank).
Totala Blood bank pb
Førde Florø Lærdal Nordfjordeid
n (%) n  (%) n (%) n (%)
Self-perceived occurrence of ticks in living area <0.001
n 1193  (100.0) 604 (50.6) 350 (29.3) 72 (6.0) 167 (14.0)
None (%) 10.1 12.9 7.4 6.9 7.2
Little (%) 21.5 22.7 19.1 37.5 15.6
Some (%) 51.0 49.0 49.7 45.8 62.9
Many (%) 17.4 15.4 23.7 9.7 14.4
pc 0.003 0.001 0.009 0.012
Total tick bites ever experienced <0.001
n  1194  (100.0) 608 (50.9) 349 (29.2) 72 (6.0) 165 (13.8)
None (%) 34.3 32.7 29.8 73.6 32.1
1 (%) 18.0 18.9 20.3 12.5 12.1
2–5 (%) 23.8 25.2 24.6 9.7 23.0
6–20 (%) 14.7 14.5 15.2 1.4 20.6
>20 (%) 9.2 8.7 10.0 2.8 12.1
pc 0.594 0.282 <0.001 0.037
Estimated mean no. of tick bites4 5.7 5.6 6.0  1.5 7.2
Recent tick bites (past 12 months) 0.006
n 1194  (100.0) 608 (50.9) 349 (29.2) 72 (6.0) 165 (13.8)
None (%) 70.0  70.4 64.2 90.3 72.1
1 (%) 14.8 15.3 18.1 2.8 11.5
2–5 (%) 11.6 11.2 12.3 5.6 13.9
6–20 (%) 2.8 2.3 4.6 1.4 1.2
>20 (%) 0.8  0.8  0.9  0.0 1.2
pc 0.859 0.017 0.002 0.309
Estimated mean no. of tick bitesd 1.2 1.1 1.5 0.4 1.1
a Numbers do not add to 1213 due to  missing data.
b p value for association between blood bank and self-reported tick occurrence/tick bites  by  using chi-square test.
c p value for difference between actual  blood bank and the  total of  the others by  Fisher’s exact test.
d Number of tick bites were estimated by  using midpoint averages as described in  the  Materials and methods section.
Discussion
The main findings of this study are that about two thirds of
healthy blood donors in Sogn and Fjordane had experienced tick
bites, and about 30% during the preceding 12 months. There were
significant differences according to geography, age, gender, edu-
cation, outdoor time, animal contact, and smoking. Among bitten
subjects, 22.7% had experienced a rash surrounding the bite.
Tick bite is a sine qua non for acquisition of tick-borne diseases.
Whether or not an infectious agent is actually transmitted from tick
to human depends on several additional factors, such as presence of
transmissible agents in the tick and duration of tick feeding (Sood
et al., 1997).
Data on tick bites and potential risk factors were collected from
blood donors using a  questionnaire. Blood donors are not com-
pletely representative of the general population. They are healthy,
and children and persons over 70 years are not represented. As
seen in Table 1, there was, however, a fair distribution regarding
gender and age groups. The area surrounding the innermost part
of the Sognefjord in our study was somewhat underrepresented,
as were some municipalities distant from the blood banks. Accord-
ing to Norwegian blood bank regulations, persons that have been
bitten by ticks should not donate blood for 4 weeks after the bite,
and persons with suspected or verified Lyme borreliosis should not
donate blood until 6 months after  adequate treatment has been
given (Comelli et al., 2011). Donors with recent tick bites and/or
Lyme borreliosis may  therefore be  underrepresented. Not all tick
bites are recognized by the bitten person, and thus will not be
reported in a questionnaire survey like this (i.e., information bias).
Responses to several of the questions are based on the respondents’
subjective estimations, and  the reliability of data must therefore be
interpreted with caution.
Comparing our results with studies from other countries, we
found that a lower percentage of the population has experienced
tick bites than in Åland (Wahlberg, 1990),  66% as contrasted to
85% (Table 2). In a survey in Alsace, France, 16.5% of the general
population had experienced one or more tick bites during the pre-
ceding year  (Mitschler et al., 2004), which is lower than reported
in our study (30%). Also  Leiby and co-workers’ findings from Con-
necticut and Wisconsin indicated a lower frequency of tick bites in
blood donors than we found (Leiby et al., 2002). Explanations for
these differences may  include variations in tick abundance, gen-
eral awareness of ticks, and outdoor and recreational habits in the
respective populations.
Two Dutch and one Belgian study showed an uneven geograph-
ical distribution of  tick bites in the different areas within the
respective countries (de Mik  et al., 1997; den Boon et al., 2004;
Vanthomme et al., 2012). The difference in sampling methods (gen-
eral practice versus blood donors) precludes any  direct comparison
with our findings other than stating that local geographical differ-
ences are an important risk factor for tick bites.
In accordance with current estimates of  tick distribution as well
as the variation of  notified cases of systemic borreliosis within the
county, we  found a significantly lower number of tick bites in the
blood donors from the easternmost blood bank of  Lærdal. Although
entirely based on their subjective estimate, the respondents from
this blood bank also reported a  correspondingly low occurrence of
ticks in their living area.
As expected, we found a  significant age-related trend in reported
total tick bites. The  somewhat lower reported number in the oldest
group of 60–69 years may  be related to sampling variation, a cohort
effect in the oldest group reflecting a change in outdoor habits in
the general population, or an increased density of ticks during the
past decades. The same age trend was also present for recent tick
bites.
Bennett and co-workers found in south-eastern Sweden that
women aged 40 years or older had a 48% higher risk than men  in
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Table 3
Reported tick bites ever and past 12 months in 1213 blood donors in the Tick-borne Infection Study in Sogn and Fjordane, 2010, in relation to demographics and risk  factors.
Characteristics n (%)a Tick bites ever Tick  bites in the past  12  months
Odds ratiob (95% CI)  Adjusted odds
ratioc (95% CI)
Estimated mean
number of tick bitesd
Odds ratiob (95% CI)  Adjusted odds
ratioc (95% CI)
Estimated mean
number of tick bitesd
Gender
Female 535 (44.8) 1 1 5.3  1 1 1.0
Male 659 (55.2) 1.1 (0.9–1.3) 1.1 (0.9–1.3) 6.0  1.0  (0.8–1.3) 1.1 (0.8–1.3) 1.3
p difference 0.500 0.634 0.994 0.933
Age
19–29 79 (6.7) 1 1 2.4  1 1 0.3
30–39 233 (19.9) 1.7 (1.0–2.7) 1.6 (1.0–2.6) 4.7  3.1 (1.5–6.3) 2.9 (1.4–6.1) 1.2
40–49 411 (35.1) 2.0  (1.3–3.1)  1.9 (1.2–2.9) 5.3  2.8 (1.4–5.7) 2.8 (1.4–5.7) 1.1
50–59 340 (29.0) 3.1 (2.0–4.9) 3.0  (1.9–4.8) 7.6  4.3 (2.1–8.6) 4.4 (2.2–9.0) 1.5
60–69 108 (9.2) 2.4 (1.4–4.2) 2.4 (1.4–4.1) 6.3  2.2 (1.0–4.8) 2.3 (1.0–5.1) 1.0
p trend <0.001  <0.001 0.014 0.006
Education
Primary school ≤9 years 83 (7.0) 1 1 3.8  1 1 0.7
Secondary school 593  (49.9) 1.5 (1.0–2.3) 1.9 (1.2–2.9) 6.1  1.7 (1.0–3.0) 1.7 (1.0–3.1) 1.3
University/college 1–4 years. 338 (28.4) 1.4 (0.9–2.1) 1.8 (1.2–2.9) 5.1  1.9 (1.0–3.4) 2.1 (1.1–3.8) 1.1
University/college >4 years 175 (14.7) 1.9 (1.2–3.1) 2.6 (1.6–4.2) 6.5  2.6 (1.4–4.8) 2.8 (1.5–5.3) 1.2
p trend 0.056 0.004 0.003 0.001
Household yearly gross income (EUR)
<50,000 154 (13.2) 1 1 4.3  1 1 0.8
50–99,000 640 (54.7) 1.4 (1.0–2.0) 1.4 (1.0–1.9) 5.9  1.6 (1.0–2.4) 1.5 (1.0–2.3) 1.1
100–150,000 352 (30.1) 1.5 (1.1–2.1) 1.4 (1.0–2.0) 6.0  1.6 (1.0–2.5) 1.4 (0.9–2.3) 1.3
>150,000 25 (2.1) 0.8 (0.4–1.8) 0.6 (0.3–1.4) 3.3  1.5 (0.6–3.7) 1.0 (0.4–2.6) 1.2
p trend 0.176 0.593 0.097 0.500
Daily smoking
No 928 (82.0) 1 1 5.9  1 1 1.3
Yes 204 (18.0) 0.7 (0.6–1.0) 0.7 (0.5–0.9) 4.7  0.7 (0.5–1.0) 0.7  (0.5–0.9) 0.7
p difference 0.032 0.007 0.089 0.024
Outdoor hours per week during summertime
≤5 275 (23.1) 1 1 4.1  1 1 0.5
6–10 409 (34.3) 1.2 (0.9–1.6) 1.2 (0.9–1.7) 4.8  1.5 (1.1–2.2) 1.6 (1.1–2.3) 0.9
>10 508 (42.6) 1.7 (1.3–2.2) 1.8 (1.3–2.3) 7.2  2.0  (1.5–2.9)  2.2 (1.6–3.1) 1.7
p trend <0.001  <0.001 <0.001  <0.001
Hunting past 12 months
No 956 (80.3) 1 1 5.0  1 1 0.8
Yes 235 (19.7) 1.8 (1.4–2.3) 2.3 (1.7–3.1) 8.5  2.6 (2.0–3.5) 3.7 (2.7–5.2) 2.5
p difference <0.001  <0.001 <0.001  <0.001
Ever active orienteer
No 1124 (94.5) 1 1 5.5  1 1 1.1
Yes 65 (5.5) 1.5 (1.0–2.4) 1.5 (0.9–2.3) 8.3  1.8 (1.1–3.0) 1.8 (1.1–3.0) 2.3
p difference 0.054 0.110 0.015 0.025
Cat or dog owner
No 637 (53.7) 1 1 5.4  1 1 1.1
Yes 549 (46.3) 1.2 (1.0–1.5) 1.2 (1.0–1.5) 6.1  1.4 (1.1–1.8) 1.4 (1.1–1.8) 1.2
p difference 0.076 0.086 0.007 0.011
Domestic animals
No 1024 (86.6) 1 1 5.4  1 1 1.1
Yes 159 (13.4) 1.5 (1.1–2.0) 1.6 (1.2–2.2) 7.7  1.7 (1.3–2.4) 1.9 (1.3–2.7) 1.6
p difference 0.010 0.002 0.001 <0.001
a Numbers do not add to 1213 due to missing data. Those who  responded answered both  questions (tick bites ever and past 12  months).
b Odds ratio was  estimated using proportional odds ratio models (logistic regression model with more than two categorical outcomes).
c Adjusted for gender, age group, and  blood bank.
d Number of tick bites were estimated by using midpoint averages as described in the method.
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Table 4
Symptoms, doctor visits and antibiotic treatment ever following a  tick bite among
875 bitten subjects in the Tick-borne Infection Study in Sogn and Fjordane, 2010.
Symptoms (n = 785) n (%)
A rash around the bite 178 (22.7)
Palsy in face or elsewhere 4 (0.5)
Fever 4 (0.5)
Headache 8 (1.0)
Joint pain or swollen joints 16  (2.0)
Seen a doctor because of tick bite
(n = 778)
99 (12.7)
Received antibiotics because of  tick  bite
or consequence thereof (n = 777)
60  (7.7)
than younger women (Bennet et al., 2007). A similar tendency is
also apparent in our study for subjects 50 years or older (Fig. 2). A
plausible hypothesis for the increased risk in elderly women  could
be the traditional, but now declining custom of picking wild berries
(e.g. blueberries, cloudberries, lingonberries) for the household,
showing a similar distribution in age and gender (Vaage, 2004).
Unfortunately, questions on this were not included in the ques-
tionnaire. Other hypotheses could be  related to other behavioural
or biological aspects of postmenopausal women, as  discussed by
Bennet et al. (2007). The reported drop in risk of tick bites in elderly
men as opposed to women is not easy to explain and might be due
to behavioural differences in exposure to ticks or to recollection
errors. Cohort effects might be important.
We found that tick bites were more common among partici-
pants with the highest educational level.  This  is in accordance with
observed life style differences in other studies (Vaage, 2004). We
found no relation between risk of tick bites and  household yearly
gross income.
After adjustment for gender, age, and blood bank, daily smok-
ing seemed to protect against tick bites according to our material
(p = 0.007), but after statistical correction also for outdoor hours per
week, this association was no longer significant (p  = 0.017).
As expected, the number of outdoor hours per week during sum-
mertime showed a significant relationship to the risk of tick bites
(Table 3). The estimated mean number of recent tick bites increased
from 0.5 in those spending <5 h  to 1.7 in subjects spending more
than 10 h outdoors per week. Similarly, Stjernberg and Berglund
found a 4% risk of being tick-bitten per 10 hours spent outdoors in
an endemic area in Sweden (Stjernberg and Berglund, 2002).
Tick bites were more common among participants having
domestic animals (sheep, cows, horses, etc.). This  group of  respon-
dents are probably mostly full or part-time farmers, expected to
spend much time in tick habitats.
Hunting, especially for deer, is a common leisure activity in Sogn
and Fjordane. More than 11,000 deer were hunted in the county
in 2009. We  found an increased risk of  tick bites in the group of
hunters, even after adjustment for “hours spent outdoors per week
in summertime” (p < 0.001 both  for  total and recent bites). How-
ever, this question does not discriminate between tick-infested and
non-infested outdoor areas, and there is reason to believe that the
increased risk in hunters reflects their activity in tick habitats.
Among our respondents, 65 (5.5%) reported to have been active
orienteers. A Swiss study published in 1991 found that 78% of 995
orienteers had experienced at  least one tick bite (Fahrer et al., 1991).
In our material, that was  the case for 92.3% (data not shown). A
Swedish study found that 53% of Swedish orienteers were bitten
by ticks in one year (Gustafson et al., 1993), and we  found a similar
rate of 53.8% (data not shown). We  found that orienteers reported
more tick bites than non-orienteers, but this association was not
statistically significant at alpha level 0.01, possibly due to small
numbers (Table 3).
Several  reports have investigated the risk for developing dis-
ease after a single tick bite, and most of them find the risk  to be
low (Fryland et al., 2011; Jacobs et al., 2008; Maiwald et al., 1998;
Nadelman et al., 2001; Nahimana et al., 2004; Shapiro et al., 1992;
Stjernberg and Berglund, 2002).
Wahlberg (1990) found that  out of  441 bitten subjects, 14
reported ever having had erythema chronicum migrans, and 73
had had other rashes around the tick bite, all  together 19.7%. In
our material, we found a similar frequency of  “rash” of 22.7%. We
did not try to discern between erythema migrans and other rashes,
as we believe that to be an  error-prone task in a retrospective ques-
tionnaire survey.
Outdoor activities are in general regarded as  positive for public
health and quality of life, and  it would be a concern if the popu-
lation chose to avoid certain recreational outdoor areas in fear of
tick bites. In  our study, 15.7% reported such avoidance. Whether
this is a  sensible approach is difficult to ascertain. The marked gen-
der difference, with avoiding behaviour in twice as  many women
than men, is not easy to explain. It may  reflect a  general gender
difference in risk avoidance.
In conclusion, a majority of blood donors in the western part
of Norway had experienced tick bites. Age, gender, outdoor activi-
ties, animal contact, and geography affected the risk. Symptoms of
disease were seldom reported.
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Seroprevalence of antibodies to Borrelia burgdorferi
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Hjetland R, Nilsen RM, Grude N, Ulvestad E. Seroprevalence of antibodies to Borrelia burgdorferi sensu lato in
healthy adults from western Norway: risk factors and methodological aspects. APMIS 2014; 122: 1114–1124.
The aim of this study was to assess the seroprevalence of antibodies to Borrelia burgdorferi sensu lato in a healthy adult
population from Sogn and Fjordane county in western Norway by different assays. Sera from 1213 blood donors at
four different blood banks were analysed in Enzygnost Lyme link VlsE/IgG (IgG), Enzygnost Borreliosis IgM (IgM),
and Immunetics C6 Lyme ELISA kit (C6). Sera showing positive or grey-zone reactivities were further examined with
Borrelia-EUROLine-RN-AT IgG blot and Borrelia-EUROLine-RN-AT IgM blot. The seroprevalences were 9.6%,
8.2%, 8.4%, 6.4% and 5.7%, respectively. The seroprevalence for IgG was lower in the eastern part of the county and
in owners of pet animals. It was higher in men, and increased with age and number of tick bites. C6 and IgG gave
comparable results. IgM only was found in 4.5%, more often in women, did not increase with age, and showed no
relationship with geography, and 56.4% were positive in IgM blot. In conclusion, antibodies to B. burgdorferi s.l. are
common in blood donors in western Norway. The results may be used for evaluation of predictive values of test results
in patients, as well as a basis for test algorithms in the laboratory.
Key words: Borrelia burgorferi; seroprevalence; Norway; blood donors.
Reidar Hjetland, Department of Microbiology, General Hospital of Førde, Postboks 1000, Førde 6807, Norway.
e-mail: reidar.hjetland@helse-forde.no
Sogn and Fjordane county, located at the western
coast of Norway, encompasses coastal, fjord and
mountainous areas at 61–62° N and 5–7° E. The
climate is temperate, with a high yearly rainfall in
the western and middle areas, but with a more
inland-like climate in the eastern part.
Ixodes ricinus is the predominating tick species in
Norway, and is present along the coast as far north
as 69° N. Its latitudinal and altitudinal distribution
limits seem to be expanding (1). It is more abundant
along the southernmost coastline. In Sogn and Fjor-
dane county, there are more ticks in the western,
coastal regions than in the eastern regions (1–3).
Among the blood donors included in the present
study, 65.7% reported having been bitten by ticks
at least once in their lifetime, and 30.0% reported
tick bites during the last 12 months (4). Fewer tick
bites were reported from the donors in the eastern
than in the western part of the county.
Lyme borreliosis is the most prevalent human
tick-borne disease in Norway, with a distribution
corresponding to that of I. ricinus. In the Norwegian
Surveillance System for Communicable Diseases
(MSIS), only cases of systemic disease and chronic
manifestations of Lyme borreliosis are notifiable,
while the most prevalent manifestation, erythema
migrans, is not (http://www.msis.no/). In the period
2001–2010, the mean reported annual incidence in
Sogn and Fjordane was 14.1 cases per 100 000
inhabitants, compared to 26.1 in the southernmost
county of Vest-Agder, and 5.3 nation-wide (http://
www.msis.no/).
Published figures of the seroprevalence of
antibodies to B. burdgdorferi sensu lato in bloodReceived 15 July 2013. Accepted 21 January 2014
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donors are not easy to compare. As far as we
know, there is no standardized way to report this;
different laboratory methods and algorithms are
used, and the methods have changed over time.
The numbers are ranging from 1.1%, using C6
ELISA in the USA (5), to 30% in Dar es Salaam,
Tanzania, using the DAKO flagellar ELISA (6). In
Europe, numbers between 4% and 20% for IgG in
different ELISAs have been published, as summa-
rized by Tjernberg et al. (7). In a report by Dessau
et al., seropositivity rates for blood donors in some
Scandinavian laboratories were presented (8), show-
ing a marked difference in prevalence depending on
the ELISA method used. One Swedish laboratory
using C6 ELISA reported a positivity rate of
16.0%, whereas three laboratories using the IDEIA
flagellar ELISA found 1.1–3.0%. Two Swedish lab-
oratories using Liaison assays had IgG rates of
7.0% and 8.0%, and IgM of 3.0% and 0%, respec-
tively. In Norway, a seropositivity rate for IgG of
18% was found in 247 blood donors from the
county of Vest-Agder, using the Enzygnost ELISA
(9). This is the county with the highest incidence of
notified cases of Lyme borreliosis in Norway.
The mainstay of serological diagnosis is the
enzyme immunoassay (EIA), of which several com-
mercial variants exist in parallel. They differ in anti-
gen composition, from single antigen assays (e.g.,
flagellum protein p41 and C6) to complex antigen
mixtures based on extracts from cultivated B. burg-
dorferi s.l. and/or synthesized antigens. In the USA
and central Europe, screening with an EIA test is
recommended to be complemented with an immu-
noblot for confirmation, known as two-tiered test-
ing (10, 11). There are also several different
immunoblot assays, with variation in antigen com-
position and preparation. As has been demon-
strated, the choice of which specific EIA and
immunoblot test to use strongly influences the
resulting conclusions (12).
In Scandinavia, the two-tier principle has never
been systematically adopted, as it is thought to
reduce sensitivity and only give a marginal add to
specificity (13). Thus, most laboratories either
perform only EIA-testing, or perform additional
testing in certain circumstances (8). In Norway,
optimal testing strategies are currently being dis-
cussed, as published in some documents available
only in Norwegian (14, 15). Different alternatives
to or variants of the two-tier testing are currently
discussed worldwide, e.g., using C6 ELISA as the
only test, or using an EIA also for second-tier
testing, different from the one used for screening
(5, 7, 16–19).
In the present study, we wanted to assess the
seroprevalence of antibodies to B. burgdorferi s.l. in
healthy blood donors in Sogn and Fjordane county,
western Norway. In addition, we wanted to relate
seropositivity to tick bites, demographics and other
risk factors. By using two different ELISAs as well




During the period 13th January to 15th June 2010, blood
donors at the four blood banks in Sogn and Fjordane,
Norway, were asked to participate in the Tick-borne
Infection Study in Sogn and Fjordane. A total of 1213
blood donors participated, resulting in a response rate of
76%. Characteristics of the participants are presented pre-
viously (4); mean age was 45.8 (range: 19–69) years and
55.2% were men. Informed consent was obtained from
each participant, and the study was approved by the
Regional Committee for Medical Research Ethics.
Questionnaire
All study participants filled in and returned a question-
naire on the day of blood donation. They were asked to
record the number of tick bites ever experienced and tick
bites experienced during the last 12 months. The responses
for both these questions were given in the categories
‘none’, ‘one’, ‘2–5’, ‘6–20’ and ‘more than 20’. In addition,
participants provided information on gender, age, marital
status, education, household income and occupation, pet
animals, farm animals, hours spent outdoors during
summertime, hunting, orienteering, smoking, symptoms
and treatment after tick bites, as well as on a number of
subjective health complaints.
Laboratory methods
Blood samples were collected in serum separator tubes
with gel, and after centrifugation, sera were frozen in
aliquots at 70 °C until testing.
Antibodies to B. burgdorferi s.l., were tested in Enzy-
gnost Lyme link VlsE/IgG, Enzygnost Borreliosis IgM
(DADE Behring, Marburg, Germany) and Immunetics C6
Lyme ELISA kit (Immunetics, Cambridge, MA, USA). Sera
showing positive or grey-zone reactivities in any of these
tests were further tested in Borrelia-EUROLine-RN-AT
IgG and Borrelia-EUROLine-RN-AT IgM (Euroimmun
AG, L€ubeck, Germany).
The Enzygnost Lyme link VlsE/IgG is based on a mix-
ture of native Borrelia antigens from B. afzelii strain PKo
and recombinant VlsE from the three genospecies B. burg-
dorferi sensu stricto, B. garinii and B. afzelii. Enzygnost
Borreliosis IgM assay is based on a detergent extract from
B. afzelii strain PKo. For both assays, sera were absorbed
with antigens from Treponema phagedenis, and for the IgM
assay they were treated with anti-IgG for removal of rheu-
matoid factor. The Enzygnost assays were processed by
automated instrumentation (Behring BEP 2000 Advance),
and the results were interpreted following the manufac-
turer’s instructions, including retesting of grey-zone results.
© 2014 APMIS. Published by John Wiley & Sons Ltd 1115
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The cut-off value referred to in this paper is the one distin-
guishing grey-zone and positive results.
The Immunetics C6 Lyme ELISA kit uses the conserved
synthetic peptide (C6 peptide) derived from the VlsE
protein as antigen, and both IgG and IgM antibodies are
detected. The analyses were performed semi-manually,
using an automatic washer and spectrophotometer. Grey-
zone results were repeated according to the manufacturer’s
instructions.
The EUROLINE-RN-AT IgG and IgM test kits are
qualitative immunoblot assays for antibodies of the IgG
and IgM class against Borrelia antigens. The IgG and
IgM assays differ in antigen composition. The assay is a
combination of the classical Western blot and a line blot,
in that some of the antigens are applied directly in lines to
membranes, while some are removed from a classical Wes-
tern blot and placed onto the test strip. Recombinantly
produced and purified VlsE antigen from the three domi-
nating B. burgdorferi s.l. genospecies are included in the
IgG assay, and OspC from the three species in the IgM
assay. The resulting blots were scanned using the Euro-
Blot Scanner, and interpreted according to the manufac-
turer’s instructions using the EuroLineScan software
(Euroimmun AG).
Statistical analysis
We used IBM SPSS Statistics version 20 (SPSS Inc., Chi-
cago, IL, USA) for statistical analyses. All p values were
two-sided and values below 0.05 were considered statistical
significant. All data were categorical and described as
frequencies and percentages, age was categorized into age
groups. ELISA results were categorized as positive or neg-
ative with grey-zone results included as positives, while
blot results were categorized as positive or negative, with
grey-zone results included as negatives.
The three ELISAs were compared using the kappa sta-
tistic to determine ‘consistency among raters’ where kappa
values <0 were interpreted as poor, 0.0–0.20 as slight,
0.21–0.40 as fair, 0.41–0.60 as moderate, 0.61–0.80 as sub-
stantial, and 0.81–1.00 as almost perfect agreement (20).
The associations between exposure variables, i.e. self-
reported tick bites and other risk factors, and the out-
comes, i.e. the prevalence rates for antibodies, were analy-
sed by binary logistic regression. The odds ratios with
95% confidence intervals were estimated with and without
adjustment for the participants’ age, gender, and blood
bank location as appropriate.
RESULTS
The various combinations of results are given in
Table 1. Using the laboratory’s routine method,
Enzygnost IgG and IgM, 117 (9.6%) of the 1213
sera were positive in IgG and 99 (8.2%) in IgM,
totalling 172 subjects (14.2%), of which 78 (45.3%)
were positive in the IgG blot, and 66 (38.4%) in
IgM blot. In the C6 assay, 102 sera (8.4%) were
positive, of which 70 (68.6%) were positive in IgG
blot, and 28 (27.5%) in IgM blot.
The reported number of tick bites and seroposi-
tivity to B. burgdorferi s.l. showed a close correla-
tion both for IgG and IgM (Table 2). Among the
409 subject reporting not to have experienced any
tick bite, 20 (4.9%) were positive in IgG and 22
(5.4%) were positive in IgM. The relationship
between tick bites, gender and seropositivity for
IgG is further elucidated in Fig. 1, showing a
close relation between tick bites and seropositivity
in men. This relationship is less obvious in
women.
The results of IgG, IgM and C6 according to
geographical location of the blood banks are pre-
sented in Table 3. Compared with the other blood
banks, there were fewer IgG positives in Lærdal
(p = 0.021), and there were more C6 positives in
Førde (p = 0.004).
Table 1. Seropositivity to Borrelia burgdorferi sensu lato in the Tick-borne Infection Study in Sogn and Fjordane,
Norway, 2010 (n = 1213)
Total, n (%1) Blot IgG, n (%2) Blot IgM, n (%2)
– +/– + – +/– +
IgG+ 117 (9.6) 30 (25.6) 13 (11.1) 74 (63.2) 71 (60.7) 12 (10.3) 34 (29.1)
IgM+ 99 (8.2) 41 (41.4) 24 (24.2) 34 (34.3) 27 (27.3) 12 (12.1) 60 (60.6)
C6+ 102 (8.4) 22 (21.6) 10 (9.8) 70 (68.6) 66 (64.7) 8 (7.8) 28 (27.5)
IgG and/or IgM and/or C6+ 198 (16.3) 86 (43.4) 34 (17.2) 78 (39.4) 109 (55.1) 20 (10.1) 69 (34.8)
IgG+, IgM+, C6+ 31 (2.6) 0 (0.0) 2 (6.5) 29 (93.5) 6 (19.4) 4 (12.9) 21 (67.7)
IgG+, IgM+, C6– 13 (1.1) 4 (30.8) 6 (46.2) 3 (23.1) 5 (38.5) 1 (7.7) 7 (53.8)
IgG+, IgM–, C6+ 44 (3.6) 3 (6.8) 2 (4.5) 39 (88.6) 38 (86.4) 3 (6.8) 3 (6.8)
IgG+, IgM–, C6– 29 (2.4) 23 (79.3) 3 (10.3) 3 (10.3) 22 (75.9) 4 (13.8) 3 (10.3)
IgG–, IgM+, C6+ 1 (0.1) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0)
IgG–, IgM+, C6– 54 (4.5) 37 (68.5) 15 (27.8) 2 (3.7) 16 (29.6) 7 (13.0) 31 (57.4)
IgG–, IgM–, C6+ 26 (2.1) 19 (73.1) 5 (19.2) 2 (7.7) 22 (84.6) 1 (3.8) 3 (11.5)
IgG–, IgM–, C6– 1015 (83.7) – – – – – –
IgG, Enzygnost Lyme link VlsE/IgG; IgM, Enzygnost Borreliosis IgM; C6, Immunetics C6 Lyme ELISA kit; Blot IgG,
EUROLINE -RN-AT IgG; Blot IgM, EUROLINE -RN-AT IgM.
1Percentages of the total population of 1213.
2Percentages within this group.
1116 © 2014 APMIS. Published by John Wiley & Sons Ltd
HJETLAND et al.
There was a positive association of IgG-seroposi-
tivity with age, and more males than females were
positive to IgG (Table 4). The results are further
elucidated in Fig. 2, showing a delayed age-related
rise in seroprevalence in women compared with men.
The relation of different risk factors to seroposi-
tivity for IgG and IgM are presented in Table 4.
Cat or dog owners had a significantly lower sero-
positivity rate for IgG. There were, however, no
statistical differences regarding educational level,
household yearly gross income, daily smoking, out-
door hours per week during summertime, hunting
during the preceding 12 months, orienteering, or
ownership of domestic animals.
Comparing the qualitative results (positive or
negative), the two EIA-methods showing the high-
est agreement were Enzygnost IgG and C6, with a
kappa value of 0.654 (CI 0.578–0.730), indicating a
substantial agreement between these two assays.
Comparing the combined seropositivity in Enzy-
gnost ELISA (IgG and/or IgM) with C6, the kappa
value was 0.502 (CI 0.428–0.576), indicating moder-
ate agreement. There was poor agreement between
C6 and isolated IgM, with a kappa value of 0.049
(CI 0.077 to 0.021).
In Fig. 3, we see that the concordance of positiv-
ity for IgG and C6 was good at strong reactions in
both assays, but there were more discrepancies
between the two tests in the lower ranges of reactiv-
ity. Thus, all IgG stronger than 260% of the cut-off
value, corresponding to 36 units/mL in the manu-
facturer’s unit, were also positive in C6, and con-
versely, all C6 stronger than 465% of the cut off
were positive in IgG. Similarly, we found that IgG
reactions stronger than 252% of the cut off (34 U/
mL) were positive in IgG blot, and for C6 EIA, the
corresponding limit was 504% (Fig. 4).
Among the 60 sera with a positive IgG weaker
than 260% of the cut off, 18 (30.0%) were positive
also in C6. Of these, 11 (61.1%) were positive in
IgG blot, while among the 42 C6 negatives, only 6
(14.3%) were positive.
Vice versa, among the 60 sera with a positive C6
weaker than 465% of the cut-off, 33 (55.0%) were
positive also in IgG. Of these, 26 (78.8%) were
positive in IgG blot, while among the 27 C6 nega-
tives, only 2 (7.4%) were positive.
A comparison of IgM accompanying a positive
IgG with isolated IgM (i.e. without a concomitant
Table 2. Prevalence of Borrelia IgG and IgM (Enzygnost) according to reported tick bites ever and tick bites latest
12 months in the Tick-borne Infection Study in Sogn and Fjordane, Norway, 2010 (n = 1213)














None 409 (34.3) 4.9 1 1 5.4 1 1
One 215 (18.0) 9.3 2.0 (1.0–3.8) 1.9 (1.0–3.7) 7.0 1.3 (0.7–2.6) 1.3 (0.6–2.6)
2–5 284 (23.8) 11.3 2.5 (1.4–4.4) 2.2 (1.2–4.0) 8.5 1.6 (0.9–3.0) 1.5 (0.8–2.7)
6–20 176 (14.8) 12.5 2.8 (1.5–5.2) 2.4 (1.2–4.6) 11.9 2.4 (1.3–4.5) 2.3 (1.2–4.3)
>20 110 (9.2) 18.2 4.3 (2.2–8.4) 3.3 (1.7–6.6) 12.7 2.6 (1.3–5.2) 2.3 (1.1–4.8)
p trend <0.001 <0.001 0.001 0.004
Tick bites last 12 months
None 836 (70.0) 7.7 1 1 6.2 1 1
One 177 (14.8) 14.1 2.0 (1.2–3.3) 1.9 (1.1–3.3) 13.6 2.4 (1.4–4.0) 2.3 (1.4–3.9)
2–5 138 (11.6) 10.9 1.5 (0.8–2.7) 1.6 (0.9–2.9) 10.1 1.7 (0.9–3.2) 1.8 (0.9–3.3)
6–20 33 (2.8) 21.2 3.2 (1.4–7.8) 3.0 (1.2–7.6) 12.1 2.1 (0.7–6.1) 2.0 (0.7–6.0)
>20 10 (0.8) 30.0 5.2 (1.3–20.5) 5.6 (1.4–22.9) 20.0 3.8 (0.8–18.2) 3.6 (0.7–17.6)
p trend <0.001 0.001 0.003 0.005
1Numbers do not total 1213 because of missing data.
2Odds ratio was estimated using binary logistic regression.
3Adjusted for gender, age group and blood bank.
Fig. 1. Relationship of number of tick bites experienced
with seroprevalence of IgG against Borrelia burgdorferi s.l.
in the Tick-borne Infections Study in Sogn og Fjordane,
Norway, 2010 (n = 1194).
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positive IgG) in relation to age and gender is shown
in Table 3 (geography) and Fig. 5 (age and gender),
irrespective of C6 result. IgM only was seen in 55
subjects (4.5%), whereas IgM concomitant with
IgG was seen in 44 subjects (3.6%). Immunoblot
for IgM was positive for 31 (56.4%) and 28
(63.6%) of these, respectively. The IgM alone
compared to IgM accompanying IgG had some dis-
tinctions: More women than men had IgM alone
(81.4% vs 35.7%, p < 0.001, Fisher’s exact test),
the mean age of the subjects with IgM alone was
lower (44.5 vs 53.4 years, p < 0.001, Student’s
T-test), and IgM alone had no statistically signifi-
cant correlation with the number of tick bites,
contrary to IgM accompanying IgG (binary logistic
regression, data not shown).
DISCUSSION
The main findings in this study were that 9.6% of
healthy blood donors in Sogn and Fjordane were
positive in Enzygnost Lyme link VlsE/IgG ELISA,
8.2% in Enzygnost Borreliosis IgM ELISA, and
8.6% in the Immunetics C6 Lyme ELISA kit. The
IgG and C6 results were comparable.
Blood donors are not fully representative of the
population in Sogn and Fjordane county, as they
are healthy, not all municipalities are equally repre-
sented, and there are no children or individuals
more than 70 years of age. There was, however, a
fair distribution in age and gender (4).
Borrelia IgG and IgM may be positive for a long
time after infection with B. burgdorferi s.l. (21).
False-positive IgM reactions without relation to
B. burgdorferi s.l. infection are well known (22, 23).
Isolated positive IgMs without obvious relation to
actual or earlier disease are a permanent problem
in everyday clinical microbiology.
As tick bites are necessary for infection with
B. burgdorferi s.l., a close correlation of the number
of bites with seropositivity for specific IgG was
expected. As seen in Table 2, this was also the case.
Notably, persons who reported to never have been
bitten had a seropositivity rate for IgG of 4.9%,
supporting the well-known clinical observation that
tick bites often go unnoticed (24, 25). The real pro-
portion of these blood donors having experienced
tick bites is therefore probably greater than the self-
reported 65.7% (4). The occurrence of ticks is lower
in the eastern, inland-like part of Sogn and Fjordane
county than in the western, coastal areas, and the
blood donors from this area (the blood bank in Lær-
dal) reported fewer tick bites than those from the
other blood banks (1, 4). As expected, we found the
seroprevalence of IgG antibodies to B. burgdorferi
s.l. to be lower in donors from this area (p = 0.021).
The difference in IgM was, however, not significant
(p = 0.268), and for isolated IgM especially, there
was no difference whatsoever (p = 1.000). Why the
donors from the blood bank in Førde had more
positive reactions in C6 than the others (Table 3) is
difficult to explain, as Nordfjordeid had the highest
seropositivity rate for IgG.
There was a positive correlation between seropre-
valence of IgG and age (Table 4). Looking at age
and gender combined, we note that the prevalence
in women rises at an older age than in men
(Fig. 2). This may be in accordance with the age
distribution of reported tick bites, as young men
Table 3. Prevalence of Borrelia IgG and IgM (Enzygnost) and C6 antibodies in the Tick-borne Infection Study in Sogn
and Fjordane, Norway, 2010, according to location of blood bank (n = 1213)
Total Blood bank p1
Førde Florø Lærdal Nordfjordeid
n (%) 1213 (100.0) 614 (50.6) 355 (29.3) 73 (6.0) 171 (14.1)
IgG (%) 9.6 10.7 7.6 2.7 12.9 0.028
p2 0.111 0.073 0.021 0.084
IgM (%) 8.2 8.8 8.2 4.1 7.6 0.617
p2 0.239 0.538 0.268 0.881
IgM only (%) 4.5 4.6 5.4 4.1 2.9 0.697
p2 1.000 0.367 1.000 0.188
IgG only (%) 6.0 6.5 4.8 2.7 8.2 0.280
p2 0.472 0.289 0.169 0.222
IgG and IgM (%) 3.6 4.2 2.8 0 4.7 0.183
p2 0.284 0.400 0.106 0.383
IgG and/or IgM (%) 14.2 15.3 13.0 6.8 15.8 0.187
p2 0.285 0.470 0.081 0.554
C6 (%) 8.4 10.7 5.9 2.7 7.6 0.015
p2 0.004 0.053 0.081 0.768
1p-value for association between blood bank and antibody prevalence by using chi-squared test.
2p-value for difference between actual blood bank and the total of the others by Fisher’s exact test.
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reported more bites than young women, while this
was reversed in subjects older than 50 years of age
(4). The steep rise in prevalence of IgM accompa-
nying IgG in elderly women may also be in accor-
dance with the self-reported increase in tick bites in
this group (Fig. 5).
For IgG, we found a significant difference in
gender; men had a higher seroprevalence than
women, 13.0 vs 5.5%. This is not fully in


























































































































































































































































































































































































































Fig. 2. Prevalence of Borrelia IgG (Enzygnost) according
to gender and age group in the Tick-borne Infection Study
in Sogn and Fjordane, Norway, 2010 (n = 1183).
Fig. 3. Relationship between quantitative results of Borr-
elia antibodies in Enzygnost IgG and C6 ELISA in the
Tick-borne Infections Study in Sogn og Fjordane, Nor-
way, 2010 (n = 1213). The X-axis represents Enzygnost
IgG reactivity, while the Y-axis represents C6 reactivity,
both in percentage of cut off. The vertical and horizontal
lines mark the boundary between negative and grey-zone
results for the two tests, at 64% and 90% of the cut-off
value, respectively. Note the logarithmic scale of both
axes.
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statistically significant difference between the gen-
ders across all age groups was found, although men
reported some more tick bites (4). Also, women
reported more tick bites before seroconversion
(Fig. 1). This lack of consistency may be caused by
differences in subjective awareness of tick bites
between the genders, leading both to reporting less
bites and not taking precautions in timely removal
of ticks in men. However, interesting differences
between the genders in clinical manifestations of
Lyme borreliosis have been reported (26–28), and
an immunological basis for these differences cannot
be ruled out. Male dominance regarding Borrelia
IgG antibodies has also been reported by others
(29), but not universally (30). The number of total
and recent tick bites in this study population
increased with hours spent outdoors during sum-
mertime, educational level, ownership of domestic
animals, and hunting (4). Although we found an
overall positive relationship of seropositivity of IgG
to the number of tick bites, the other associations
mentioned above were not reflected in IgG seropre-
valence (Table 4). Interestingly, we found a lower
seroprevalence in owners of pet animals (cats or
dogs), although this group reported some more tick
bites (4). This is in contrast to the findings of
Dehnert et al., who, in Germany, found a higher
seroprevalence in children and adolescents from
households with cats (29).
Discerning «clinical» from «biological» specificity
might be fruitful when it comes to healthy popula-
tions like blood donors. Many studies of assays for
antibodies to B. burgdorferi s.l. provide reactivity in
blood donors as a measure of the specificity, and pos-
itives in this group are regarded as false-positives.
Fig. 4. Box plots of the relationship between strength of
reaction in ELISA and result of immunoblot in 198 sera
reactive in one or more ELISAs. The circles denote out-
liers and the stars are extreme values. 0 = negative, 1 =
indeterminate, 2 = positive.
Fig. 5. Prevalence of Borrelia IgM alone and accompany-
ing IgG (Enzygnost) according to gender and age group
in the Tick-borne Infection Study in Sogn and Fjordane,
Norway, 2010 (n = 1183).
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However, many of these positive reactions are in fact
biologically specific in that they reflect earlier or
actual, most often asymptomatic infections. How-
ever, some genuinely biologically false-positive
results not bearing any relationship with B. burgdor-
feri s.l. at all are found as well. Immunoblots may
also be biologically false-positive, especially for IgM
antibodies (23, 31), as well as clinically false-positive,
i.e. reflecting earlier infection not relevant to the clin-
ical picture at hand. In addition, immunoblots are
known to be less sensitive than EIAs in early disease
(5, 16).
The C6 ELISA has been reported to be more
specific than EIAs with other antigens. Wormser
et al. reported a specificity of 99.2% for C6 ELISA
in blood donors from non-endemic and 98.6% in
blood donors from endemic areas for Lyme borreli-
osis in USA, contrasted to 95.9% and 96.5% for a
whole cell sonicate ELISA for IgG/IgM, respec-
tively (5). In endemic areas in Europe, the reported
specificities for the C6 assay are not as high. Thus,
in Italy, the specificity of this assay was 97.6% in
210 blood donors from a non-endemic area, and
87.5% in 24 donors from an endemic area (32).
High seropositivity rates in blood donors for C6
antibodies are also found in some Scandinavian
laboratories, where 16% and 8% has been reported
(7, 8). In this study, we found a seroprevalence of
8.4% in C6, giving a specificity of 91.6%, not very
different from that of Enzygnost IgG (90.4%). The
proportions of IgG immunoblot positives were
comparable between these two assays, 63.2% and
68.6%, respectively. The main difference seems to
be that the C6 ELISA did not detect the isolated
IgMs found in the Enzygnost assay, even though
the C6 assay detects IgM as well as IgG antibodies.
In conclusion, the C6 and IgG had comparable
characteristics in our material.
In 89 patients, among them 59 with suspected
Lyme borreliosis, Ang et al. (12) found a kappa
value of 0.86 when comparing the Enzygnost IgG
and/or IgM with C6. This was a better agreement
than the 0.502 found in our study. They also found a
higher proportion of Enzygnost IgG and/or IgM and
C6 positives being positive in blot (83–100% and 77–
100%, respectively) than we did (60.6%, data not
shown). The reasons for this discrepancy most prob-
ably are related to the patient mix, as our study only
included asymptomatic, healthy individuals.
It has been suggested that C6 antibodies tend to
normalize after the clinical infection is resolved (33,
34), but others dispute this (35, 36). Our findings of
a relatively high prevalence of C6 antibodies in this
healthy population support the latter view.
The concordance of positivity for IgG, C6 and
IgG blot for strong reactivities indicates that strong
responses in these ELISAs do not have to be veri-
fied by blot or the other ELISA, as one can pre-
sume that they are positive. Ang et al. (12)
similarly found a good correspondence between the
strength of the reactions in C6 and blot in patients,
in that almost all samples stronger than 400% of
the cut-off in C6 also were positive in blots. How-
ever, this correspondence was not as good for
another EIA (Vidas), indicating that this relation-
ship should be investigated for each assay sepa-
rately. Using C6 as a second-tier test in weak
positive IgG or vice versa might thus be an alterna-
tive to blot. However, as this study is performed on
healthy blood donors, we do not know if these
presumptions are valid for ill patients with Lyme
borreliosis or other diseases.
The clinical significance of finding IgM antibod-
ies only in the absence of IgG antibodies to
B. burgdorferi s.l. in patients suspected of having
Lyme borreliosis is a continuous dilemma. A posi-
tive IgM may indicate an early phase of Lyme
borreliosis, and repeat specimens to look for the
development of IgG are often suggested by the lab-
oratory. In the absence of development of specific
IgG during e.g., 6 weeks, the IgM only is generally
regarded as of no consequence. American guidelines
thus argue against using IgM blot in the second-tier
testing when disease duration is longer than
1 month (10). As these specimens were obtained in
the period January–June, there is little reason to
presume that these IgM-only positives are indica-
tive of early Lyme borreliosis. In spite of positive
immunoblot for IgM in more than half of these
sera, most of them being positive towards OspC,
there is reason to believe that they are non-specific,
also in the biological sense. The specificity of
OspC-antibodies have been discussed in the litera-
ture (37), and the company Euroimmun AG has
recently released a new immunoblot test, the ‘EUR-
OLINE-RN-AT-adv’, which includes a new formu-
lation of OspC antigen, and is claimed to be 30%
more specific than the one used in this study, the
‘EUROLINE-RN-AT’.
In endemic areas for Lyme borreliosis, the posi-
tive and negative predictive values of test results
are important factors for the overall evaluation of
patients suspected of suffering from an actual,
symptomatic Lyme borreliosis. In this context, the
positive results from this study represent ‘clinically
false positives’. As shown in Table 4, the seropreva-
lence was lower in women and in the younger age
groups. The positive predictive value of IgG thus
will be higher in these groups in our geographical
area. The evaluation of the pre-test probability of
disease, the history and clinical picture, is therefore
of utmost importance. Unfortunately, there is much
1122 © 2014 APMIS. Published by John Wiley & Sons Ltd
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uncertainty among primary care physicians of the
clinical manifestations of Lyme borreliosis. E.g., the
clinical information ‘chronic fatigue’ and ‘musculo-
skeletal symptoms’ are frequent stated reasons for
testing in our laboratory, resulting in very low posi-
tive predictive values of the tests. Thus, Dessau
et al. in Denmark have shown that among sera
submitted from persons with suspected Lyme
arthritis, a rare disease in Scandinavia, the rate of
seropositivity did not exceed the background preva-
lence for Danish blood donors (38).
A test algorithm reducing the positivity rate in
normal individuals while still detecting a maximum
of clinical cases would be preferable. As our data
reflect normal individuals only, constructing an
algorithm for clinical situations based on these is
not possible. However, our data do suggest that a
two-tiered test strategy using only Enzygnost IgG
or C6 as screening could eliminate the problem of
probable unspecific solitary IgM results. A positive
screening test should be followed by testing for
IgM, and for weak positives also the other ELISA
(C6 or IgG as appropriate). Including IgM ELISA
in the second-tier test would give some information
on whether the infection is recent. Blot could be
reserved for weak positive isolated C6 or IgG in
clinically suspect cases. The algorithm would miss
cases with isolated IgM as a single early finding. In
our experience, this is seldom in adult patients suf-
fering from Lyme borreliosis. An option could be
to include IgM in the screening for selected patients
with a short clinical history. Follow-up test after
some weeks in case of negative screening test would
be sensible if clinical suspicion is still present. In
children, a screening including IgM seems prudent.
In conclusion, we have shown that seropositivity
to B. burgdorferi s.l. was common in healthy blood
donors in western Norway. The seroprevalence of
IgG increased with age, male gender and number
of tick bites. Owners of cats or dogs had a lower
prevalence. IgG and C6 ELISA were comparable in
this group of blood donors, and specimens strongly
reactive in IgG and C6 were all positive in immu-
noblot for IgG. False-positive IgM results, includ-
ing immunoblot positive, seem to be a challenge.
The findings may help laboratories in developing
prudent testing algorithms and in assessing predic-
tive values of testing for these antibodies.
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Subjective health complaints are not
associated with tick bites or antibodies to
Borrelia burgdorferi sensu lato in blood donors
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Abstract
Background: There is controversy about chronic health consequences of tick-borne infections, especially Lyme
borreliosis. This study aims to assess whether general function, physical fitness and subjective health complaints are
associated with tick bites or antibodies to Borrelia burgdorferi sensu lato in blood donors.
Methods: Sera from 1,213 blood donors at four different blood banks in Sogn and Fjordane county in western
Norway were obtained during January to June 2010, and analysed for specific IgG and IgM antibodies. A
questionnaire including questions on tick bites, subjective health complaints, general function and physical fitness
was completed.
Results: Tick bites had been experienced by 65.7 % of the study population. 78 (6.4 %) were positive for IgG (9.7 %
in men, 2.4 % in women), and 69 (5.7 %) for IgM (6.1 % in men, 5.1 % in women), verified by immunoblot. No
association between number of experienced tick bites or seropositivity for Borrelia antibodies and subjective health
complaints, reduced general function or reduced physical fitness was found.
Conclusion: The results do not support any association between tick bites or Borrelia antibodies and subjective
health complaints in blood donors in an endemic area for Lyme borreliosis.
Keywords: Lyme disease, Lyme borreliosis, Blood donors, Subjective health complaints, Tick bites
Background
There is much controversy about chronic health conse-
quences of treated and untreated Lyme borreliosis (LB)
[1–4]. Symptoms from many organ systems are ascribed
to “chronic LB”, including fatigue, stiff neck, migrating
arthralgias, myalgia, chest pain, palpitations, abdominal
pain, nausea, back pain, headaches, etc. [3]. In addition,
other agents transmitted by ticks, e.g., Rickettsia spp.,
are increasingly claimed to cause health problems [5].
In follow-up studies of patients with Lyme neurobor-
reliosis (LNB), several symptoms have been found to
persist in some of the patients compared to controls,
including malaise, fatigue, memory problems, concentra-
tion difficulties and paresthesias [6, 7].
Population based follow-up studies of patients treated
for LB in general have given discrepant results regarding
long-term consequences. Some American studies have
reported that LB patients experience long-lasting symp-
toms [8, 9], while other investigations found that symp-
toms at follow-up did not exceed that of a control
population [10–14].
European studies have also shown that patients having
suffered from early LB report a number of symptoms;
however, these did not exceed the corresponding symp-
toms in matched controls [15, 16].
In a recent Swedish study, patients bitten by Borrelia-
infected ticks were compared to patients bitten by non-
infected ticks [17]. The frequency of subjects reporting
symptoms was higher in the group bitten by Borrelia-
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infected ticks compared to subjects bitten by uninfected
ticks. There were, however, no differences between
subjects bitten by a Borrelia-positive tick and subjects
bitten by a Borrelia-negative tick when comparing the
frequency of reported experience of several symptoms,
such as fatigue, myalgia/arthralgia, headache, and
neck pain.
It thus seems that long-lasting symptoms after LNB
are frequent in adults; however, in properly controlled
studies, lasting symptoms are rarely seen after early dis-
ease manifestations such as erythema migrans or after
bites with Borrelia-infected ticks.
A majority of blood donors in Sogn and Fjordane
county have experienced tick bites [18], and the sero-
prevalence of antibodies to B. burgdorferi s.l. is substan-
tial [19]. The aim of this study was to assess the
association, if any, of general function, physical fitness
and subjective health complaints with reported tick bites




During the period January 13th to June 15th 2010, blood
donors at the four blood banks in Sogn and Fjordane were
asked to participate in the Tick-borne Infection Study in
Sogn and Fjordane. A total of 1,213 blood donors partici-
pated, a response rate of 76 %. The mean age was
45.8 years, ranging from 19 to 69. Men constituted 55.2 %.
Further characteristics of the participants are presented
elsewhere [18]. Informed consent was obtained from each
participant, and the study was approved by the Regional
Committee for Medical Research Ethics. This investiga-
tion included a questionnaire in addition to testing serum
samples for antibodies to B. burgdorferi s.l., tick-borne en-
cephalitis virus and Anaplasma phagocytophilum. The re-
ported occurrence of tick bites and the results of the
antibody tests in this study population have been pub-
lished elsewhere [18–20].
Questionnaire
The questionnaire included questions about demograph-
ics such as gender, age, marital status, education, house-
hold income and occupation. Questions on pet animals,
farm animals, hours spent outdoors during summertime,
hunting, orienteering, smoking, and symptoms and
treatment after tick bites were also included.
The questionnaire included two questions on tick
bites; tick bites ever experienced, and tick bites expe-
rienced during the last 12 months. The responses for
both questions were given in the categories “none”,
“one”, “2-5”, “6-20” and “more than 20”. The number of
tick bites ever experienced was used in the present
study.
Another section of the questionnaire included the
Subjective Health Complaints (SHC) Inventory, a set of
questions designed to measure common and prevalent
health complaints in the general population [21–23].
The respondents reported to what extent they had been
affected by 29 different health disturbances during the
last month. The response options were “Not at all”
(score 0), “A little” (score 1), “Some” (score 2), and “Ser-
ious” (score 3). In addition, the respondents were asked
to record the duration of these symptoms (1–30 days).
The question related to general function was “How do
you assess your ability to perform ordinary activity, your
general function, is today?” The response options were
“Good, as it usually is” (score 0), “Hardly reduced at all”
(score 1), “Not much reduced” (score 2), “Moderately re-
duced” (score 3) and “Much reduced” (score 4), adapted
from [24].
Physical fitness was assessed by the question “«Dur-
ing the past 2 weeks: What was the hardest physical
activity you could do for at least 2 min?», with the
response alternatives «Very heavy (ex. run, at fast
pace)» (score 0), « Heavy (ex. jog, at slow pace)»
(score 1), « Moderate (ex. walk, at a fast pace)»
(score 2), «Light (ex. walk, at a medium pace)» (score 3),
and «Very light (ex. walk, at a slow pace or not able to
walk)» (score 4). This question was taken from the
COOP/WONCA charts [25].
The questionnaires were answered anonymously, and
most were completed during the time spent at the blood
bank for routine donation.
Laboratory methods
For testing of antibodies to B. burgdorferi s.l., all sera
were tested in Enzygnost Lyme link VlsE/IgG and
Enzygnost Borreliosis IgM (DADE Behring, Marburg,
Germany) and in Immunetics C6 Lyme ELISA kit
(Immunetics, Cambridge, MA, USA). Sera showing
positive or grey-zone reactivities in any of these tests
were further tested in Borrelia-EUROLine-RN-AT IgG
and Borrelia-EUROLine-RN-AT IgM (Euroimmun AG,
Lübeck, Germany) immunoblots. Further details are pre-
sented elsewhere [19]. The results of the immunoblots are
used in the present study, and are here-after referred to as
IgG and IgM.
Risk factors
The three risk factors included in the present analyses
were the number of self-reported tick bites ever experi-
enced, positive IgG, and positive IgM for B. burgdorferi
sensu lato. With the exeption of the questions on gen-
eral function and physical fitness (Table 1), the numbers
of tick bites were dichotomised into less than two versus
two or more in the analyses.
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Outcome
The outcome variables in this study were the responses
to questions on subjective health complaints (SHC), gen-
eral function, and physical fitness.
For general function and physical fitness, the response
was categorized in the categories 0–3, i.e., categories 3
and 4 were merged, because of few respondents in cat-
egory 4.
For the SHC-questions, we calculated the total num-
ber of complaints reported by each participant. In
addition, a total SHC score was computed as the sum of
the severity scores of all 29 items in the questionnaire,
the computation of this score was allowed if 18 or more
of the questions were answered.
The proportion of subjects reporting any complaint
within five subscales are reported as well; these include
“musculoskeletal” complaints (headache, neck pain,
shoulder pain, pain in arms, pain in upper back, low
back pain, leg pain, and pain in the feet during exercise),
“pseudoneurological” complaints (extra heartbeats, heat
flushes, sleep problems, tiredness, dizziness, anxiety and
sadness/depression), “gastrointestinal” complaints (heart-
burn, stomach discomfort, ulcer/non-ulcer dyspepsia,
stomach pain, bloating, diarrhoea and constipation),
“allergic” complaints (asthma, breathing difficulties, ec-
zema, allergies and chest pain) and “flu” (cold/flu and
cough). These subscales are based on factor analysis and
the factors have shown good reliability in previous stud-
ies [21]. The computation of these proportions allowed
for a certain number of missing values, which were ig-
nored if constituting less than half of the questions
within the subscale.
For the statistical evaluation of each individual SHC
we chose to dichotomize all responses into “no com-
plaint” versus any degree of complaint, as very few
scored the two most serious responses 2 and 3.
Statistical analysis
We used IBM SPSS Statistics version 21 (SPSS Inc.,
Chicago, Illinois) for statistical analyses except for
Table 3, where Stata/SE version 13.1 for Windows
(StataCorp LP, College Station, Texas) was used.
Immunoblot results for IgG and IgM were categorized
as positive or negative, with grey-zone results included
as negatives.
For the questions on general function and physical
fitness, the association between the score and number of
self-reported tick bites was analysed by using propor-
tional odds models, i.e., logistic regression models with
more than two ordinal categorical outcomes, with and
without adjustment for gender, age group and location
of blood bank [26].
Table 1 Overall function and physical fitness in relation to tick bites and Borrelia antibodies
Risk factor Reduced overall function Reduced physical fitness
Odds ratio2 (95 % CI) Adjusted odds ratio3 (95 % CI) Odds ratio2 (95 % CI) Adjusted odds ratio3 (95 % CI)
Total tick bites ever experienced
n1 1167 1145 1179 1157
None (%) 34.1 1 1 1 1
1 (%) 18.1 1.9 (1.0 - 3.5) 1.7 (0.9 - 3.2) 1.2 (0.9 - 1.6) 1.1 (0.8 - 1.5)
2-5 (%) 23.7 0.7 (0.4 - 1.5) 0.7 (0.4 - 1.6) 0.8 (0.6 - 1.0) 0.7 (0.5 - 0.9)
6-20 (%) 15 1. 9 (1.0 - 3.5) 1.8 (0.9 - 3.5) 0.6 (0.5 - 0.9) 0.5 (0.4 - 0.7)
>20 (%) 9.2 2.1 (1.0 - 4.4) 2.0 (0.9 - 4.2) 0.9 (0.6 - 1.3) 0.7 (0.4 - 1.0)
p trend 0.086 0.117 0.012 <0.001
IgG
n1 1179 1157 1191 1169
negative (%) 93.8 1 1 1 1
positive (%) 6.2 1.6 (0.8 - 3.5) 1.7 (0.8 - 3.7) 1.1 (0.7 - 1.7) 1.1 (0.7 - 1.7)
p difference 0.216 0.204 0.725 0.688
IgM
n1 1179 1157 1191 1169
negative (%) 94.3 1 1 1 1
positive (%) 5.7 1.5 (0.7 - 3.5) 1.5 (0.7 -3.4) 1.1 (0.7 - 1.7) 0.9 (0.6 - 1.5)
p difference 0.296 0.340 0.760 0.726
1Numbers do not add to 1,213 due to missing data
2Odds ratio was estimated using proportional odds ratio models (logistic regression model with more than two categorical outcomes)
3Adjusted for gender, age group and blood bank
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For SHC, both individually for each complaint as
well as for the five sub-scales, the associations be-
tween the risk factors and outcome variables were
analysed by binary logistic regression, with and with-
out adjustment for gender, age group and location of
blood bank.
Differences in the total number of complaints and the
total SHC score between groups with and without the
risk factors were estimated by using linear regression
model with robust variance estimation. All p values were
two-sided and values below 0.05 were considered statis-
tical significant.
Results
Among participants, 65.7 % had experienced tick bites dur-
ing their life time. One tick bite was reported by 18.0 %,
2–5 bites by 23.8 %, 6–20 by 14.7 %, and more than 20
bites by 9.2 %. The estimated mean number of tick bites
was 5.7, as published elsewhere [18].
Borrelia IgG antibodies verified by immunoblot were
present in 6.4 % (9.7 % in men and 2,4 % in women),
whereas Borrelia IgM antibodies were demonstrated in
5.7 % (6.1 % in men and 5.1 % in women) [19].
Overall, 5.0 % reported to have received antibiotics be-
cause of tick bite or consequences thereof. Among IgG
and/or IgM blot positives, antibiotics had been received
by 11.9 %.
The results for the relationship between the risk factors
tick bites ever experienced, Borrelia IgG and Borrelia IgM,
and the outcomes general function and physical fitness
are presented in Table 1. The proportion reporting re-
duced general function did not differ significantly between
subjects with and without the risk factors. The number of
tick bites was positively associated with good physical fit-
ness (adjusted p for trend < 0.001).
The relationship between the proportion reporting any
complaint within the five subscales of subjective health
complaints and the risk factors are presented in Table 2,
and results for each of the individual 29 complaints are
presented in the Additional file 1.
There were no significant associations between the
proportion reporting “musculoskeletal pain” or the indi-
vidual related complaints with any of the risk factors.
For the group of “pseudoneurological” complaints, there
were fewer complaints in the subjects with Borrelia
IgG than in those without these antibodies (adjusted
Table 2 Odds ratio for reporting any degree of subjective health complaint (SHC), grouped in five subscales
Complaint/Risk factor (RF) n1 Proportion with complaint (%) Odds ratio2 (OR) for complaint when risk factor present
RF absent RF present Unadjusted p3 Adjusted4 p3
Musculoskeletal pain
Tick bites >1 1139 66.6 68.1 1.1 (0.8 - 1.4) 0.583 1.1 (0.8 - 1.4) 0.578
IgG + 1151 67.1 69.0 1.1 (0.6 - 1.8) 0.743 1.3 (0.7 - 2.2) 0.374
IgM + 1151 66.9 72.6 1.3 (0.7 - 2.3) 0.359 1.5 (0.8 - 2.7) 0.172
Pseudoneurology
Tick bites >1 1136 40.8 39.2 0.9 (0.7 - 1.2) 0.570 0.9 (0.7 - 1.1) 0.264
IgG + 1148 41.1 23.9 0.5 (0.3 - 0.8) 0.005 0.5 (0.3 - 0.8) 0.010
IgM + 1148 40.2 37.1 0.9 (0.5 - 1.5) 0.624 0.8 (0.5 - 1.5) 0.522
Gastrointestinal complaints
Tick bites >1 1136 41.5 42.1 1.0 (0.8 - 1.3) 0.829 1.0 (0.8 - 1.3) 0.991
IgG + 1148 42.0 38.0 0.8 (0.5 - 1.4) 0.515 0.9 (0.5 - 1.4) 0.557
IgM + 1148 41.4 46.8 1.2 (0.7 - 2.1) 0.408 1.1 (0.7 - 1.9) 0.632
Allergy
Tick bites >1 1136 20.2 19.8 1.0 (0.7 - 1.3) 0.870 0.9 (0.7 - 1.2) 0.534
IgG + 1148 20.2 16.9 0.8 (0.4 - 1.5) 0.497 0.8 (0.4 - 1.5) 0.415
IgM + 1148 19.7 25.8 1.4 (0.8 - 2.6) 0.245 1.4 (0.7 - 2.5) 0.324
Flu
Tick bites >1 1161 29.3 31.4 1.1 (0.9 - 1.4) 0.434 1.2 (0.9 - 1.5) 0.264
IgG + 1174 29.7 36.5 1.4 (0.8 - 2.2) 0.222 1.3 (0.8 - 2.2) 0.273
IgM + 1174 29.5 42.2 1.7 (1.0 - 2.9) 0.033 1.3 (0.8 - 2.2) 0.273
1n does not reach 1213 because of missing data
2Odds ratio for subjects without the risk factor is 1
3Binary logistic regression
4Adjusted for gender, age group and blood bank location
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p = 0.010). None of the individual complaints in this
group of questions were significantly associated with
any of the risk factors. However, for all questions
there were fewer in the IgG positive group reporting
symptoms than among IgG negatives (Additional file 1).
In the subscale “gastrointestinal” complaints, some
more subjects with more than one tick bite reported
ulcer- and non-ulcer dyspepsia (adjusted p = 0.079), and
there was a trend towards more IgM positives reporting
constipation (Additional file 1; adjusted p = 0.081).
There were no significant associations between
the number of subjects reporting complaints within the
“allergy” subscale or the individual related complaints
with any of the risk factors.
The “flu”-related questions all showed a higher per-
centage of IgM positives reporting symptoms, however,
this associations were weakened when adjusted for gen-
der, age group and blood bank location.
We found no significant associations between the total
number of subjective health complaints or the total SHC
score and any of the risk factors (Table 3) when adjusted
for gender, age, and location of blood bank.
The additional questions on duration of the different
symptoms were answered by only 60 % (38-73 %) of the
subjects reporting any degree of the complaints. There-
fore, these data were not considered satisfactory for statis-
tical evaluation and are not shown.
Discussion
The main finding in this study was the lack of association
between the risk factors tick bites and Borrelia antibodies
with the outcomes subjective health complaints, reduced
Table 3 Number of subjective health complaints and total SHC score relative to tick bites and Borrelia antibodies
No. subjects1 Median (IQR)2 Mean (SEM)3 Adjusted mean (SEM)3,4
Number of complaints
Tick-bites
≤1 624 3.0 (1.0-5.0) 3.59 (0.14) 3.62 (0.13)
>1 570 3.0 (1.0-5.0) 3.64 (0.13) 3.60 (0.14)
p difference 0.785 0.903
IgG
- 1135 3.0 (1.0-5.0) 3.62 (0.10) 3.63 (0.10)
+ 78 2.0 (1.0-4.0) 3.29 (0.50) 3.42 (0.51)
p difference 0.527 0.603
IgM
- 1144 3.0 (1.0-5.0) 3.58 (0.10) 3.60 (0.10)
+ 69 3.0 (1.0-5.0) 3.94 (0.51) 3.87 (0.51)
p difference 0.480 0.600
Total SCH score5
Tick-bites
≤1 595 3.0 (1.0-6.0) 4.71 (0.24) 4.76 (0.25)
>1 541 3.1 (1.0-6.0) 4.58 (0.20) 4.51 (0.20)
p difference 0.672 0.440
IgG
- 1077 3.0 (1.0, 6.0) 4.62 (0.14) 4.60 (0.14)
+ 71 3.0 (1.0, 5.0) 5.22 (1.31) 5.36 (1.26)
p difference 0.644 0.550
IgM
- 1086 3.0 (1.0-6.0) 4.57 (0.14) 4.57 (0.14)
+ 62 3.1 (2.0-7.0) 6.06 (1.41) 5.94 (1.35)
p difference 0.295 0.313
1The number of subjects does not reach 1213 because of missing data
2Interquartile range (IQR)
3Standard error of the mean (SEM) predicted by linear regression with robust variance estimation
4Adjusted for gender, age and blood bank location
5SCH: Subjective health complaints. Total SHC score: See text
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general function and reduced physical fitness. On the
contrary, we found a positive association between tick
bites and good physical fitness, and between presence of
Borrelia IgG and low occurrence of “pseudoneurological”
complaints. For most complaints, however, we found no
association.
The risk factor “number of tick bites” was included in
this study to explore the possibility that seronegative LB
or other tick-borne infectious agents not tested for, e.g.
Anaplasma phagocytophilum, Rickettsia spp., etc., could
give rise to chronic health problems of some magnitude.
IgG and IgM antibodies to B. burgdorferi s.l. verified
by blot were chosen as risk factors in this study in order
to avoid including false positive ELISA results. However,
biologically false positive IgM blot results still are a
problem, and American guidelines thus argue against
using IgM blot in the second-tier testing when disease
duration is longer than one month [27]. A proportion of
the IgM blot positive specimens in this study are prob-
ably biologically false positive, as discussed elsewhere
[19]. Also, many will lose their antibodies after a while,
whether treated or not. However, antibodies against
B. burgdorferi s.l., especially IgG, should be an indicator
of former or present infection with this organism.
In several studies of symptoms after LB, the Medical
Outcomes Study 36-Item Short-Form Health Survey
(SF-36) has been used [6, 8–10]. In addition, several
questionnaires for assessing somatic symptoms in the
general population exist [28]. The unique contribution
of the current study was to include the SHC question-
naire, which was designed to measure common and
prevalent health complaints in the general population,
and has been used in several studies of the general
population as well as different patients groups [29–32].
Compared to other surveys using the SHC Inventory
in the general population, summarised by Eriksen et al.
in 1999 [21], and for a working population more recently
by Ihlebæk and co-workers [29], the proportion of sub-
jects with any complaint were lower in our material for
most complaints, reflecting the overall healthy status of
the blood donors (Additional file 1).
Comparing our results to those of other studies is not
straight forward, of two main reasons. Firstly, the selec-
tion of study population differs between studies, e.g.,
blood donors, subjects having been bitten by ticks, pa-
tients having suffered from LB, patients having suffered
from LNB, etc. Secondly, the choice of questionnaire
also varies. We are not aware of other studies using the
SHC inventory in blood donors or in relation to LB.
Nevertheless, in the following, a tentative comparison is
attempted.
In a study of 1156 male military recruits in Germany,
Treib and co-workers found that Borrelia IgG positive
subjects reported significantly more fatigue, general
malaise and limb pain, compared to seronegatives [33].
This is in contrast to our findings, where musculo-
skeletal pain in different locations as well as “tiredness”,
“reduced general function” and “reduced physical fitness”
was reported as often by seronegatives as by seropositives
for IgG.
Studies by Shadic and co-workers from 1994 and 1999
found that persons with a history of LB had more mus-
culoskeletal impairment and a higher prevalence of ver-
bal memory impairment when compared with those
without a history of LB [8, 9]. As these reports are based
on a different study population as well as a different
questionnaire, they are not directly comparable with our
present study. However, our results do not corroborate
these findings, as musculoskeletal pain and reduced gen-
eral function were not found associated with seropositiv-
ity or number of tick bites.
In agreement with our results, Seltzer and co-workers
[10] reported that persons having suffered from LB gen-
erally did not report more symptoms than controls, in-
cluding memory problems, numbness, fatigue, swollen
joints, headaches, neck pain, or problems with sleeping
and exercise. Also, supporting our findings, in two re-
cent Slovenian studies of patients treated for erythema
migrans, the researchers did not find any association be-
tween cases and controls in non-specific symptoms
6 months after treatment [15, 16]. In long-term follow-
up of patients with culture-confirmed LB, Wormser and
co-workers did not find evidence of severe fatigue or
fibromyalgia attributable to LB [11, 12], and summary
scores of physical and mental health were similar to
those of the general population [14].
As part of the Swedish “STING-study”, Fryland and
co-workers [17] compared symptoms in patients bitten
by ticks infected with Borrelia burgdorferi sensu lato
with patients bitten with non-infected ticks. They found
a higher frequency of patients reporting any symptom in
the former group, but no differences between the groups
when comparing the frequency of each of several symp-
toms. In the present study, we found that the count of
subjective health complaints had no relation with any of
the risk factors (Table 3).
In a prospective investigation of patients treated for
LNB in Norway, Eikeland and co-workers found that
LNB-treated patients scored lower on all the SF-36 sub-
scores except on bodily pain, and they reported fatigue,
memory problems and concentration difficulties more
often than matched controls [6]. Notable was that in
contrast to the results from Shadic et al., pain was not
more common among LNB-treated patients than among
controls, neither assessed by direct question nor by
SF-36. These data are not comparable to our study,
as very few, if any, of our study subjects have suffered
from LNB [18].
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According to alternative views on LB, there are many
undiagnosed patients with nonspecific chronic symp-
toms attributable to the disease [3]. Among the listed
symptoms, some are included in the SHC inventory. The
prevalence of these was not significantly higher for any
of the risk factors tick bites, IgG or IgM in our study.
However, a number of symptoms are not explicitly in-
cluded in the SHC inventory. If these symptoms were of
any significance in our study population, it should be
reflected in the score on “reduced general function”
in subjects with the risk factors. This was, however,
not the case.
The clear correlation between the number of tick bites
and physical fitness is not surprising. Persons more ex-
posed to ticks are presumably more involved in outdoors
activities such as hiking and hunting, and are in a gener-
ally good physical condition.
The negative association of “pseudoneurological” com-
plaints and Borrelia IgG antibodies, but not number of
tick bites or IgM, is difficult to explain. Also here, a
spurious relationship connected to confounding lifestyle
factors can be suspected.
The strength of this study is the relatively large repre-
sentation of healthy subjects from Sogn and Fjordane
county, the good response rate, and the frequent occur-
rence of tick bites and seropositivity to B. burgdorferi
s.l., as well as the scope of the questionnaire, covering a
broad range of health complaints. Thus, major chronic
health effects of tick bites and seropositivity to B. burg-
dorferi s.l. should be detected.
On the other hand, blood donors are not completely
representative of the general population. They are
healthy, and children and persons over 70 years are not
represented. There was, however, a fair distribution re-
garding gender and age groups. According to Norwegian
blood bank regulations, persons that have been bitten by
ticks should not donate blood within four weeks of the
bite, and persons with suspected or verified LB should
not donate until six months after adequate treatment
has been given [34]. Donors with recent tick bites and/
or LB may therefore be underrepresented. Not all tick
bites are recognized by the bitten person, and thus will
not be reported in a questionnaire survey like this (i.e.,
information bias). This is supported by the seropre-
valence rate for immunoblot verified IgG antibodies to
B. burgdorferi s.l. of 2.4 % in subjects not reporting any
tick bite [19].
It is to be expected that persons with significant chronic
health problems do not volunteer as blood donors, or will
be excluded. Persons of this category are therefore prob-
ably underrepresented in this material. However, given the
commonness of these “soft” symptoms also in blood
donors (Table 2), one would expect that mild degrees of
such complaints should be represented.
Conclusions
This study of blood donors in western Norway assessed
the association between three risk factors – the number
of tick bites ever experienced and the presence of Borrelia
IgG and IgM antibodies – with the questionnaire-based
outcomes general function, physical fitness and 29 differ-
ent subjective health complaints.
A limitation of this study is that very few of the study
subjects reported ever having had symptoms indicative
of systemic LB.
There was no association between general function
and the risk factors. However, we found a clear correl-
ation between the number of tick bites ever experienced
and good physical fitness. This most probably represents
a spurious relationship as both risk factor and outcome
are related to a healthy life style.
We did not find any association between more subject-
ive health complaints and tick bites or Borrelia antibodies.
Seeing the «pseudoneurological» group of complaints
together, there were fewer complaints in subjects with
Borrelia IgG antibodies, also probably a non-causal
relationship.
The results do not support any association between
tick bites or Borrelia antibodies and subjective health
complaints in blood donors in an endemic area for Lyme
borreliosis.
Additional file
Additional file 1: Individual subjective health complaints relative to
tick bites and Borrelia antibodies.
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Additional file Individual subjective health complaints relative to tick bites and Borrelia antibodies 
Complaint/ 






complaint (%)  
 Odds ratio (OR) for complaint when risk factor present 
(binary logistic regression) 






 Unadjusted  p  Adjusted2  p 
Headache                    
    Tick bites >1 1148 47.8  36.4 34.2  0.9 (0.7 - 1.2) 0.447  1.0 (0.8 - 1.3) 0.841 
    IgG + 1159 6.1  35.7 31.0  0.8 (0.5 - 1.4) 0.425  1.2 (0.7 - 2.1) 0.469 
    IgM + 1159 5.3  35.7 29.0  0.7 (0.4 - 1.3) 0.285  0.9 (0.5 - 1.6) 0.726 
Neck pain                    
    Tick bites >1 1137 47.8  25.9 25.6  1.0 (0.8 - 1.3) 0.900  1.0 (0.7 - 1.3) 0.949 
    IgG + 1149 6.2  26.1 21.1  0.8 (0.4 - 1.4) 0.358  0.8 (0.5 - 1.5) 0.572 
    IgM + 1149 5.5  25.8 25.4  1.0 (0.5 - 1.8) 0.946  1.0 (0.5 - 1.8) 0.974 
Upper back pain                    
    Tick bites >1 1121 47.5  10.4 13.1  1.3 (0.9 - 1.9) 0.152  1.2 (0.8 - 1.8) 0.325 
    IgG + 1133 6.2  11.8 11.4  1.0 (0.5 - 2.1) 0.934  1.0 (0.4 - 2.1) 0.953 
    IgM + 1133 5.6  11.7 12.7  1.1 (0.5 - 2.4) 0.808  1.0 (0.5 - 2.3) 0.934 
Lower back pain                    
    Tick bites >1 1137 47.6  30.9 32.7  1.1 (0.8 - 1.4) 0.505  1.0 (0.8 - 1.4) 0.726 
    IgG + 1149 6.1  31.5 34.3  1.1 (0.7 - 1.9) 0.629  1.1 (0.7 - 1.9) 0.679 
    IgM + 1149 5.3  32.1 24.6  0.7 (0.4 - 1.3) 0.224  0.7 (0.4 - 1.3) 0.287 
Arm pain                    
    Tick bites >1 1127 47.4  17.2 16.1  0.9 (0.7 - 1.3) 0.622  0.8 (0.6 - 1.1) 0.178 
    IgG + 1139 6.1  16.6 15.9  1.0 (0.5 - 1.8) 0.881  0.8 (0.4 - 1.6) 0.572 
    IgM + 1139 5.4  16.2 24.2  1.7 (0.9 - 3.0) 0.101  1.5 (0.8 - 2.9) 0.172 
Shoulder pain                    
    Tick bites >1 1143 48.0  27.3 30.2  1.2 (0.9 - 1.5) 0.269  1.0 (0.8 - 1.4) 0.792 
    IgG + 1155 6.1  28.6 28.6  1.0 (0.6 - 1.7) 1.000  1.0 (0.5 - 1.7) 0.877 
    IgM + 1155 5.3  28.1 37.7  1.6 (0.9 - 2.6) 0.107  1.5 (0.9 - 2.6) 0.129 
Migraine                    
    Tick bites >1 1126 47.5  6.3 8.0  1.3 (0.8 - 2.1) 0.248  1.2 (0.7 - 1.9) 0.447 
    IgG + 1138 6.2  7.0 7.0  1.0 (0.4 - 2.6) 0.997  1.1 (0.4 - 2.9) 0.864 
    IgM + 1138 5.4  7.0 8.2  1.2 (0.5 - 3.1) 0.714  1.2 (0.5 - 3.3) 0.651 
Pain in feet after 
strain     
               
    Tick bites >1 1138 47.8  9.9 11.2  1.1 (0.8 - 1.7) 0.483  1.1 (0.7 - 1.6) 0.754 
    IgG + 1150 6.3  10.3 13.9  1.4 (0.7 - 2.8) 0.338  1.3 (0.6 - 2.8) 0.433 
    IgM + 1150 5.4  10.3 14.5  1.5 (0.7 - 3.1) 0.295  1.4 (0.7 - 3.0) 0.376 
Palpitations                    
    Tick bites >1 1136 47.6  7.6 8.7  1.2 (0.8 - 1.8) 0.488  1.1 (0.7 - 1.8) 0.566 
    IgG + 1148 6.1  8.4 2.9  0.3 (0.1 - 1.3) 0.115  0.3 (0.1 - 1.4) 0.140 
    IgM + 1148 5.4  7.8 12.9  1.7 (0.8 - 3.8) 0.159  1.7 (0.8 - 3.7) 0.200 
2 
 
Heat flushes                    
    Tick bites >1 1138 47.8  10.1 10.5  1.0 (0.7 - 1.5) 0.834  0.7 (0.4 - 1.0) 0.075 
    IgG + 1150 6.1  10.5 8.6  0.8 (0.3 - 1.9) 0.615  1.2 (0.5 - 3.3) 0.665 
    IgM + 1150 5.4  10.3 10.3  1.1 (0.5 - 2.5) 0.802  1.0 (0.4 - 2.6) 0.973 
Sleep problems                    
    Tick bites >1 1137 47.8  17.7 16.0  0.9 (0.7 - 1.2) 0.457  0.8 (0.6 - 1.1) 0.142 
    IgG + 1149 6.2  17.3 11.3  0.6 (0.3 - 1.3) 0.191  0.6 (0.3 - 1.3) 0.208 
    IgM + 1149 5.4  17.3 11.3  0.6 (0.3 - 1.4) 0.225  0.6 (0.3 - 1.3) 0.203 
Tiredness                    
    Tick bites >1 1140 47.8  24.7 25.7  1.1 (0.8 - 1.4) 0.703  1.0 (0.8 - 1.4) 0.826 
    IgG + 1152 6.2  25.8 15.5  0.5 (0.3 - 1.0) 0.056  0.6 (0.3 - 1.1) 0.103 
    IgM + 1152 5.3  25.1 25.8  1.0 (0.6 - 1.9) 0.906  1.0 (0.6 - 1.9) 0.957 
Dizziness                    
    Tick bites >1 1135 47.8  7.1 6.1  0.9 (0.5 - 1.4) 0.501  0.8 (0.5 - 1.3) 0.427 
    IgG + 1147 6.2  6.8 5.6  0.8 (0.3 - 2.3) 0.708  0.8 (0.3 - 2.4) 0.702 
    IgM + 1147 5.4  6.5 9.7  1.5 (0.6 - 3.7) 0.341  1.6 (0.6 - 3.9) 0.313 
Anxiety                    
    Tick bites >1 1138 47.6  3.9 2.6  0.7 (0.3 - 1.3) 0.228  0.6 (0.3 - 1.2) 0.148 
    IgG + 1150 6.2  3.3 2.8  0.8 (0.2 - 3.6) 0.813  0.8 (0.2 - 3.5) 0.759 
    IgM + 1150 5.5  3.2 3.2  1.5 (0.4 - 5.0) 0.508  1.4 (0.4 - 4.6) 0.628 
Depressed                    
    Tick bites >1 1136 47.6  6.2 6.3  1.0 (0.6 - 1.6) 0.963  1.0 (0.6 - 1.7) 0.881 
    IgG + 1148 6.2  6.3 4.2  0.7 (0.2 - 2.1) 0.482  0.7 (0.2 - 2.5) 0.609 
    IgM + 1148 5.4  6.0 9.7  1.7 (0.7 - 4.1) 0.245  1.7 (0.7 - 4.1) 0.252 
Heartburn                    
    Tick bites >1 1144 47.6  19.0 17.8  0.9 (0.7 - 1.2) 0.611  0.9 (0.6 - 1.2) 0.369 
    IgG + 1156 6.2  18.2 23.6  1.4 (0.8 - 2.4) 0.252  1.2 (0.7 - 2.1) 0.589 
    IgM + 1156 5.4  18.1 25.4  1.5 (0.9 - 2.8) 0.151  1.3 (0.7 - 2.5) 0.343 
Stomach discomfort                    
    Tick bites >1 1134 47.4  4.9 5.4  1.1 (0.7 - 1.9) 0.689  1.0 (0.6 - 1.7) 0.918 
    IgG + 1146 6.2  5.3 4.2  0.8 (0.2 - 2.6) 0.694  0.6 (0.2 - 2.1) 0.423 
    IgM + 1146 5.4  5.4 3.2  0.6 (0.1 - 2.5) 0.470  0.5 (0.1 - 2.1) 0.353 
Ulcer and non-ulcer 
dyspepsia     
               
    Tick bites >1 1134 47.7  0.5 1.7  3.3 (0.9 - 12.4) 0.073  3.6 (0.9 - 14.8) 0.079 
    IgG + 1146 6.2  0.9 4.2  4.7 (1.3 - 17.5) 0.021  3.0 (0.7 - 12.7) 0.140 
    IgM + 1146 5.4  7.8 6.6  3.3 (0.7 - 15.0) 0.131  3.3 (0.6 - 16.9) 0.159 
Stomach pain                    
    Tick bites >1 1132 47.6  7.1 8.2  1.2 (0.8 - 1.8) 0.493  1.2 (0.8 - 2.0) 0.357 
    IgG + 1144 6.1  7.5 10.0  1.4 (0.6 - 3.1) 0.456  1.7 (0.7 - 3.9) 0.248 
    IgM + 1144 5.3  7.8 6.6  0.8 (0.3 - 2.4) 0.733  0.9 (0.3 - 2.6) 0.835 
Bloating                    
3 
 
    Tick bites >1 1142 47.6  24.9 23.7  0.9 (0.7 - 1.2) 0.636  0.9 (0.7 - 1.2) 0.375 
    IgG + 1154 6.2  24.5 22.2  0.9 (0.5 - 1.6) 0.664  0.9 (0.5 - 1.6) 0.688 
    IgM + 1154 5.5  24.4 23.8  1.0 (0.5 - 1.8) 0.918  0.8 (0.4 - 1.5) 0.456 
Diarrhoea                    
    Tick bites >1 1136 47.7  10.3 10.5  1.0 (0.7 - 1.5) 0.891  1.1 (0.7 - 1.6) 0.688 
    IgG + 1148 6.2  10.3 12.7  1.3 (0.6 - 2.6) 0.528  1.3 (0.6 - 2.8) 0.450 
    IgM + 1148 5.4  10.7 6.5  0.6 (0.2 - 1.6) 0.296  0.6 (0.2 - 1.6) 0.302 
Constipation                    
    Tick bites >1 1133 47.7  3.4 4.1  1.2 (0.7 - 2.2) 0.541  1.2 (0.6 - 2.4) 0.518 
    IgG + 1145 6.1  3.7 4.3  1.2 (0.3 - 3.8) 0.810  1.4 (0.4 - 4.9) 0.623 
    IgM + 1145 5.3  3.5 8.2  2.5 (0.9 - 6.5) 0.069  2.5 (0.9 - 6.8) 0.081 
Asthma                    
    Tick bites >1 1133 47.7  3.5 2.0  0.6 (0.3 - 1.2) 0.132  0.5 (0.2 - 1.1) 0.089 
    IgG + 1145 6.1  2.9 2.9  1.0 (0.2 - 4.2) 0.990  0.9 (0.2 - 3.9) 0.879 
    IgM + 1145 5.4  2.7 6.5  2.5 (0.9 - 7.4) 0.095  2.3 (0.8 - 7.0) 0.130 
Breathing difficulties                    
    Tick bites >1 1135 47.6  2.0 2.0  0.8 (0.3 - 2.0) 0.662  0.7 (0.3 - 1.7) 0.453 
    IgG + 1147 6.2  1.9 2.8  1.5 (0.4 - 6.7) 0.571  1.0 (0.2 - 4.4) 0.962 
    IgM + 1147 5.4  1.8 4.8  2.9 (0.8 - 9.9) 0.099  1.9 (0.5 - 7.0) 0.310 
Eczema                    
    Tick bites >1 1137 47.6  8.7 10.2  1.2 (0.8 - 1.8) 0.406  1.1 (0.7 - 1.6) 0.693 
    IgG + 1149 6.1  9.7 4.3  0.4 (0.1 - 1.3) 0.142  0.4 (0.1 - 1.2) 0.104 
    IgM + 1149 5.4  9.2 12.9  1.5 (0.7 - 3.2) 0.334  1.4 (0.6 - 3.1) 0.394 
Allergies                    
    Tick bites >1 1141 47.8  9.6 8.4  0.9 (0.6 - 1.3) 0.509  0.9 (0.6 - 1.4) 0.590 
    IgG + 1153 6.2  9.1 8.5  0.9 (0.4 - 2.2) 0.843  1.1 (0.4 - 2.7) 0.851 
    IgM + 1153 5.4  8.8 14.5  1.8 (0.8 - 3.7) 0.133  1.8 (0.9 - 3.9) 0.114 
Chest pain                    
    Tick bites >1 1135 47.6  2.9 2.6  0.9 (0.4 - 1.9) 0.785  0.7 (0.3 - 1.5) 0.381 
    IgG + 1147 6.2  2.6 5.6  2.2 (0.8 - 6.6) 0.143  1.5 (0.5 - 4.5) 0.504 
    IgM + 1147 5.4  2.6 6.5  2.6 (0.9 - 7.7) 0.083  2.0 (0.7 - 6.3) 0.211 
Cold, flu                    
    Tick bites >1 1152 47.9  25.8 26.6  1.0 (0.8 - 1.4) 0.759  1.1 (0.8 - 1.4) 0.504 
    IgG +     1165 6.3  25.6 32.9  1.4 (0.9 - 2.4) 0.175  1.4 (0.8 - 2.4) 0.181 
    IgM + 1165 5.4  25.6 34.9  1.6 (0.9 - 2.7) 0.103  1.5 (0.9 - 2.6) 0.153 
Cough                    
    Tick bites >1 1140 47.8  11.9 11.7  1.0 (0.7 - 1.4) 0.921  1.0 (0.7 - 1.4) 0.929 
    IgG + 1151 6.3  11.9 9.7  0.8 (0.4 - 1.8) 0.585  0.7 (0.3 - 1.7) 0.493 
    IgM + 1151 5.6  11.3 18.8  1.8 (0.9 - 3.5) 0.076  1.5 (0.8 - 3.0) 0.239 
 
1 n does not reach 1213 because of missing data 
2 Adjusted for gender, age group and blood bank location 
 
